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Abstract 
Mu opioid receptors (MOPs) in the pain pathway contribute to morphine 
analgesia. Morphine also stimulates reward/reinforcement through disinhibition 
of dopaminergic (DA) neurones in the ventral tegmental area (VTA), an effect 
implicated in its abuse and dependence. We hope to develop approaches to 
achieve sustained analgesia without affecting reward by exploiting differential 
MOP signalling mechanisms in the pain and reward pathways. MOPs, delta 
opioid receptors (DOPs) and β-arrestin2 (BAR2) are all necessary components of 
the signalling complex in nociceptive neurones for morphine analgesic tolerance; 
c-Src (a tyrosine kinase), thought to couple to MOP receptors through BAR2 has 
also been implicated.  
 
To investigate opioid receptor signalling in response to morphine we used a 
variety of different techniques that included behavioural measures of 
nociception, reinforcement and locomotion and electrophysiological methods to 
study DRG neurones from the pain pathway and brain slices containing VTA 
neurones. 
 
This study in mice confirms that morphine administered subcutaneously (SC) 
causes analgesia, analgesic tolerance, and has psychomotor effects leading to 
enhanced locomotion and reinforcement. In VTA neurones morphine and the 
selective MOP receptor agonist DAMGO caused concentration-dependent 
inhibition of the frequency of IPSCs. All these actions of morphine were absent 
xxii 
 
from MOP-/- mice. Morphine exhibited reduced potency as 1) an analgesic, 2) 
stimulator of locomotion, 3) a reinforcer in CPP and 4) an inhibitor of sIPSC 
frequency, when applied to MOP+/- mice or their VTA neurones. Morphine 
analgesic tolerance developed faster and to a greater extent in MOP+/- mice 
than in WT mice. DOP-/- mice exhibited morphine analgesia with less tolerance, 
as did BAR2-/- mice. BAR2-/- mice also exhibited reduced morphine locomotion 
and an increased sensitivity to morphine reinforcement. Morphine tolerance 
was absent from BAR2-/-//DOP-/- mice. The inhibition of sIPSC frequency by 
morphine was reduced in BAR2+/- and BAR2-/- VTA neurones. Dasatinib and PP2 
(c-Src tyrosine kinase inhibitors) prevented the development of morphine 
tolerance in WT and MOP+/- mice and dasatinib caused its reversal in the latter. 
The drugs had no significant analgesic effect alone. Dasatinib did not affect 
morphine preference or locomotor activation. PP2 reduced morphine’s 
inhibition of sIPSC frequency. 
 
As c-Src inhibition does not appear to alter the psychomotor effects produced by 
morphine and it acts to reduce morphine analgesic tolerance. We believe that c-
Src is an attractive target to prevent the development of morphine analgesic 
tolerance without affecting hedonic homeostasis. 
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Chapter 1: Introduction 
  
2 
 
1.1 Opium 
Opioid drugs have been exploited for centuries for both their analgesic and 
hedonistic effects. The poppy plant was cultivated in the ancient civilisations of 
Persia, Egypt, Greece and Mesopotamia. Opium is an extract from the poppy 
plant Papavera Somniferum, which is also known as the white poppy. Although 
there are many varieties of poppy there are very few from which active alkaloid 
compounds can be harvested. There have been findings of fossilized opium 
poppy seeds dating from 30,000 years ago suggesting that these plants were 
used by Neanderthal man (Dormandy, 2012).  
 
The first known written reference to the opium poppy appears in a Sumerian 
text dating from approximately 4,000 BC, the Sumerians called the flower hul gil, 
‘the plant of joy’ (Brownstein, 1993). The first written record of its use does not 
occur until much later when in the second century Galen, a prominent Greek 
physician described some of what he considered to be its medical indications 
(Waldhoer et al., 2004). He wrote that opium: "...resists poison and venomous 
bites, cures chronic headache, vertigo, deafness, epilepsy, apoplexy, dimness of 
sight, loss of voice, asthma, coughs of all kinds, spitting of blood, tightness of 
breath, colic, the lilac poison, jaundice, hardness of the spleen stone, urinary 
complaints, fever, dropsies, leprosies, the trouble to which women are subject, 
melancholy and all pestilences" (Braithwaite, 2007). 
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In the western world use of opium was not widespread until the 17th century. 
The drug became much more available as trade increased with Asian countries 
and the so called opium wars. The discovery that the potency of the drug was 
increased when it was extracted using alcohol instead of water by Paracelsus in 
the 16th century led to the development of laudanum (Jay, 2012). Thomas 
Sydenham a medical practitioner in 17th century England further adjusted and 
standardised this formula but kept the name laudanum (Van Ree et al., 1999). 
He wrote that; "Among the remedies which it has pleased Almighty God to give 
to man to relieve his sufferings, none is so universal and so efficacious as opium" 
(Braithwaite, 2007). 
 
By the nineteenth century laudanum and other opium containing products were 
freely available from many outlets in England and the rest of Europe (Obladen, 
2015). Opium and laudanum were viewed by the majority as medicine and not 
as drugs of abuse; there is very little documentation of harm associated with 
their use at this time (Dormandy, 2012). There were many well-known people 
that were consumers of the drug both within the general population and also 
the medical and scientific circles of the time. Several famous writers are known 
to have consumed the drug to varying degrees, including Samuel Coleridge, Sir 
Walter Scott and John Keats (Ober, 1968). One of the most well-known accounts 
of the effects of opium was published by Thomas De Quincey in 1821/2. He had 
previously been secretary to Samuel Coleridge and the publication was titled 
‘Confessions of an English opium eater’ (Jay, 2012). There were areas of the 
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country where use of the drug in varying forms was particularly high, these 
included Lincolnshire, Cambridgeshire and Norfolk (Berridge, 1979). 
  
Papavera Somniferum grows wild in areas ranging from Southern Europe and the 
Far East to the USA. The largest quantities come from three areas of the world: 
the ‘Golden Triangle’ (Laos, Burma, Thailand), the ‘Golden Crescent’ 
(Afghanistan, Pakistan, Iran), and Mexico (Dormandy, 2012). Opium is collected 
from the capsules that remain following the flowering of the plant. To do this 
shallow incisions are made into the wall of the capsule after which a milky 
substance called latex oozes out and it is this that is collected as it contains the 
active opiate alkaloid compounds (Schiff, 2002).  
 
Opium resin, formed when the latex dries, contains a very complex chemical 
cocktail with inactive compounds and numerous active alkaloids, most notably 
morphine (8% - 17%), codeine (0.7% - 5%), noscapine (1% - 10%), papaverine 
(0.5% - 1.5%), and thebaine (0.1% - 2.5%) (Schiff, 2002). All of the latter, apart 
from thebaine, are or have been used for a long time medicinally as analgesics 
and to treat diarrhoea. Thebaine is now used as a precursor in the synthesis of 
several drugs including oxycodone, naloxone, naltrexone and buprenorphine 
(Pasternak, 2014a). In 1806 the German chemist Sertürner was the first to 
isolate the opium alkaloids, one of which he called morphine after Morpheus the 
Greek god of dreams (Schiff, 2002).  
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At this time the long-term consequences of opium use were becoming more 
noted as a public health issue due to the rapidly escalating use. Between 1825 
and 1850 imports to Britain grew from 23,300 to 138,000 kilos per year 
(Dormandy, 2012). This was the start of the search that is still ongoing today for 
a non-addictive alternative to opium and morphine that still provides analgesia 
for severe pain. In 1874, an English pharmacist called C.R. Alder Wright produced 
diacetylmorphine; at the time that this finding was published its importance was 
not recognised. However the German pharmaceutical company, Bayer, went on 
to successfully repeat this experiment in the late 1800’s and began to administer 
the compound first to animals and then people. They named the drug heroin 
(diamorphine) and it was marketed as a non-addictive and more powerful 
painkiller than morphine (Koob et al., 2014). The drug was very well received and 
sales swiftly increased. However, we now know that diamorphine is a prodrug 
that requires deacetylation to morphine to produce any significant effect (Way 
et al., 1960). It became increasingly apparent that while diamorphine was indeed 
a very potent analgesic, it was not free from the addictive side effects of 
morphine. Increasing public awareness of the problems associated with the use 
of these drugs and the associated morbidity and mortality led to the controls 
placed on their sale, distribution and use in the early twentieth century.  
 
Despite these controls there are ongoing issues with illicit drug use and 
escalating legal prescriptions for opioid containing drugs. In parallel to the 
increasing use of opioid containing drugs is the rise in drug related deaths. In 
2014 there were 613 deaths in Scotland related directly to drug use, this 
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represents a 16% rise on 2013 and a 72% rise since 2004 (Scotland, 2015).  While 
these are figures for Scotland a similar pattern has been observed both in 
England and the USA (Kuo et al., 2015, Weisberg et al., 2014). 
 
Opioid receptor agonists can be grouped into three categories, the first of these 
is the opiates, this group encompasses the opium alkaloids for example 
morphine, codeine and thebaine, the second is the opioids. This group includes 
the semi-synthetic opioids (for example diamorphine, oxycodone and etorphine) 
and the synthetic opioids methadone and fentanyl. The third group is that of the 
endogenous opioid peptides, these are peptides that are naturally occurring 
within the brain and the rest of the nervous system (Waldhoer et al., 2004). 
These and the rest of the opioid receptor agonists display differing degrees of 
selectivity for each of the opioid receptors (Table 1.1).  
 
MOP receptor agonists remain the drugs of choice for treating both acute and 
chronic severe pain, (Stein et al., 2000, Trescot et al., 2008). As these drugs 
remain our most effective agents for the treatment of severe pain there is a 
significant ongoing problem with the side effects that are produced by their use. 
Their clinical utility continues to be limited by the compromise between efficacy 
and side effects. Some of the commonly described side effects include 
constipation, urinary retention, bronchospasm, nausea, sedation, respiratory 
depression, hypotension, miosis and cough suppression (Rang et al., 2000).  
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As well as the effects described previously opioid drugs also produce analgesic 
tolerance. Tolerance is defined as the requirement for an increasing dose of drug 
to gain the same analgesic effect over time (Way et al., 1969, Ossipov et al., 
2004). They also cause physical dependence and can be addictive. Dependence is 
a physiological response to the chronic administration of opioid, it is observed in 
all subjects who are maintained on a chronic opioid regimen. In contrast 
addiction is defined in ICD-10 as “A cluster of behavioural, cognitive, and 
physiological phenomena that develops after repeated substance use” (WHO, 
2015). Within this definition is included the description of an overwhelming 
compulsion to take the drug involved, an inability to control the use of the drug 
despite this being detrimental to their life and relationships, a description of 
drug use that is placed to be more important than any other events or 
obligations within life and a tolerance to the pharmacological effects of the drug.  
 
It is now known that the opioid receptors have many different roles 
encompassing nociception, reward, respiration, cardiovascular function, bowel 
transit, consumption of food, learning and memory, locomotor activity, 
thermoregulation, hormone secretion and immune function (Rang et al., 2000). 
The fact that they are involved in so many varied pathways and behaviours 
suggests that this is a complex system with multiple different outcomes 
depending on the combination of signalling engaged. I will focus primarily on 
nociception, reward/ reinforcement and locomotor activity as the study of the 
effects of opioid drugs on these outcomes will provide useful information about 
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the signalling pathways involved in the development of the side effects of the 
drugs. 
 
 
Table 1.1: The differing selectivity’s of the endogenous and exogenous opioid receptor 
agonists.  
 
1.2 Opioid receptors 
Opioid receptors belong to a large superfamily of seven transmembrane 
spanning (7TM) G protein coupled receptors (GPCRs). This family of receptors is 
of fundamental physiological importance due to its role in mediating the actions 
of the majority of known neurotransmitters and hormones (Waldhoer et al., 
2004). They can be activated by both exogenously administered agents and 
endogenously produced compounds. There are three opioid receptors, the mu 
opioid (MOP) receptor, the delta (DOP) opioid receptor and the kappa (KOP) 
opioid receptor (nomenclature as per IUPHAR guidelines; (Cox et al., 2015). A 
MOP DOP KOP
Endogenous 
agonists
Beta-Endorphin
Met-Enkephalin
Leu-Enkephalin
Endomorphin
Dynorphin
+++
++
+
+++
++
+++
+++
+++
-
+
+++
-
-
-
+++
Exogenous 
agonists
Morphine
DAMGO
Fentanyl
Methadone
DPDPE
SNC-80
Deltorphin
Salvinorin A
+++
+++
+++
+++
-
-
-
-
+
-
+
-
++
++
++
-
+
-
-
-
-
-
-
+++
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fourth receptor has also been identified that shares sequence homology with the 
other opioid receptors, it was previously called the opioid receptor like (ORL-1) 
receptor but this has now been altered and it is called the nociceptin/orphanin 
(NOP) receptor (Mollereau et al., 1994, Cox et al., 2015). The endogenous ligand 
for this receptor was identified soon after its discovery (Meunier et al., 1995). 
Neither the endogenous or exogenous ligands at the MOP, DOP or KOP 
receptors  (Table 1.1) show significant binding activity through this receptor and 
I am therefore not going to discuss it further (Waldhoer et al., 2004). 
 
Opioid receptors belong to the class A (rhodopsin) family of Gi/Go protein 
coupled receptors. Classically upon activation of the receptor by agonist binding, 
a conformational change leads to coupling to these heterotrimeric pertussis 
toxin sensitive proteins (Law et al., 2000). Following receptor activation and 
recruitment of the G protein complex GDP associated with the Gα subunit is 
replaced for GTP and the G protein complex dissociates into Gα and Gβγ 
subunits. Both G protein components interact with multiple cellular effector 
systems including inhibition of adenylyl cyclase and voltage activated Ca2+ 
channels (VACCs), and activation of inwardly rectifying K+ channels (GIRKs) and 
phospholipase Cβ (Williams et al., 2001). The overall result is a decrease in 
neuronal cell excitability and a reduction in neurotransmitter release (Figure 
1.1). There is a high degree of G protein heterogeneity, with 16 gene products 
for Gα, 5 for Gβ and 11 for Gγ (Raehal and Bohn, 2011). This allows for multiple 
different subunit compositions and differing signalling outcomes. There is 
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evidence that opioid receptors can recruit alternative G proteins other than 
Gi/Go under certain conditions. 
 
Opioid receptor activation can also lead to the recruitment of beta-arrestin2 
(BAR2), a scaffolding protein that interacts with various signal transducers 
including c-Src, Akt, and MAP kinases (Pierce and Lefkowitz, 2001, Yano et al., 
2008) (Figure 1.1). BAR2 is recruited to the MOP receptor following 
phosphorylation by G protein receptor kinases (GRKs). Receptor phosphorylation 
can also occur through a number of different pathways including second 
messenger dependent protein kinases such as PKA and PKC (Ferguson, 2001). 
The BAR2 mediated pathway provides an alternative signalling mechanism that 
is thought to play a role in receptor desensitisation and endocytosis, in addition 
to the activation of alternative intracellular signalling pathways as mentioned 
previously. 
 
The development in the understanding of this alternative signalling pathway that 
occurs following agonist binding at the opioid receptor and at other 7TMR’s has 
led to the concept of biased agonism or functional selectivity. This concept 
describes the ability of a ligand to selectively recruit one signalling pathway over 
another to produce differing intracellular effects (Urban et al., 2007, Kelly et al., 
2008, Kenakin and Miller, 2010). 
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Figure 1.1: Opioid receptor signalling. The classical GPCR signalling pathway 
activates intracellular G proteins and leads to the inhibition of adenylyl cyclase, 
inhibition of VACCs, activation of GIRKs and an increase in inwardly rectifying K+ 
channels and activation of the MAPK/ ERK signalling pathway. However the MOP 
receptors can also recruit BAR2 following the binding of agonist leading to a number of 
different intracellular events. 
 
1.3 Constitutive activity 
Costa and Herz (1989) were the first to demonstrate agonist independent 
constitutive receptor activity in their pioneering study of DOP receptors in the 
NG108-15 cell line. This led to a change in the way that activation of GPCRs was 
conceptualised. The existence of spontaneously active receptors gave rise to the 
idea that agonists stabilise the active state by conformational selection rather 
than inducing activation as a consequence of binding. A number of investigators 
subsequently demonstrated spontaneous activity of MOP receptors in various 
cellular models. The level of constitutive activity of MOP receptors under normal 
circumstances is thought to be low but it can be demonstrated when the 
receptors are overexpressed (Burford et al., 2000) or altered by specific 
mutations (Brillet et al., 2003). The concept of constitutive receptor activity led 
α β
γ
MAPK/ERKCa2+cAMP
GTP BAR2
-
c-Src AKT
Cell response
K+
MOP
GRK
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to the designation of several ligands, previously considered antagonists, as 
inverse agonists. These are ligands that preferentially bind to, and stabilise, the 
inactive receptor conformation.  
 
Since the original report by Costa and Herz (1989), DOP receptor constitutive 
activity has also been demonstrated in a variety of different cell based models 
using inverse agonists (Chiu et al., 1996, Merkouris et al., 1997, Szekeres and 
Traynor, 1997). Inverse agonists are useful tools to investigate constitutive 
activity as when these drugs are added alone to the system they can produce a 
decrease in basal activity if there is constitutive activity and this action can be 
competitively inhibited by neutral competitive antagonists (Strange, 2002, Costa 
and Cotecchia, 2005). The drugs naloxone and naltrexone, long thought to be 
antagonists are now known to be MOP receptor inverse agonists (Bilsky et al., 
2010, Liu and Prather, 2001, Liu et al., 2001), while 6α-naloxol, 6β-naloxol and 
6β-naltrexol (hydroxyl derivatives of naloxone and naltrexone respectively) are 
neutral competitive antagonists (Wang et al., 2001, Wang et al., 2004, Raehal et 
al., 2005, Sadee et al., 2005). 
  
Long term exposure to opioid drugs such as morphine can produce an increase in 
constitutive activity in both cell based systems (Wang et al., 2001, Burford et al., 
2000), and in the striatum of morphine dependent mice (Wang et al., 2004).  
Mice that have been chronically treated with morphine also exhibit an increase 
in naloxone mediated conditioned place aversion and withdrawal behaviour, not 
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seen with administration of the neutral MOP receptor antagonists (Shoblock and 
Maidment, 2006). In DRG neurones from BAR2-/- mice it has been demonstrated 
that there is increased MOP receptor constitutive activity (Walwyn et al., 2007). 
These animals also demonstrate basal analgesia, this phenomenon appears to be 
the result of MOP receptor constitutive activity within the pain pathway because 
it is inhibited by inverse agonists but not neutral antagonists (Lam et al., 2011). 
This suggests that constitutive activity may be involved in opioid dependence 
and withdrawal. BAR2 appears to regulate constitutive activity of MOP receptors 
as its removal from the system results in basal analgesia and increased MOP 
receptor activity. Constitutive MOP receptor activity is also upregulated in the 
pain pathway during persistent hyperalgesia induced by injection of complete 
Freund’s adjuvant into the mouse paw (Corder et al., 2013). Mechanical 
hyperalgesia declines within 7 days and can be reinstated by administration of 
inverse agonists but not neutral MOP receptor antagonists. 
 
1.4 The endogenous opioid system 
Opioid binding sites were first proposed in the early 1950’s (Beckett and Casy, 
1954), and they were discovered in mammalian tissue in 1973 by Pert and 
Snyder, at which time they identified binding sites in the brain and intestine for 
the opioid antagonist naloxone (Pert and Snyder, 1973). In 1975 Hans Kosterlitz 
at the University of Aberdeen extracted the endogenous opioid met-enkephalin 
from pig brain. This compound inhibited contractions in guinea pig ileum 
(Hughes et al., 1975), an effect that was later shown to be blocked by naloxone.  
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The endogenous opioid system is now known to be involved in the regulation of 
a number of different processes. It is thought to be responsible for setting pain 
threshold (nociception) and controlling nociceptive processing. It is also thought 
to participate in the modulation of gastrointestinal, endocrine and autonomic 
function and cognitive function (McDonald and Lambert, 2005). There are three 
genes encoding the endogenous opioid peptides that have been identified, they 
are pro-opiomelanocorntin (POMC), proenkephalin (Penk) and prodynorphin 
(Pdyn) (Trigo et al., 2010).  Most of these peptides have some activity at each of 
the three opioid receptors (Table 1.1). The endogenous peptides that exhibit 
increased selectivity for DOP receptors are met-enkephalin and leu-enkephalin, 
these peptides are encoded by proenkephalin and were the first to be identified 
(Hughes et al., 1975). Prodynorphin encodes the endogenous opioid peptides 
with an increased selectivity for KOP receptors, dynorphin A and B. Pro-
opiomelanocortin encodes beta endorphin, this peptide does not appear to be 
selective and exhibits agonist activity at all three of the opioid receptors. 
Endomorphin 1 and 2 have been identified as endogenous peptides at MOP 
receptors however, the precursor protein and the gene that encodes them 
remains unknown (Zadina et al., 1997, Pasternak and Pan, 2013).  
 
Genetic manipulation of the production of these peptides has allowed the study 
of their role in hedonic homeostasis. Following the generation of mice lacking 
beta-endorphin (Bend-/-) by manipulation of exon 3 of the POMC gene 
(Rubinstein et al., 1996), Penk-/- mice (Konig et al., 1996, Ragnauth et al., 2001) 
and Pdyn-/- mice (Sharifi et al., 2001, Zimmer et al., 2001) numerous studies 
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have been performed. These have investigated the effects of these 
manipulations on natural reward and pharmacological agents that produce 
reward. Stress induced analgesia produced by the forced swim test is not 
present in the Bend-/- mice but is still present in the Penk-/- mice (Rubinstein et 
al., 1996, Konig et al., 1996). Naloxone administration can reduce the 
consumption of food and decrease the response rate to a normally reinforcing 
food reward suggesting a role for the opioid system; further supporting this is 
the fact that this behaviour is altered in both the Bend-/- and Penk-/- mice 
(Hayward et al., 2002, Hayward et al., 2004). When the aversive properties of 
naloxone are studied, Bend-/- mice find naloxone aversive but Penk mice do not 
suggesting that naloxone is aversive to WT mice due to the presence of 
endogenous enkephalin (Skoubis et al., 2005, Shoblock and Maidment, 2007). Of 
interest is the observation that morphine conditioned place preference (CPP) is 
unchanged in both the Bend-/- and mice that have a double knockout for Bend-
/-//Penk-/- expression when compared to WT mice, so opioid mediated 
reinforcement is not altered in the absence of these peptides (Skoubis et al., 
2005).  It appears that endogenous enkephalin may be involved in the normal 
hedonic state but that beta-endorphin and the dynorphins are important in 
stressful situations (Le Merrer et al., 2009). 
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1.5 The genetic manipulation of the opioid receptor system 
In the early 1990’s genes encoding MOP, DOP and KOP receptors were identified 
(termed Oprm1, Oprd1 and Oprk1, respectively). The first of the receptor genes 
to be cloned was for DOP receptors (Evans et al., 1992, Kieffer et al., 1992), 
clones of genes encoding MOP receptors (Chen et al., 1993, Thompson et al., 
1993, Wang et al., 1993), and the genes encoding KOP receptors (Meng et al., 
1993, Minami et al., 1993, Kong et al., 1994), followed shortly thereafter.  
 
There is a high degree of structural similarity across all three of the opioid 
receptors. They have three intracellular and three extracellular loops and all 
contain an intracellular C-terminus and an extracellular N-terminus (Allouche et 
al., 2014).  The three opioid receptors (MOP, DOP and KOP) show a 60 - 70% 
sequence identity (Pasternak and Pan, 2013). The structural similarity of the 
receptors is highest in the intracellular loops which are involved in the 
interactions with intracellular G proteins and lowest in the extracellular loops 
that participate in ligand binding. The N-terminal region contains potential 
glycosylation sites that are thought to be important in DOP receptor maturation 
and trafficking to the cell membrane (Petäjä-Repo et al., 2000). In contrast 
glycosylation of this region of MOP receptors does not appear to affect function 
(Befort et al., 2001). 
 
There are three known opioid receptor genes but alternative splicing is thought 
to explain the observed variety of pharmacological receptor phenotypes 
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(Pasternak, 2014b). Shortly after the cloning of these genes they were deleted 
from the genome of mice using the technique of homologous recombination. 
This has enabled the development of mouse lines that have had individual or 
combinations of the opioid receptors knocked out.  
 
1.6 MOP knockout mice 
There have been several MOP receptor knockout mice created. These models 
have targeted different exons of the gene. Targeted deletion of Exon 1 (Sora et 
al., 1997, Tian et al., 1997, Schuller et al., 1999), of the Oprm1 gene produces a 
mouse that exhibits no signs of morphine analgesia compared to WT but in 
which the efficacy of diamorphine and morphine-6-glucuronide analgesia 
remains intact (Schuller et al., 1999). These mice also exhibit impaired sexual 
function and alterations in haematopoiesis (Tian et al., 1997). In contrast mice 
that have either or both Exon 2 and 3 targeted are healthy with no apparent 
detrimental effects on sexual health or immunity (Matthes et al., 1996, Loh et 
al., 1998). These mice gain no analgesia or reward from morphine (Matthes et 
al., 1996) and also demonstrate that MOP receptors are required for the 
immunosuppressive effects of morphine (Gavériaux-Ruff et al., 1998). These 
mice also exhibit no reward or locomotor activation following the administration 
of diamorphine (Contarino et al., 2002). There have been conflicting accounts of 
alterations in basal sensitivity to noxious heat in MOP-/- mice. An increased 
sensitivity to noxious heat was noted in the mice with a deletion of Exon 1 (Sora 
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et al., 1997) but no significant difference was reported in the Exon 2 deletion 
mice (Matthes et al., 1996). 
 
Morphine CPP and self-administration are abolished in MOP receptor knockout 
mice (Becker et al., 2000). It is interesting to note that in these mice ethanol self-
administration is abolished (Roberts et al., 2000, Becker et al., 2002), and 
preference for nicotine (Berrendero et al., 2002) and delta9-
tetrahydrocannabinol (THC) (Ghozland et al., 2002) are also abolished. These 
data suggest a role for the MOP receptors in the rewarding and reinforcing 
effects of drugs other than opioids. Behaviourally these mice also exhibit a 
number of other traits including decreased impulsivity (Olmstead et al., 2009), a 
decreased motivation to eat (Papaleo et al., 2007), decreased food anticipatory 
behaviour (Kas et al., 2004) and decreased maternal attachment (Moles et al., 
2004). 
 
No compensatory changes to DOP or KOP opioid receptor expression have been 
identified in MOP-/- mice (Kitchen et al., 1997) and while a partial reduction in 
DOP receptor response to selective agonists was identified there was no 
significant alteration in KOP receptor response to selective agonist in MOP-/- 
mouse model (Matthes et al., 1998). Supporting this finding is the report that 
the analgesic efficacy of DOP receptor agonists may be decreased in these mice 
(Fuchs et al., 1999). 
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1.7 DOP receptor knockout mice 
Mice lacking DOP receptors were produced by disruption of either Exon 2 of the 
Oprd1 gene (Zhu et al., 1999) or Exon 1 (Filliol et al., 2000). There have been no 
detectable effects on the health or reproduction of these mice by removing DOP 
receptors. In radioligand binding studies the binding of [3H]DPDPE and 
[3H]deltorphin were completely abolished from brain tissue (Zhu et al., 1999). 
There have been no identifiable compensatory changes in the receptor 
expression levels of either MOP or KOP receptors in these mice (Zhu et al., 
1999). 
 
Behaviourally DOP knockout mice exhibit increased anxiety and depressive like 
behaviour (Filliol et al., 2000) and increased ethanol self-administration (Roberts 
et al., 2001). The increased ethanol consumption that these mice display appears 
to alleviate anxiety caused by DOP receptor gene deletion. There have been 
differing reports of morphine reinforcement in these mice, with it being 
reported as decreased (Chefer and Shippenberg, 2009) and unchanged (Le 
Merrer et al., 2012). However, morphine self-administration, which is a more 
direct measure of the rewarding properties of a drug, is unchanged (Lutz and 
Kieffer, 2013). Therefore the role of DOP receptors in morphine preference and 
reward remains unclear. 
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1.8 KOP receptor knockout mice 
One genetic knockout mouse model that targets KOP receptors has been 
developed. This KOP-/- mouse was produced by target deletion of exon 1 of the 
KOP receptor gene Oprk1 (Simonin et al., 1998). These mice exhibit no 
alterations in the analgesia that they receive from morphine when tested using 
either the tail withdrawal assay or the hot plate test suggesting that the KOP 
receptor is not involved in this response. The mice also display no significant 
difference in morphine preference (tested using a CPP paradigm), locomotor 
alteration or anxiety when compared to WT mice (Simonin et al., 1998). 
 
1.9 Structural models of the opioid receptors 
Structural models of MOP, DOP and KOP receptors were published in 2012 
(Manglik et al., 2012, Granier et al., 2012, Wu et al., 2012), respectively. Further 
structural models for DOP receptors (Fenalti et al., 2014) and MOP receptors 
(Huang et al., 2015) in association with agonists have recently been published. 
 
These structural models have provided evidence that opioid receptors can form 
dimers particularly in the case of MOP receptors (Manglik et al., 2012). This 
could be an artefact of crystallisation, but there is other experimental evidence 
supporting receptor oligomerisation. Cvejic and Devi (1997) first demonstrated 
opioid receptor dimerization in early work on recombinant epitope-tagged DOP 
receptors using cross linking and immunoprecipitation. Shortly thereafter, using 
similar approaches, Jordan and Devi showed that DOP receptors can also 
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heterodimerise with KOP receptors (Jordan and Devi, 1999). George and 
colleagues were the first to demonstrate dimerization of recombinant MOP and 
DOP receptors (George et al., 2000). Since then there have been numerous 
reports of MOP receptors combining with a variety of other GPCRs (Fujita et al., 
2014). There is limited evidence for functional properties of MOP/DOP dimers 
distinct from those of MOP or DOP expressed alone. Their combined expression 
in GH3 cells led to an elevation of intracellular Ca2+ when the MOP selective 
agonist DAMGO was applied (Charles et al., 2003, Charles and Hales, 2004). 
Signalling by putative MOP/DOP dimers was also resistant to pertussis toxin, 
which inhibits Gi/o mediated processes, implicating an alternative pathway to 
that of MOP and DOP receptors when expressed alone (George et al., 2000). 
However, all of this work was done with recombinant receptors expressed in cell 
lines. A role for heterodimers or, perhaps, larger hetero-oligomeric complexes in 
vivo is less well established. In DRG and brainstem neurones that have been 
chronically exposed to morphine there is a demonstrable increase in MOP/DOP 
heterodimers revealed by antibody staining (Gupta et al., 2010). An antibody 
selective for the MOP/DOP receptor interface was used in this study. This reveals 
the importance of MOP/ DOP heterodimers in nociceptive signalling both at the 
spinal level and within brainstem centres involved in regulating descending 
inhibitory pathways. A peptide that mimics the first transmembrane domain of 
the MOP receptor, when coupled to the TAT peptide, can cross cell membranes 
and disrupts MOP/DOP association (He et al., 2011). This approach was used to 
explore the requirement for MOP/DOP interactions in morphine analgesia. The 
peptide reduced morphine analgesic tolerance suggesting that MOP/DOP 
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receptors exist in the pain pathway where they mediated analgesic responses to 
morphine. A requirement for DOP receptor expression in DRG neurones for full 
function on MOP receptor agonists, including morphine also implies the 
existence of MOP/DOP receptors in the pain pathway (Walwyn et al., 2009).  
 
There is also evidence for a role of MOP/DOP dimers in BAR2 recruitment. 
Studies have demonstrated that both MOP and DOP receptors need to be 
present to co-localise with BAR2 within the cell membrane in the absence of 
agonist application (Rozenfeld and Devi, 2007).  
 
1.10 The arrestin system 
As mentioned above, activation of many GPCRs including the opioid receptors 
leads to the recruitment of BAR1 and/or 2, this process has been implicated in 
signalling, receptor desensitisation and trafficking (Reiter and Lefkowitz, 2006). 
Agonist binding at the receptor also initiates GRK mediated phosphorylation and 
this leads to inhibition of G protein receptor coupling (Shenoy and Lefkowitz, 
2003). The arrestin family consists of four members. Arrestin 1 and 4 are found 
to be located in the retinal rods and cones and arrestin 2 and 3 (also called β-
arrestin1 and 2) which are ubiquitously expressed. The two BARs share a high 
sequence homology with each other and also with visual arrestin (arrestin-1). In 
vitro they act to desensitise GPCR’s by physically preventing the interaction of 
the phosphorylated receptor and the heterotrimeric G-protein (Pierce and 
23 
 
Lefkowitz, 2001, DeWire et al., 2007). As well as this role in the silencing of 
GPCRs they are also implicated in receptor trafficking and intracellular signalling. 
 
The GRK family consists of seven different genes, GRK 1 and 7 have a restricted 
distribution being found only in the retinal rods and cones respectively, where 
they form the GRK1 subfamily. GRK4 also exhibits a restricted distribution 
pattern, it has been found in the testis, cerebellum and kidney and comprises 
the GRK2 subfamily. The remaining GRKs (2, 3, 5 and 6) are all ubiquitously 
expressed and comprise the GRK4 subfamily (Watari et al., 2014, Reiter and 
Lefkowitz, 2006). 
 
Various studies have investigated the roles of GRK2, 3, 5 and 6 both in vitro and 
in vivo. The GRK2 knock out is embryonically lethal due to the ubiquitous nature 
of this protein, however cellular studies and in vitro studies utilising targeted 
siRNA knockdown have suggested that both GRK2 and GRK3 are involved in 
opioid receptor phosphorylation, BAR recruitment and functional uncoupling 
(Whistler and von Zastrow, 1998, Bohn et al., 2004). They have also been 
implicated in receptor endocytosis (Kim et al., 2008). GRK3 knock out mice 
exhibit a reduction in tolerance in response to fentanyl administration compared 
to WT mice but morphine induced tolerance is not altered (Terman et al., 2004, 
Kuhar et al., 2015). GRK6 is highly expressed in brain and gastrointestinal cells, in 
vitro it regulates MOP receptors by enhancing the recruitment of BAR2 and 
receptor internalisation. In vivo no difference in morphine induced tolerance 
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could be identified in GRK6 knockout mice but locomotor activation and 
sensitisation was altered and morphine was less constipating in these mice 
(Raehal et al., 2009). GRK5 knockout mice exhibit reduced analgesia from 
morphine but not fentanyl with no differences identified in acute morphine 
tolerance when compared to WT mice. However these mice do exhibit 
significantly reduced preference for morphine tested using a conditioned place 
preference (CPP) paradigm (Gluck et al., 2014). All of these results reveal the 
importance of opioid receptor phosphorylation in the subsequent cellular 
response to agonist. 
 
Studies of GPCR phosphorylation by GRKs have led to the development of the 
barcode hypothesis (Butcher et al., 2011). This suggests that the specific 
phosphorylation pattern created by an agonist following binding to the receptor 
influences the downstream effects that are produced (Reiter et al., 2012). In 
addition to the role of BARs in receptor desensitisation and trafficking these 
proteins can also participate in signalling by recruiting various kinases to GPCRs. 
These include non-receptor tyrosine kinases such as the proto-oncogene Src (c-
Src), other members of the c-Src family (Hck, Fgr, and Yes), c-Jun amino terminal 
kinase (JNK), ERK1 and 2, mitogen activated protein kinase (MAPK), Raf, MEK and 
Akt (Reiter and Lefkowitz, 2006). 
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1.11 Beta-arrestin2 knockout mice 
Mice lacking β-arrestin1 (BAR1-/-) and BAR2-/- have been generated and 
characterised, (Schmid and Bohn, 2009). The double knock out of both BAR1 and 
2 is embryonically lethal (Pierce and Lefkowitz, 2001). BAR2-/- mice appear 
phenotypically normal but develop negligible tolerance to opioid analgesia (Bohn 
et al., 1999, Bohn et al., 2000, Bohn et al., 2002). In addition the mouse’s 
endogenous opioid pain killing mechanism becomes persistently active without 
the requirement for drug administration. This occurs with no evidence of the 
hedonic effects typically associated with opioid drug taking (Lam et al., 2011). 
The persistent analgesia is inhibited by naloxone and naltrexone (both inverse 
agonists), but not by neutral competitive antagonists (Hayward et al., 2004). It is 
also associated with constitutive MOP receptor coupling to VACCs in primary 
afferent neurones from BAR2-/- mice, a phenomenon that can be reproduced in 
WT neurones by directly inhibiting c-Src activity implicating tyrosine kinase-
mediated phosphorylation in this process (Walwyn et al., 2007).  
 
The BAR2-/- mice still exhibit physical dependence following morphine 
administration and this has been reported as both not significantly different to 
that observed in WT mice (Bohn et al., 2000) and decreased when compared to 
WT mice (Raehal and Bohn, 2011). However it has also been reported that these 
mice exhibit an increased preference for morphine when tested using a CPP 
paradigm (Bohn et al., 2003). Consistent with this observation is the report that 
morphine stimulated striatal extracellular dopamine levels are also increased in 
the BAR2-/- mice when compared to WT mice without any differences in the 
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baseline levels (Bohn et al., 2003). As well as the reduction in morphine 
tolerance that has been recorded in these mice there is also a reduction in 
several other morphine induced side effects including locomotor activation, 
respiratory depression and constipation (Raehal et al., 2005) implicating BAR2 in 
these effects.  
 
1.12 Pain and nociception 
The International Association for the Study of Pain (IASP) defines pain as “an 
unpleasant sensory and emotional experience associated with actual or potential 
tissue damage, or described in terms of such damage”(IASP, 2014). The 
emotional aspects of pain, which may be affected by opioid administration, are 
challenging to study in animal models. Despite this limitation there are a number 
of well validated tests of nociception in rodents that are available. These 
encompass a number of different nociceptive mechanisms including mechanical, 
thermal, chemical and inflammatory pain models. Models of thermal nociception 
include the tail withdrawal assay using either radiant heat or hot water and the 
hot plate test. The latency for tail withdrawal is straightforward to study and 
provides a quantification of pain perception (nociceptive pain). 
 
Both the hot plate test (Woolfe and MacDonald, 1944) and the tail withdrawal 
assay (D'Amour and Smith, 1941) involve exposing the rodent to a noxious 
thermal stimulus with a maximum exposure time to avoid tissue damage 
occurring. There are several different methods that have been described for the 
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tail withdrawal assay, some utilise radiant heat targeted to a specific area of the 
tail and others immersion of the tail in hot water. To investigate nociception the 
method that we have chosen to utilise is tail withdrawal from hot water 
following immersion, this is a modification of D’Amour and Smith’s method 
(1941). The tail withdrawal assay is a simple and reproducible test that is highly 
responsive to opioid drugs (Wilson and Mogil, 2001, Barrot, 2012), but it does 
require restraint of the mouse which can cause a stress response. This stress 
response can manifest itself as measurable analgesia in the absence of 
exogenous drug (Butler and Finn, 2009). However, the advantage of this version 
of the test is that due to the significant surface area of the tail that is exposed to 
the hot water there is a rapid increase in the temperature of the tail and a 
reproducible spinal reflex response (Le Bars et al., 2001).  
 
The tail flick reflex is a spinal reflex that is generally regarded to respond to 
spinal analgesia (Kieffer, 1999) although it is influenced by some descending 
supraspinal inputs (Irwin et al., 1951, Barton et al., 1980). This is in contrast to 
the hotplate test that is subject to a variety of supraspinal influences and 
requires the integration of a number of varying system inputs (Pasternak and 
Pan, 2013).  
 
To assess nociception from mechanical stimuli Von Frey filaments can be used 
(Gregory et al., 2013). These filaments come in different sizes to produce a 
graded increase in pressure.  The filaments are particularly useful for studying 
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mechanical allodynia. This is when a normally non-noxious stimulus results in 
pain. In rodents this results in paw withdrawal at a level of pressure that would 
not have previously produced this effect (Barrot, 2012). To study the response to 
electrical stimulation a technique called electrical threshold testing can be 
performed, however this is an unnatural non-specific stimulus and is therefore 
generally only used for baseline testing of animals involved in studies that use 
footshock techniques as part of the study protocol (Mogil, 2009). The response 
to noxious chemical stimuli can be investigated using a variety of different 
agents. These include the formalin paw injection, this process can also be used 
to model inflammatory pain. Other chemical agents that are commonly used to 
model inflammatory pain include the carrageenans and complete Freund’s 
adjuvant (CFA). These agents are used more commonly as they produce a longer 
lasting inflammatory response when compared to formalin, this longer lasting 
response is due to their ability to produce immune activation (Barrot, 2012). 
Other animal models to study pain include models of neuropathic pain such as 
complete nerve transection which results in self-mutilation behaviour and 
chronic nerve constriction. Both of these models require the animal to undergo 
surgery, the most common nerve that is targeted for chronic nerve constriction 
is the sciatic nerve (Mogil, 2009, Barrot, 2012). Many of the tests that are 
currently used in pain studies measure spinal withdrawal reflexes, spino-bulbo 
spinal reflexes (such as jumping behaviour) or general behaviour such as 
vocalisation, licking or guarding.  
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Opioid analgesia is mediated within both the central and peripheral nervous 
system (Van Ree et al., 1999). Nociceptive stimuli are detected by a collection of 
peripheral nerve fibres termed nociceptors. Their cell bodies are located within 
the dorsal root ganglia (DRG) of the spinal cord. The inhibition of presynaptic 
VACCs within the DRGs is thought to give rise to the opioid-mediated reduction 
of excitatory neurotransmission in the pain pathway (Heinke et al., 2011). There 
may also be a role for neuronal hyperpolarisation through activation of the 
inwardly rectifying K+ channel (Luscher and Slesinger, 2010). Yaksh and Rudy 
(1976) were the first investigators to demonstrate that morphine has direct 
analgesic effects on the spinal cord, by administering the drug intrathecally and 
subsequently testing nociceptive responses. 
 
We now know that MOP, DOP and KOP receptors are all located in a high density 
within the superficial layers (lamina I and II) of the spinal cord with lower levels 
found in the deeper lamina. In the dorsal horn of the spinal cord MOP receptors 
account for 70% of the opioid receptors present with a small amount of DOP 
receptors (24%) and an even smaller proportion of KOP receptors (6%) (Davis 
and Pasternak, 2009). The opioid receptors have been identified at both pre and 
post synaptic sites within the dorsal horn of the spinal cord (Besse et al., 1990). 
As well as directly inhibiting receptors within the DRG neurones, morphine also 
activates descending inhibitory pathways that run from the brainstem to the 
DRG neurones and act to inhibit the activity of the nociceptive pathway 
(Basbaum and Fields, 1984). 
30 
 
A study by Corder (Corder et al., 2013) that used CFA administration to the hind 
paws of mice demonstrated that constitutively active MOP receptor activity 
limits the duration of inflammatory hyperalgesia. In this study they could 
reinstate hyperalgesia by the administration of inverse agonists such as 
naltrexone but not in the presence of neutral receptor antagonists suggesting 
the presence of constitutive activity of the MOP receptor. 
 
1.13 Genetic influences on rodent nociceptive responses 
It has been noted that there are significant strain differences in response to 
nociceptive testing between different commonly used laboratory mouse strains 
suggesting that genetic variation can significantly affect pain behaviour (Mogil et 
al., 1999, Leo et al., 2008).  Gender differences in the response of rodents to 
opioid drugs have also been reported. In male rats an increased analgesic effect 
of morphine has been noted using both the hot plate and the tail withdrawal 
assays, suggesting that this gender difference affects both spinal and supraspinal 
mechanisms (Cicero et al., 1996). In contrast no gender differences were noted 
in the baseline sensitivity of mice to morphine but female mice exhibited a 
greater degree of tolerance to the analgesic effects of morphine following 
chronic administration and testing using the tail withdrawal assay (Kest et al., 
2000). These differences may reflect a combination of species and genetic 
differences as studies investigating the analgesic effects of morphine over a wide 
range of laboratory mice with different genetic backgrounds have identified that 
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the observed sex differences are genotype dependent (Chesler et al., 2002, Kest 
et al., 1999, Kest et al., 2002). 
 
There are also conflicting results regarding gender differences in tail withdrawal 
time from hot water, with a reported increase in baseline tail withdrawal time in 
male C57Bl/6 mice compared to females (Kest et al., 1999) but a subsequent 
study was not able to identify a gender difference using the same strain of mice 
and the identical nociceptive test (Kieffer et al., 1992). While there may be 
gender differences present it is apparent that they are not easy to identify and 
may well be multifactorial. The majority of animal studies that have been 
published to date have only included male rodents which also limit the 
conclusions that can be drawn at the present time. 
 
1.14 Tolerance 
Tolerance to opioid drugs requires escalating doses to gain the equivalent 
analgesic effect. This is a significant clinical problem limiting the use of analgesic 
opioids in clinical practice (Nestler, 1992, Koob et al., 1998, Williams et al., 
2013). Tolerance develops to the opioid drug side effects at differing rates, 
meaning that analgesia may not be adequate due to a reduction in analgesic 
potency but at the time the drug may be producing respiratory depression that 
limits the dose that can be safely administered, it is also often specific to the 
administered opioid allowing improved analgesia with a switch to an alternative 
compound (Pasternak and Pan, 2013). Caution is required in this approach due 
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to the possibility of overdose. Although conversion tables for opioid switching 
exist and are useful, they provide a direct dose equivalent without allowing for 
the increased potency of the new drug. The new opioid prescription therefore 
requires to be of a significantly lower dose than the calculated equipotent 
amount of the existing drug (Mercadante and Bruera, 2006). The degree to 
which this occurs is not clear at the present time. 
 
Tolerance to opioid analgesics develops on several different levels. It can be 
measured at a cellular, synaptic or network/whole animal level. It is currently 
unclear how changes at the cellular and synaptic level contribute to whole 
system tolerance but understanding the changes that occur at this level will 
allow the integration of knowledge of events over the larger pathways involved. 
With regards to the cellular mechanisms that have been linked to opioid 
analgesic tolerance, receptor desensitisation, receptor endocytosis, up 
regulation of adenylyl cyclase and CREB (cAMP response element binding 
protein) activation have all been investigated (Sim-Selley et al., 2000, Williams et 
al., 2001, Connor et al., 2004, Christie, 2008, Williams et al., 2013).  
 
Receptor desensitisation is thought to involve a reduction coupling of the MOP 
receptor to the intracellular G protein mediated signalling pathways (Williams et 
al., 2013). The extent to which this uncoupling occurs appears to vary across 
different neuronal populations within the CNS of rats treated with chronic opioid 
when binding studies are performed (Sim-Selley et al., 2000). The binding of 
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BAR2 to MOP receptors following receptor phosphorylation by GRK is thought to 
be involved in receptor desensitisation. This process is also implicated in the 
beginning of the receptor internalisation pathway as MOP receptor endocytosis 
is thought to occur through a BAR2/ dynamin dependent mechanism (Connor et 
al., 2004).  However MOP receptors can still desensitise in the absence of BAR2 
(Walwyn et al., 2007, Dang et al., 2011) suggesting that this is not the sole 
mechanism by which this occurs.  
 
Following internalisation the receptors can be targeted for lysosomal 
degradation or recycling back to the cell membrane. Internalisation of the 
receptors is not required for desensitisation (Williams et al., 2001). Morphine 
produces less receptor internalisation compared to other MOP receptor agonists 
suggesting that it may be receptor desensitisation that has a larger role in the 
development of drug tolerance (Williams et al., 2001, Christie, 2008, Williams et 
al., 2013). 
 
While one of the accepted end-points of classical GPCR signalling is a reduction 
in cAMP through inhibition of adenylyl cyclase, it is well documented that 
following continuous exposure of MOP receptors to agonist there is a point at 
which a switch to increased cAMP levels occurs (Christie, 2008). This 
compensatory increase in adenylyl cyclase activity has been suggested to be the 
underlying mechanism that results in tolerance and dependence (Koob and 
Bloom, 1988). It is thought that the phosphorylation of adenylyl cyclase and GRK 
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2/3 by protein kinases may be involved in the observed increase in adenylyl 
cyclase activity (Zhang et al., 2013). 
 
CREB is a cellular transcription factor that can up or down regulate gene 
transcription. Activation of the MAPK/ERK pathway following agonist binding to 
MOP receptors can result in the phosphorylation of CREB within the cellular 
nucleus and subsequent alteration in gene transcription (Williams et al., 2001). It 
does not appear to be MOP receptors that are affected directly by this process 
as MOP receptor mRNA levels have not been found to be significantly different 
following treatment with chronic opioid (Christie, 2008). However it can also 
affect the transcription of multiple other receptor systems, adenylyl cyclase and 
a number of other signalling proteins (Carlezon et al., 2005). 
 
1.15 The RAVE hypothesis 
One theory as to why some opioid drugs produce much greater tolerance than 
others is the RAVE (Relative Activity Versus Endocytosis) theory (Whistler et al., 
1999). The ability of MOP receptor agonists to promote endocytosis does not 
correlate with their potency or efficacy as activators of the receptor. For 
example morphine, which effectively triggers G protein signalling, is poor at 
initiating receptor endocytosis (Keith et al., 1996, Keith et al., 1998, Whistler and 
von Zastrow, 1998). This is in contrast to the selective MOP receptor agonist 
DAMGO (an encephalin analogue) that produces marked receptor endocytosis 
with a similar ability to trigger G protein mediated signalling. Morphine is 
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therefore said to have a high RAVE value when compared to DAMGO (Whistler 
et al., 1999). Following exposure to morphine MOP receptors remain within the 
cell membrane where they undergo phosphorylation and desensitisation, in 
contrast exposure to DAMGO produces rapid endocytosis which is thought to 
allow resensitisation of the receptor and its return to the cell membrane 
(Mollereau et al., 1994). It is the prolonged receptor activation that has been 
suggested to be responsible for analgesic tolerance with cAMP super-activation 
being a cellular marker of this phenomenon (Finn and Whistler, 2001, Williams et 
al., 2001).  
 
There are several studies that have co-administered a second opioid drug (that 
has a lower RAVE value) alongside morphine at a sub-analgesic dose. When 
DAMGO was administered alongside morphine to rats a reduction in analgesic 
tolerance was observed compared to the measured effects of morphine alone 
(He et al., 2002). Also when methadone was co-administered to rats at a sub-
analgesic dose then the development of acute tolerance was reduced in these 
animals compared to those treated with morphine alone (He and Whistler, 
2005). These observations are of particular interest as they suggest that the 
presence of a second drug at MOP receptors can enable recovery from morphine 
induced tolerance. This implies that endocytosis is required for recovery of MOP 
receptor function.  
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1.16 Opioid receptor desensitisation in tolerance 
An alternative theory as to the mechanism of drug tolerance involves receptor 
desensitisation rather than internalisation. Receptor desensitisation can occur 
through several different mechanisms, two of these have been described. The 
first is GRK mediated receptor phosphorylation that leads to the recruitment of 
the BARs and the second involves phosphorylation of the receptor by second 
messenger dependent protein kinases such as PKA, PKC and calcium/ calmodulin 
dependent kinase II (Ferguson, 2001, Bailey and Connor, 2005). There have been 
at least 20 phosphorylation sites identified on MOP receptors (Chavkin et al., 
2001), these generally involve serine, tyrosine and threonine sites within the 
COOH tail of the receptor (Zhang et al., 2009).  
 
Although early work suggested that morphine did not produce receptor 
desensitisation (Alvarez et al., 2002), several investigators have now 
demonstrated that morphine can produce desensitisation although to a lesser 
extent than other agonists at the receptor (Bailey et al., 2003, Bailey, 2004, Dang 
and Williams, 2005, Johnson et al., 2006, Bailey et al., 2009a). Its ability to do so 
appears to vary among tissue/ cell types. The mechanism by which MOP 
receptor desensitisation occurs appears to be dependent on the agonist that 
binds to the receptor possibly due to phosphorylation of the receptor at 
different binding sites. The binding sites that are available may depend on the 
conformational changes in receptor structure produced by the binding of 
different agonists. It has been suggested that desensitisation occurs via a PKC 
dependent mechanism following morphine binding (Bailey, 2004, Bailey et al., 
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2009b, Johnson et al., 2006), and a GRK dependent mechanism following 
exposure to DAMGO (Johnson et al., 2006, Bailey et al., 2009b). This is important 
as PKC inhibition has been demonstrated to reduce morphine tolerance (Gabra 
et al., 2007, Hull et al., 2010), and BAR2-/- mice develop less tolerance to 
morphine (Bohn et al., 1999, Bohn et al., 2000, Bohn et al., 2002, Raehal et al., 
2005). GRK inhibition alters tolerance to DAMGO and fentanyl but does not 
affect morphine tolerance to the same extent (Terman et al., 2004, Hull et al., 
2010). Receptor internalisation does not correlate with desensitisation 
suggesting that these events are independent of each other and therefore that 
the RAVE hypothesis does not fully explain the mechanism of tolerance (Bailey 
and Connor, 2005).  
 
1.17 The role of DOP receptors and BAR2 in tolerance 
There is evidence to suggest that DOP receptors and BAR2 play important roles 
in both analgesia to morphine and in the development of tolerance to analgesic 
effects of the drug. When either MOP or DOP receptors are expressed alone in 
the cell membrane they are not co-localised with BAR2 but when they are 
expressed together they do. This suggests that both MOP and DOP receptors are 
required for the recruitment of BAR2 at the cell membrane and the subsequent 
activation of BAR2 mediated intracellular signalling (Rozenfeld and Devi, 2007). It 
is thought that DOP receptors are not required for morphine-mediated 
analgesia, but their absence leads to blunted morphine analgesic tolerance (Zhu 
et al., 1999). As previously mentioned it has been reported that the BAR2-/- mice 
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exhibit basal analgesia and also significantly reduced morphine tolerance 
compared to WT (Bohn et al., 1999, Bohn et al., 2000, Bohn et al., 2002, Raehal 
et al., 2005). These data implicate both BAR2 and DOP receptors in the 
development of morphine tolerance.  
 
1.18 Pharmacokinetics of morphine in rodents 
Morphine metabolism in mice differs considerably from the human metabolism. 
In humans morphine is broken down into morphine 6 glucuronide (M6G) and 
morphine 3 glucuronide (M3G) (Wittwer and Kern, 2006). These metabolites are 
themselves pharmacologically active. Mice produce only a small amount of M6G 
from morphine and M3G is therefore the main metabolite. The half-life of 
morphine in C57Bl/6J mice is 28 minutes following IV administration (Handal et 
al., 2002). Morphine administered subcutaneously (SC) to mice has a similar half-
life to that administered via the IV route and it has a significantly higher 
bioavailability than an identical dose administered via the intraperitoneal route 
(IP) due to the first pass metabolism that occurs with this route of administration 
(Handal et al., 2002).  
 
1.19 Mesocorticolimbic reward pathway 
Opioid receptors are highly expressed throughout the central nervous system. 
They are particularly concentrated within the cortex, limbic system and 
brainstem. The expression of each of the receptor types varies between 
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structures with MOP receptors showing its highest expression levels in the 
amygdala, thalamus, mesencephalon and certain brainstem nuclei. The highest 
expression of DOP receptors occurs in the olfactory tract, cortices, regions of the 
amygdala and the striatum. While the highest expression of KOP receptors 
occurs in the olfactory tubercule, striatum (including the nucleus accumbens), 
preoptic area, hypothalamus and pituitary gland (Le Merrer et al., 2009). 
 
Although dopaminergic cells only make up <1% of the total brain neuronal 
population (Arias-Carrion et al., 2010), three areas in the midbrain (retrorubal 
field, substantia nigra pars compacta and the VTA) contain 70-75% of them 
(Grillner and Mercuri, 2002). Within the VTA differing cell populations have been 
reported. (Ungless and Grace, 2012) reported that the composition is 70% 
dopaminergic cells, 30% GABAergic and 2-3% glutamatergic, which agrees with 
the work of Chieng et al (2011). However, Margolis et al (2012) have reported 
that 22% VTA neurons are neither GABAergic nor dopaminergic when assessed 
using immunostaining. These differences may be due to differences between rat 
and mouse or to the precise location assessed within the VTA as this is a 
heterogeneous area. This heterogeneity has been increasingly appreciated as the 
role of this brain area and influence on behaviour has been investigated (Lammel 
et al., 2011, Lammel et al., 2012, Lammel et al., 2014). Yamaguchi et al (2015) 
reported that there were neuronal populations that stained for either VGlut2 
alone, TH alone or co-stained for both. This is interesting as signalling involving 
both the dopaminergic and glutamatergic systems has been identified as 
important in motivated behaviours (Stuber et al., 2010). Dopaminergic neurones 
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from the VTA project mainly to the nucleus accumbens (NA) within the ventral 
striatum as well as the pallidum, prefrontal cortex, amygdala and hippocampus 
(Figure 1.2). Together these projections form the mesocorticolimbic dopamine 
system (Korotkova et al., 2004).   
 
There are a number of behaviours that are associated with survival of the 
species such as eating, drinking water and reproduction. These behaviours are 
naturally rewarding (Agmo et al., 1993) and have been demonstrated to involve 
the opioid receptors (Glass et al., 1999). Antagonists of MOP and DOP receptors 
suppress the reinforcing properties of natural rewards and those of the opioid 
and non-opioid drugs (Shippenberg and Elmer, 1998). The VTA in the midbrain 
has been identified to be important for a number of different behaviours 
including initiating reward and goal directed behaviour (McBride et al., 1999, 
Ungless and Grace, 2012). The rewarding effects of opioids are thought to occur 
through both dopamine dependent and dopamine independent mechanisms 
(Meye et al., 2012). MOP receptor agonists reduce the frequency of GABAergic 
inhibitory postsynaptic currents (IPSCs) in the VTA disinhibiting dopaminergic 
neurones, increasing dopamine release and stimulating reward (Johnson and 
North, 1992b, Matsui and Williams, 2011)(Figure 1.3). Both the GABAergic and 
the dopaminergic neurones of the VTA receive inputs from several different 
areas of the brain. These inputs can produce excitatory, modulatory or inhibitory 
effects. It is becoming increasingly apparent that neuronal subpopulations exist 
within the VTA and these subpopulations belong to different circuits that 
produce differing behavioural responses (Beier et al., 2015). A number of 
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different GABAergic inputs synapse onto VTA neurones, these originate from 
either local interneurones, NA or RMTg (Barrot et al., 2012, Cui et al., 2014, 
Matsui et al., 2014). Matsui et al (2014) demonstrated in rat brain slices that 
opioid inhibition of GABAergic IPSCs within the VTA was projection specific, with 
a significant input from terminals arising in the RMTg. Differences in cell type 
distribution and function have also been identified across the anterior/ posterior 
sections of the VTA (Sanchez-Catalan et al., 2014). It is increasingly recognised 
that this brain area is complex and further investigation is required to fully 
understand the role of the differing neuronal subtypes on function. 
 
Pain is comprised of both sensory and affective components. The VTA is being 
increasingly recognised as important in the emotional/affective components of 
pain (Russo and Nestler, 2013). Sciatic nerve ligation in rodents (a model of 
chronic pain) leads to a decrease in the rewarding effects of MOP receptor 
agonists through a reduction in MOP receptor signalling within the VTA (Niikura 
et al., 2010).  This is consistent with the report that the level of dopamine 
release observed in the nucleus accumbens following morphine treatment is 
significantly reduced in rodents that have had a sciatic nerve ligation performed 
compared to that of unaffected animals (Ozaki et al., 2003). 
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Figure 1.2: The dopaminergic component of the mesocorticolimbic reward 
pathway. Dopaminergic projections travel from the VTA to the nucleus accumbens and 
prefrontal cortex. There are also GABAergic and Glutamatergic projections to the VTA 
and other important brain regions involved in rewarding processes. PFC – prefrontal 
cortex, NA – nucleus accumbens, VP – ventral pallidum, VTA – ventral tegmental area, 
SNr – substantia nigra, PAG – periaqueductal gray, RMTg – rostromedial tegmental 
nucleus.  
 
 
Figure 1.3: Signalling within the mesocorticolimbic reward pathway. GABA 
interneurones provide a continuous inhibitory tone onto the dopaminergic neurones of 
the VTA. Following agonist binding to presynaptic MOP receptors disinhibition of the 
dopaminergic signalling pathway occurs and dopamine release is stimulated in the 
nucleus accumbens. 
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1.20 Psychomotor effects of morphine 
1.20.1 Locomotor activation 
The administration of morphine in common with many other drugs of abuse 
results in increased locomotor activity in mice, the extent to which morphine 
stimulates locomotor activity is dependent on the genetic background of the 
mouse (Brase et al., 1977). C57Bl/6 mice exhibit a robust dose dependent 
increase in locomotor activity in response to morphine while in contrast DBA/2J 
mice do not display significant locomotor activation (Brase et al., 1977). The 
129Sv mice from which embryonic stem cells are used in the development of 
MOP, DOP and BAR2 knockout mice also display a significant locomotor 
activation following the administration of morphine although the C57Bl/6 mice 
display a greater locomotor response (Murphy et al., 2001). This is important as 
alterations in psychomotor behaviour following genetic manipulation need to be 
understood as compared to the appropriate WT controls.  
 
The other easily observed effect of the administration of morphine to mice is 
Straub tail, whereby mice hold their tails up over their back. This was first 
described by Straub in 1911 and it is produced by the effects of the drugs on the 
action of the sacro-coccygeus dorsalis muscle but also requires an intact lumbo-
sacral cord outflow and blood supply (Bilbey et al., 1960). This process involves 
the activation of dopamine receptors within the CNS (Hasegawa et al., 1990).  
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The locomotor activation produced by opioids is important in the study of the 
rewarding effects of opioid drugs because increases in mesolimbic dopamine 
release have been implicated in both locomotor activation and drug seeking and 
reward related behaviours (Wise and Bozarth, 1987). This locomotor activation is 
thought to be mediated via a dopamine D1 receptor mechanism as D1-/- mice 
exhibit a reduced locomotor response to morphine (Urs et al., 2011). BAR2-/- 
mice also exhibit a reduced locomotor activation response compared to WT mice 
following the administration of morphine (Bohn et al., 2003). This implicates 
BAR2 in the locomotor response observed following the administration of 
morphine to WT mice. BAR1 is not involved in this process and does not 
compensate for the absence of BAR2 as BAR1-/- mice do not exhibit any 
significant difference in locomotor response to morphine when compared to WT 
mice (Urs et al., 2011). 
 
Activation of the D1 receptor pathway involved in locomotor activity recruits the 
BAR2/MAPK complex. Five separate groups of MAPK have been identified at the 
present time, these include ERK 1+2, JNK1, 2+3, p38 isoforms, ERK 3+4, and ERK 
5 (Sacks, 2006). The MAPK pathway consists of a three kinase cascade. MEKK 
(MAPK kinase kinase) activates MEK (MAPK/ERK kinase) following 
phosphorylation. This event in turn leads to a phosphorylation dependent 
increase in the activity of MAPK (Sacks, 2006). Systemic administration of the 
MEK inhibitor, SL327, to WT mice inhibits morphine induced locomotor 
activation in a dose dependent manner (Urs et al., 2011).  SL327 has been shown 
to inhibit phosphorylation of ERK in the striatal brain regions of the mouse 
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(Beaulieu et al., 2005). This suggests that the MEK-ERK pathway may be 
important in the locomotor activation produced by morphine.  
 
1.20.2 Reinforcement 
The reinforcing effects of addictive drugs in rodents can be established using the 
technique of conditioned place preference (CPP). This technique is dependent on 
Pavlovian conditioning, whereby the mice associate the drug effect with a 
particular environment that has been paired with it and display a preference for 
that environment (Shippenberg et al., 1992). When WT mice are conditioned 
with naloxone this produces a conditioned place aversion which does not occur 
in MOP-/- mice. Suggesting that MOP receptors are involved in hedonic 
homeostasis (Skoubis et al., 2001). This basal hedonic state is mediated by 
endogenous enkephalins but does not affect the acquisition of morphine 
preference (Skoubis et al., 2005). WT mice will self-administer morphine directly 
into the VTA and the amount that they administer can be significantly reduced 
by the administration of systemic naloxone (David et al., 2008). The ability of 
rodents to self-administer opioids and other rewarding drugs via cannulas 
implanted directly into the VTA and injection of these drugs into this area can be 
studied to investigate the effects of these drugs on CPP (see (McBride et al., 
1999) for review). Mice will also self-administer DAMGO and DPDPE directly into 
the VTA and this administration can produce CPP (Devine and Wise, 1994). Since 
DPDPE produces this effect through the VTA this implicates DOP receptors in the 
process of reward and reinforcement as this is thought to be an important part 
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of the reward pathway. It suggests that DOP receptors may be present and 
functional within the VTA although it does not exclude the possibility that the 
observed effect may be occurring via MOP receptors. There is some evidence 
that GABAergic neurones of the VTA express MOP receptors but not DOP opioid 
receptors (Matsui and Williams, 2011), however this is conflicting with other 
receptor localisation studies suggesting that DOP receptors are present within 
the VTA (Erbs et al., 2015).  
 
1.21 c-Src and the opioid receptors 
Src family non-receptor tyrosine kinases (SFKs) are a family with several 
members. These kinases are expressed at variable levels in different tissue types. 
There are 11 tyrosine kinases that are currently recognised to be part of this SFK 
family, of which c-Src, Fyn, Yes, Lck and Lyn are expressed at a high level in brain 
tissue (Keenan et al., 2015). Src family kinases were initially described in 
processes relating to cell proliferation and differentiation but they are widely 
expressed throughout the central nervous system in varying levels and involved 
in many different cellular processes (Salter and Kalia, 2004). Neurones in 
particular express two different splice variants of c-Src that are known as N-Src 
(N1 and N2) as they have only been identified in neuronal cells (Keenan et al., 
2015). Their role in intracellular signalling appears to be complex. They can be 
directly activated by GPCRs, this is thought to occur via either the Gα or Gβγ 
subunits with differing receptor systems favouring different subunit linkages 
(Luttrell and Luttrell, 2004). They are also involved in the activation of 
47 
 
intracellular signalling processes and pathways through the formation of 
signalling complexes with BAR2 and GRK2. It has also been suggested they are 
involved in opioid receptor phosphorylation (Zhang et al., 2009). c-Src has been 
identified in proximity to synaptic vesicles and it has been demonstrated that it 
will bind neuronal vesicular proteins including dynamin, α-adaptin and synapsin 
but does not directly phosphorylate these proteins suggesting that c-Src is 
involved in membrane trafficking in neuronal cells (Foster-Barber and Bishop, 
1998). BAR2 not only mediates receptor desensitisation and internalisation but 
also the recruitment of c-Src following agonist binding. When BAR2 is bound to a 
GPCR it can provide a binding site for c-Src with the result that c-Src is part of a 
GPCR signalling complex with BAR2 (Luttrell and Luttrell, 2004).  
 
There are a number of nonreceptor tyrosine kinase inhibitors that are in clinical 
use for the treatment of malignancy. Dasatinib is a c-Src inhibitor that is used 
clinically to treat leukaemia, it has the ability to cross the blood brain barrier 
without modification (Lagas et al., 2009, Porkka et al., 2008). It is a potent c-Src 
inhibitor that is normally administered orally to patients despite a low oral 
bioavailability. It has a Kd for c-Src of 0.21 nM but it has also been suggested to 
be able to target PDGFRβ with a Kd of 0.63 nM (Karaman et al., 2008). 
 
The tyrosine kinase inhibitor, 3-(4-chlorophenyl) 1-(1,1-dimethylethyl)-1H-
pyrazolo[3,4-d]pyrimidin-4-amine (PP2), which is a specific inhibitor of c-Src 
((Bain et al., 2007, Uitdehaag et al., 2012), has been demonstrated in WT DRG 
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neurones to replicate the enhanced constitutive MOP receptor inhibitory 
coupling to VACCs that occurs in BAR2-/- DRG neurones (Walwyn et al., 2007). 
This suggests that tyrosine kinase mediated phosphorylation may attenuate 
opioid analgesia and be a target to ameliorate opioid induced analgesic 
tolerance. 
 
A study in rats suggested that the tyrosine kinase inhibitor, imatinib, abolished 
morphine analgesic tolerance (Wang et al., 2012). In this study imatinib had 
been modified to allow it to cross the BBB as it is not able to do this when 
administered in its standard formulation. The tyrosine kinase target of imitanib is 
thought to be PDGFRβ for which it has a dissociation constant (Kd) of 14 nM 
(Karaman et al., 2008). Imitanib can bind to c-Src but with a much lower affinity 
(Kd >10 μM) compared to its other kinase targets (Seeliger et al., 2007). However 
c-Src substrates have also been implicated in PDGFR signalling (Amanchy et al., 
2009). There have been a number of different mechanisms for this suggested, 
with Src implicated in signalling upstream of the PDGFRβ (Tanimoto et al., 2002) 
and also as an intermediate in downstream receptor signalling (Barone and 
Courtneidge, 1995). Together this suggests that the reduction in tolerance 
observed in the Wang et al (2012) study may be mediated through c-Src 
inhibition of PDGFRβ signalling rather than a direct receptor effect.  
 
49 
 
1.22 Aims and Hypotheses 
The studies reviewed above implicate BAR2, DOP receptors and c-Src in the 
failure of persistent MOP receptor mediated analgesia. Disruption of these 
components of the opioid signalling system may provide an approach for 
inhibiting tolerance to opioid analgesics such as morphine. It will be important if 
such an approach is to be clinically viable to establish whether there are 
associated changes in the actions of opioids in the reward pathway. 
 
Our working hypothesis is that opioid receptors in the pain and reward pathways 
differ in their BAR mediated signalling mechanisms. We will test the hypothesis 
that the BAR2/c-Src system is differentially involved in opioid signalling in 
nociceptive pain and reward. To do this we will utilise mice that lack MOP 
receptors, DOP receptors and BAR2. We will also study the effects of morphine 
administration on the behaviour of a mouse that lacks both BAR2 and DOP 
receptors (BAR2-/-//DOP-/-). For all of these mouse models we aim to 
investigate the effects of these genetic manipulations on basal analgesia, 
analgesic tolerance and the development of morphine preference (Figure 1.4). 
We are also interested in the effects of c-Src on these parameters. The aims of 
the project are to test the following hypotheses: 
 
1) The VTA lacks MOP/DOP receptor oligomers and consequently coupling 
through BAR2/c-Src does not participate in opioid reward. I will determine the 
involvement of DOP receptors and BAR2 in opioid-mediated reward and in 
opioid-induced disinhibition of dopaminergic neurones in the VTA. 
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 2) MOP/DOP receptor oligomers in the pain pathway couple to the BAR2/c-Src 
signalling pathway. We hypothesise that this results in an absence of constitutive 
inhibitory coupling to VACCs and allows opioid analgesic tolerance. I will test the 
role of DOP receptors and BAR2 in opioid analgesia in vivo and opioid receptor 
signalling in primary afferent neurones in vitro.  
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Figure 1.4: The involvement of BAR2, c-Src and MOP and DOP receptors in analgesia, 
tolerance and reinforcement. In the diagrams MOP and DOP receptors are depicted as 
physically interacting in the form of dimers. This is based on reports of dimer formation 
and the recent crystal structure of MOP receptors which supports this theory (Manglik 
et al., 2012). (A) When expressed recombinantly MOP receptors, DOP receptors and 
BAR2 colocalise (Rozenfeld and Devi, 2007). This is depicted as the hypothetical scenario 
in WT neurones. The absence of DOP receptors (B), BAR2 (C), both DOP receptors and 
BAR2 (D), or the inhibition of c-Src (E) have the consequences summarised in each case. 
In each case the scenario is represented schematically.   
  
MOP/MOP
(DOP-/-//BAR2-/-)
? Tolerance
? Basal analgesia
? Reinforcement
? VTA signalling
No tolerance
Basal analgesia
? Reinforcement
? VTA signalling
MOP/DOP(BAR2-/-)
BAR2
Tolerance
No basal analgesia
Morphine preference 
? VTA signalling
MOP/DOP/BAR2
c-Src
BAR2
No tolerance
? Basal analgesia
? Reinforcement
? VTA signalling
MOP/MOP (DOP-/-)
BAR2 recruit
c-Src
BAR2
? Tolerance
? Basal analgesia
? Reinforcement 
? VTA signalling
MOP/DOP/BAR2
C-Src inhibition
c-Src
X
A
B
C
D
E
52 
 
 
 
 
Chapter 2: Methods 
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2.1 Breeding Colony Maintenance and Housing 
MOP-/- mice were first generated by Dr Brigitte Kieffer’s lab in 1996 (Matthes et 
al., 1996), they disrupted the Oprm1 gene utilising a technique called 
homologous recombination. This involved the insertion of a neomycin resistant 
cassette into Exon 2 of the gene and was performed on embryonic stem cells 
from the 129/Sv mouse line. Continued breeding was performed with C57BL/6J 
mice and the mice are now available fully backcrossed onto C57BL/6J 
background from Jackson Labs (stock number 007559). Exon 1 of the gene has 
also been targeted but this produced mice with impaired sexual function and 
breeding and also altered haematopoiesis (Sora et al., 1997, Tian et al., 1997).  
 
DOP-/- mice were first generated by Dr John Pintar’s lab in 1999 (Zhu et al., 
1999). The DOP-/- mice transferred to our lab from Dr Wendy Walwyn were first 
generated by Dr Brigitte Kieffer’s lab. They inactivated the Oprd1 gene by 
targeting Exon 1 for deletion with a neomycin cassette. This was inserted into 
embryonic stem cells from the 129/Sv mouse line and further breeding was 
performed with C57BL/6J mice (Filliol et al., 2000). The mice are now available 
fully backcrossed onto C57BL/6J background from Jackson Labs (stock number 
007557). 
 
The BAR2-/- mice were initially developed by Dr Robert Lefkowitz’s lab in 1999. 
These mice were created by utilising a homologous recombination technique 
targeting Exon 2 of the β-arrestin 2 gene on Chromosome 11. These mice were 
again created using embryonic stem cells from the mouse line 129/Sv and 
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further breeding and backcrossing performed on the C57BL/6J background 
(Bohn et al., 1999). These mice are also available from Jackson Labs stock 
number 011130. 
 
MOP-/-, DOP-/-, BAR2-/- and BAR2-/-//DOP-/- mice were kindly transferred from 
Dr Wendy Walwyn at UCLA, these mice were maintained on a C57BL/6J 
background. BAR2-/-//DOP-/- mice were obtained by mating BAR2-/- and DOP-/- 
mice and subsequent offspring until the required double knockout was obtained. 
Since these mice have arrived with us they have been further backcrossed onto 
the C57BL/6J background. BAR2-/-//DOP-/- mice have been subsequently 
outbred using JAX C57BL/6J mice and appropriately re-crossed to obtain the 
double knockout model. All mice were maintained in the Medical Resource Unit 
in accordance with Home Office regulations. They had free access to food and 
water with 12 hour cycles of light and dark corresponding to day/ night 
externally. All of our experiments were performed in the light phase. When 
required mice were culled utilising a schedule 1 method. 
 
2.2 Genotyping 
Genotyping was initially performed in house using the following protocols but 
subsequently contracted to Transnetyx (USA). All test samples utilised tissue 
from ear clipping, tissue was collected from the mice once they were greater 
than six weeks of age and they were ear-tagged. For mice that were used to 
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generate brain slices or DRG preparations ear tissue was collected post mortem 
and analysed to confirm genotype.  
 
Genomic DNA was extracted from ear clippings using the following protocol. 
Extraction solution (Sigma) 50 μL was added to the ear clip sample along with 
12.5 μL of tissue preparation solution (Sigma); these were allowed to incubate at 
room temperature for 10 minutes then at 95°C on the heat block for a further 3 
minutes. Neutralisation solution (50 μL, Sigma) was then added to stop the 
reaction. The resulting genomic DNA was either used immediately for PCR or 
stored at -20°C until required. 
 
A master-mix was created for each PCR reaction as required (Table 2.1) and the 
samples set up on the thermo-cycler using the appropriate programme (Table 
2.3). The primers used for each reaction consisted of a forward, reverse and 
middle primer, the sequences of which can be viewed in Table 2.2, they were 
obtained from Sigma. Following completion of the PCR reactions the samples 
were kept at 4°C until an electrophoresis gel could be run.  
 
We used 1% agarose TAE gel with ethidium bromide (10 μL / 100 mls, Sigma) to 
run the MOP and BAR2 reactions and a 2% agarose TAE gel with ethidium 
bromide for the DOP reaction as this allowed better separation of the bands for 
this reaction. We added 10 μL of loading dye to each 50 μL PCR reaction and 
loaded 30 μL of each reaction to the gel. A 1 kb DNA ladder (Fisher) was used for 
the MOP and DOP reactions and a 100 bp ladder (Invitrogen) for the BAR2 
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reaction. Electrophoresis gels were run at 100 V for 60 – 80 minutes until 
adequate band separation had occurred and imaged using a UV light source. For 
the MOP results we expect to see a WT band visible at 700 bp and a KO band 
visible at 400 bp. For the DOP reaction we expect to observe a band at 1000 bp 
and a KO band at 600 bp. The BAR2 reaction produced a WT band at 188 bp and 
a KO band at 400 bp. For all of the reactions one band was present to represent 
either WT or KO and heterozygote animals were identified by the presence of 
both bands. 
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Table 2.1: The PCR master-mix recipe for each of the mouse genotypes. This was 
varied between the genotypes as detailed above. The primer sequences for each 
reaction can be viewed in a separate figure. Reagents were supplied by Sigma and 
Fisher. 
 
 
 
Table 2.2: The forward, reverse and middle primer sequences required for genotyping 
each genetically modified mouse line. 
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Table 2.3: The PCR thermo-cycler conditions for (A) the MOP PCR reaction (B) the 
DOP PCR reaction and (C) the BAR2 PCR reaction. 
A 
B 
C 
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2.3 Behavioural Studies 
For three days prior to each experiment mice were handled and habituated to 
the room where the tests were to take place. The room temperature was 
maintained between 19 and 21°C. All experiments took place during daytime 
hours. All drug doses were calculated using individual body weight, maximum 
volume administered in a single injection was 200 μL. Groups of mice were made 
up of equal numbers of males and females where possible and balanced 
numbers when not. Mice were aged from 7 weeks to 24 weeks of age at the time 
of their participation in the tasks. At the end of each experimental protocol the 
mice were killed using a schedule one method. 
 
2.3.1 Assessing morphine analgesia 
The hot water tail withdrawal assay was used to assess morphine analgesia. We 
used an electronic thermostatic circulating water bath (Thermostatic circulator 
bath Optima general purpose digital +5°C to 100°C, 12L stainless steel tank 
Fisher Scientific) that maintained the temperature within ± 0.1 °C of that set. 
Prior to the start of each experiment we performed a baseline tail withdrawal 
assay using 48°C water with a maximum cut-off exposure time of 15 seconds. If a 
mouse left its tail in the water for the maximum time at any point throughout 
the experiment we removed it to prevent damage. The mice were restrained 
gently in a plastic tube from their home cage to allow the immersion of the distal 
3 cm of their tail in the hot water. They were habituated to this restraint during 
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the three day handling period prior to the start of the experiment. Before and 
after each test the mice were maintained in their home cages.  
 
To investigate analgesic dose response mice were treated with cumulative doses 
of morphine sulphate (Sigma) of 0.1, 0.3, 1, 3, 10 and 30 mg/Kg; this was 
prepared in an aseptic environment and filtered using a 0.2 μm syringe filter 
prior to use. Morphine was diluted in 0.9% NaCl at varying concentrations to 
allow correct dose/volume of the drug to be administered. Injections of 
morphine were performed subcutaneously (SC) into the scruff of the neck. Thirty 
minutes after each morphine dose the tail withdrawal assay was performed. 
Results were calculated as a percentage of maximal possible effect (MPE: % MPE 
= 100*((drug latency – basal latency) / (15 s – basal latency))). Once a mouse had 
reached the 15 second maximum it received no further doses of drug. 
 
2.3.2 Morphine tolerance 
To investigate the development of analgesic tolerance to morphine we treated 
mice with 10 mg/Kg morphine sulphate via a subcutaneous injection once daily 
for 10 days. The injections were performed at the same time each day and all 
experiments took place during the light phase. On each experimental day we 
performed a baseline tail withdrawal assay using the circulating hot water bath 
(bath settings 48°C, 15 s maximum exposure time). The mice then received a 1 
mg/Kg injection of morphine sulphate administered subcutaneously and a repeat 
tail withdrawal assay was performed thirty minutes later. Following this they 
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received an injection of 10 mg/Kg morphine sulphate administered 
subcutaneously, with a repeat tail withdrawal assay again performed thirty 
minutes after the morphine dose.  
 
2.3.3 Psychomotor testing: Locomotor activation and CPP 
We used a two compartment model of conditioned place preference to 
investigate morphine reinforcement in mice. One chamber had a wallcovering 
consisting of black and white horizontal stripes and the other black and white 
vertical stripes. The floor material was the same in each of the chambers; it 
consisted of 1 cm square wire grid flooring material. The grid direction of this 
material differs depending on its orientation. We utilised this property to 
provide a difference in the floor between each chamber. The direction of the 
grid matched the wall stripe direction in each chamber. Each test arena 
measured 28 x 28 cm and was 19 cm high. Two test arenas, each consisting of a 
two compartment apparatus, are contained within an operant box (Figure 2.1). 
The test apparatus was matched to mice of specific genders and only mice of the 
same gender were placed in the same operant box set-up. The majority of the 
mice placed in the same operant box for testing were cage mates, but this could 
not always be ensured for the male mice. These boxes are soundproofed and 
allow the light levels to be controlled at approximately 70 lumens, the 
temperature of the room was maintained between 21 and 23°C. The boxes also 
contain fans but we did not use them during the course of these experiments as 
due to their location on one side of the operant box we were concerned that 
they would affect the conditioning phase of the experiment for the test arena 
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closest to the fan. For each experimental protocol we used eight mice, four male 
and four female. All of the mice used for the behavioural experiments were 
handled for three days prior to the start of the study. This allowed habituation to 
handling, the experimental room and other mice to be used in the experiment. 
On day one of the study the mice were habituated to the testing environment 
and allowed free access to both chambers for 15 minutes. Time spent in each 
chamber and the distance that they travelled was recorded using a CCTV camera 
connected to a PC and analysed using AnyMaze software with a point fixed on 
the mid-point of each mouse’s body.  
 
After habituation equal numbers of mice were assigned to either the horizontal 
or vertical chamber to receive a subcutaneous injection of 0.9% saline (volume 
matched to that of the morphine injection). Four hours later the mice received a 
subcutaneous injection of morphine sulphate in the opposite chamber from 
where they received their first injection. After each injection they were confined 
to the corresponding chamber for thirty minutes and the distance that they 
travelled was tracked using AnyMaze software. In between conditioning sessions 
the mice were returned to their home cages. We performed the injections in this 
order due to the duration of action of morphine. If we counterbalanced the 
injections there may still be a morphine effect at the time of the second 
conditioning session. All mice were killed using a schedule 1 method when they 
completed their involvement in the study. 
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WT, MOP-/-, DOP-/-, BAR2-/- and BAR2-/-//DOP-/- mice were conditioned at 
both 3 mg/Kg and 10 mg/Kg of morphine sulphate. MOP+/- mice were 
conditioned at both 10 mg/Kg and 30 mg/Kg. We used groups of 8 mice from 
each genotype for each dose of morphine that was tested. On the fifth day of 
the CPP protocol the mice were allowed free access to both of the chambers for 
fifteen minutes, this was the test period. We recorded the time that they spent 
in each chamber and then compared the two. Preference scores for morphine 
paired chambers were calculated by subtracting the time spent in the saline 
paired chamber from the time spent in the morphine paired chamber. 
 
For the experiments involving c-Src inhibition, dasatinib (Bristol Squibb Myer) 
was dissolved in DMSO (Sigma) to give a 50 mg/ml stock.  The final concentration 
of the solution for injection was 1 mg/ml dasatinib to allow administration of 5 
mg/Kg. This consisted of a 2% DMSO and 2% Kolliphor EL (Sigma) in a 0.9% saline 
solution.  
 
The matched vehicle injection contained the same constituents but without the 
active drug. PP2 (Tocris) was also dissolved in DMSO at its solubility limit of 25 
mM and diluted in a 0.9% saline solution to give a final concentration of 1 mg/ml 
(16% DMSO and 16% Kolliphor EL). PP3 (1-Phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-
amine; Tocris) has a higher solubility limit and so was made up in DMSO at 100 
mM and diluted in a 0.9% saline solution to give a final concentration of 1 mg/ml 
(5% DMSO and 5% Kolliphor EL). These drugs were all administered via the 
intraperitoneal (IP) route. 
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Figure 2.1: CPP apparatus. (A) We have four operant boxes each containing two sets 
of CPP apparatus. (B) Each box has a camera positioned directly above it to monitor 
mouse movement and location, the light level has been set at 70 lumens using LED 
lighting strips. (C) The camera system feeds into both a recording system and the 
computer AnyMaze software. 
 
2.4 Dorsal Root Ganglion neurone culture preparation 
Mice were killed using cervical dislocation, following which dorsal root ganglia 
(DRG) were harvested from C57BL/6J mice at postnatal day (PN) 17 to 21. When 
possible, matched mice were utilised for brain slicing and DRG harvest. Cells 
were collected in ice cold Ca2+ and Mg2+ free Hank’s balanced salt solution (HBSS, 
Invitrogen) and then dissociated both enzymatically (collagenase type 1 (Sigma)/ 
dispase (Sigma, 4 mg/ml) and papain (Sigma, 40 units/ml)) and physically by 
trituration using a fire polished glass pipette. The neurones were plated onto 
poly-D-lysine (Sigma) and laminin (Sigma) coated 13 mm diameter coverslips 
housed within 35 mm cell culture dishes (VWR) (Walwyn et al., 2007). Cells were 
cultured in Dulbecco’s modified Eagle medium (DMEM)/ F-12 nutrient mixture 
(Invitrogen), supplemented with heat inactivated fetal bovine serum (FBS, 10%, 
Invitrogen) nerve growth factor (NGF, 50 ng/ml, Life technologies) and penicillin 
(100 μg/ml) and streptomycin (100 units/ml, Invitrogen) at 37°C and 5% CO2. 
A B C 
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Neurones were used for electrophysiological recordings on days 1 to 3 in culture. 
After this, if dishes remained cells were re-suspended and plated on newly 
coated coverslips to allow recording for up to 3 more days at appropriate cell 
density to allow single neurone recording. This procedure did not affect the 
properties of Ca2+ currents with regard to the effects of morphine. 
 
Whole cell patch recordings were obtained from the DRG neurones, Ca2+ 
currents mediated by VACCs were activated by depolarising small diameter (<25 
μm) DRG neurones from -80 mV to +10 mV (as described previously by (Walwyn 
et al., 2007, Walwyn et al., 2009). The experiments were performed using an 
extracellular solution containing 130 mM TEA, 10 mM CaCl2, 5 mM HEPES, 25 
mM glucose and 500nM tetrodotoxin (TTX, Tocris) at a pH of 7.2 (obtained by 
adjusting with CsOH).  
 
Borosilicate glass pipettes of 2-3 MΩ (World Precision Instruments, 1.5/1.12 
OD/ID (mm)) were manufactured for recording and filled with intracellular 
solution. The intracellular solution contained 105 mM CsCl 40 mM HEPES, 2.5 
mM MgCl2, 10 mM EGTA, 5 mM glucose, 2 mM ATP and 0.5 mM GTP, this 
solution was also pH adjusted to 7.2 using CsOH. Morphine sulphate was diluted 
into the extracellular solution from frozen stocks as required on the day of the 
experiment and subsequently spritzed onto the cell of interest at 15 psi. 
 
Data was collected and recorded using an Axopatch 200A amplifier (Molecular 
devices, CA, USA). Data were low pass filtered at 2kHz, digitised at 8 kHz using a 
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digidata 1322A interface, acquired and analysed using pClamp 10.2 software 
(from molecular devices). A linear regression was performed for each recording 
to compensate for rundown and inhibition of VACC by morphine calculated. 
 
2.5 Immunohistochemistry 
Brain slices were fixed overnight in a 1% PFA solution containing picric acid 
(TAAB Labs). To make 200 ml of the fixative solution 1% paraformaldehyde (2 g) 
was heated in ddH2O in a fume cupboard until hot at which point 400 μl of 4 M 
NaOH was added to dissolve the PFA. To this solution 30 ml of saturated picric 
acid and 100 ml of 0.2 M phosphate buffer were added and the whole solution 
was diluted with ddH2O to reach a total volume of 200 ml, the final pH was 
between 7.2 and 7.4.  
 
The 0.2 M phosphate buffer solution contains a 4:1 ratio of (A) 0.2 M dibasic 
sodium phosphate (Na2HPO4*7H2O) and (B) 0.2 M monobasic sodium phosphate 
(NaH2PO4*2H2O). After fixation the slices were washed three times in 0.1 M 
phosphate buffer (0.2 M phosphate buffer diluted 1: 1 with ddH2O) containing 
0.05% sodium azide and stored at 4°C until required.  
 
The first step of the immunohistochemistry staining protocol was to wash the 
brain slices three times, (each wash was for 15 minutes), in 0.1 M phosphate 
buffer containing 0.3% Triton (PBT) to permeabilise the cells. We then blocked in 
10% bovine serum in PBT for 30 minutes at room temperature. The primary 
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antibody we used to identify the dopaminergic neurones was rabbit anti-tyrosine 
hydroxylase which we used at a 1:1000 dilution (Millipore AB152) in 10% bovine 
serum PBT. This was incubated with the slices for 2 nights at 4°C gently rocking. 
The slices were then washed three times, again for 15 minutes each wash, in 
PBT. To identify the neurones that we had recorded from we added biocytin 1% 
to our intracellular recording solution and allowed this to diffuse into the cell. 
 
For the second blocking step we used 0.2% BSA in 0.1 M PBT for 1 hour at room 
temperature. Incubation in our secondary antibody mix then took place in the 
dark in 0.2 % BSA in PBT overnight at 4°C gently rocking. The secondary antibody 
mix comprised anti-rabbit IgG conjugated AlexaFluor 594 at a dilution of 1:1000 
(Invitrogen A-21207) to identify the TH labelled cells and Streptavidin conjugated 
AlexaFlour 488 at a dilution of 1: 200 (Invitrogen S-11223) to identify the biocytin 
containing cells. The slices were then washed in PB (three times 15 minute 
washes) in the dark and mounted on slides with FluorSave reagent (Millipore). 
The slides were then left to cure at 4°C in the dark and subsequently imaged 
using confocal microscopy. 
 
The slices were examined under a Leica TCS SP-5 confocal microscope (Leica) and 
images were obtained at 10x and 40x magnification. The AlexaFluor 594 bound 
to the primary anti-tyrosine hydroxylase antibody was excited at 594 nm and the 
emitted fluorescence was collected between 600 nm and 650 nm. The 
Streptavidin conjugated AlexaFluor 488 was excited at 488 nm and the emitted 
fluorescence was collected between 500 nm and 550 nm. 
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2.6 Slice Electrophysiology 
Mouse brain slices were prepared from C57BL/6J (Wild type) mice aged 
postnatal day (PN) 17 – 21. Mice were killed by cervical dislocation. Immediately 
following decapitation the brain was removed and placed in ice cold solution 
bubbled with 95% O2/5% CO2. This solution used for slicing contained a high 
concentration of sucrose instead of NaCl as this is thought to improve the VTA 
cell viability. The solution comprised: 234 mM sucrose, 26 mM NaHCO3, 10 mM 
glucose, 10 mM MgSO4, 2.5 mM KCl, 1.25 mM NaH2PO4, and 0.5 mM CaCl2. 
Horizontal slices of 250 µm thickness containing the VTA were cut in ice cold 
sucrose solution using a Leica vibratome, set at a speed of 0.14 mm/s and 
amplitude of 1 mm. These horizontal slices corresponded to Bregma -4.12 to 
Bregma -4.44 (Paxinos and Franklin, 2013). Slices were then incubated in 
extracellular solution bubbled with 95% O2/5% CO2 for ≥ 1 hr at room 
temperature, this solution consisted of 126 mM NaCl, 26 mM NaHCO3, 10 mM 
Glucose, 3 mM KCl, 2 mM MgCl2, 2 mM CaCl2, 1.3 mM NaH2PO4. We added 2 
mM kynurenic acid sodium salt (Abcam) to this solution as required for recording 
this was done to inhibit glutamatergic events. When mIPSC recording was 
required tetrodotoxin (TTX) was added to this solution at a final concentration of 
500 nM, this was omitted when recording of sIPSC events was required. 
 
Borosilicate glass pipettes of 2-5 MΩ (World Precision Instruments, 1.5/1.12 
OD/ID (mm)) were manufactured for recording and filled with intracellular 
solution containing: 138 mM CsCl, 10 mM HEPES, 10 mM EGTA, 1 mM CaCl2, 2 
mM MgCl2, 2 mM Mg-ATP, 5 mM QX-314 (Tocris) (pH 7.4 with CsOH). Slices were 
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held in position with a small grid fashioned from platinum wire and nylon tights. 
Recordings were made from slices superfused with a continuously oxygenated 
(95% O2/5% CO2) saline based extracellular solution and maintained at 36°C with 
an in-line temperature controller (HPT-2 heated perfusion tube, ALA Science). An 
infrared differential interference contrast microscope with a water immersion 
objective (x40) was used to obtain images displayed on a video monitor.  
 
Recordings were also obtained in current clamp mode. This allowed the study of 
the effects of morphine and naloxone on action potential (AP) frequency. For 
these recordings the intracellular solution consisted of 123 mM KCl, 15 mM NaCl, 
10 mM HEPES, 10 mM EGTA, 2 mM MgCl2, 2 mM ATP and 1 mM CaCl2. This 
solution was adjusted to pH 7.2 – 7.3 using CsOH. For these recordings kynurenic 
acid was omitted from the extracellular solution. 
 
Whole cell voltage clamp recordings were obtained at -60mV and current clamp 
recordings at 0 mA using an Axopatch 200B, the data collected were filtered at 5 
kHz, digitised at 10 kHz (National Instruments NADAQ-MX) and acquired using 
Strathclyde Electrophysiology Software. All chemicals were supplied by Sigma 
unless otherwise stated. 
 
Spontaneous inhibitory postsynaptic current (sIPSC) parameters were 
investigated in the absence and presence of a variety of drugs (morphine 
(Sigma), DAMGO (Sigma), DPDPE (Abcam), ondansetron (Sigma), PP2 (Tocris), 
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PP3 (Tocris), SL327 (Tocris), naloxone (Tocris) and bicuculline (Sigma)). All drug 
solutions were prepared as required on the day of use from frozen stock 
solutions and all were diluted in the extracellular solution containing 2 mM 
kynurenic acid (Abcam).  
 
All recordings were obtained and analysed offline using Strathclyde 
Electrophysiology Software, WinEDR and WinWCP. Each recording segment (i.e. 
control or drug) consisted of at least 450 s, this was then divided into three 120 s 
segments and the event frequency of this segment analysed and averaged.  To 
allow for the kinetic analysis the IPSCs were threshold detected (amplitude -4 
pA, duration 3 ms) and visually inspected, a minimum of 50 events per recorded 
segment were used for analysis. This analysis included peak amplitude, rise time 
and decay time.  
 
The decay phase of the averaged IPSCs (from each control/ drug treated 
segment) were best fitted (98–5% of the peak amplitude) with a double 
exponential function (y(t) = Afast.e (-t / τ fast) + Aslow.e (-t / τ slow)), where t was time, A 
was the amplitude, and τ was the decay time constant. A weighted decay time 
constant (Tω) was also calculated for the averaged events from the calculation: 
Tω = T1P1+ T2P2, where T1 and T2 are the decay time constants and P1 and P2 are 
the proportions of the decay relative to each of the component parts (Maguire 
et al., 2014). 
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2.7 SW620 cell culture 
SW620 human colon cancer cells (Catalog No. CCL-227) were obtained directly 
from American Type Culture Collection (ATCC). These cells have high levels of c-
Src activity and were used here to confirm the inhibitory effects of dasatinib and 
PP2. Phosphorylated c-Src (pc-Src) is the activated form of c-Src within the cell, 
comparison of the ratio of c-Src to pc-Src can provide information about activity 
(Roskoski Jr, 2015). Cells were maintained in Dulbecco’s Modified Eagle Medium 
(DMEM) supplemented with 10% heat inactivated fetal bovine serum (FBS), 
2 mM L-glutamine and 1% penicillin/streptomycin (Invitrogen) at 37 °C and 5% 
CO2. Cells were passaged twice weekly, plated on 60 mm culture dishes and 
incubated with dasatinib, PP2 and PP3 all at a 10 μM concentration for 24 hours 
prior to collection. 
 
2.8 Western Blotting 
To obtain protein for western blotting the SW620 cells were collected and lysed 
using RIPA buffer (Fisher). Alternatively tissue was harvested post mortem from 
mice treated with the drugs of interest during behavioural studies. Brain and 
DRG tissue were homogenised using RIPA buffer and the Tissue-Tearor (Biospec 
products). The protein levels obtained from both methods were measured using 
the Pierce BCA protein assay kit (Fisher).  
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For each sample between 5 and 50 μg of protein was added to an SDS loading 
buffer (containing 125 mM Tris-HCl, 40 % glycerol, 20 % β-mercaptoethanol, 8 % 
SDS and 0.008 % bromophenol blue) and H2O to give a final sample volume of 20 
μl for each well required. This mix was heated at 95°C for 5 minutes and then 
loaded onto a NuPAGE Bis-Tris 4 -12 % 10 well mini gel (Invitrogen). The gel was 
run with a MOPS-SDS running buffer (Invitrogen) for 90 minutes at 120 V. We 
used actin (Abcam) as a loading control for the SW620 experiment, GAPDH 
(Abcam) for the experiments utilising brain and DRG tissue and the ladder used 
for both was SeeBlue Plus 2 prestained standard (Invitrogen). 
 
For protein transfer chromatography paper (6 pieces per gel)(Sigma) and 
nitrocellulose transfer membrane (GE healthcare)(1 piece per gel) were soaked 
in transfer buffer containing Tris (2.42 g/ L) and glycine (14.4 g/ L) in ddH2O and 
20 % methanol and compiled. The transfer was performed in transfer buffer at 
4°C at 200 mA for 90 minutes. After completion the nitrocellulose membrane 
was removed and soaked in Ponceau solution (1 mg/ml) for 2 minutes to reveal 
the protein bands. The membrane was then washed with ddH2O and cut to size. 
The first one hour blocking step was performed at room temperature in 5% BSA 
for the membrane containing Src and p-Src and 5% milk protein for the 
membrane containing the loading controls. The primary antibodies were then 
diluted in the relevant blocking buffer to which 0.02% sodium azide was also 
added. The Src antibody (rabbit)(Cell signalling #2108) was diluted to 1:2000 as 
was the p-Src antibody (rabbit)(Cell signalling #2101). The actin antibody 
(mouse)(Abcam) was diluted to 1:1000 and the GAPDH (rabbit)(Abcam) was 
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diluted to 1:1000. They were incubated with the membranes at 4°C overnight 
gently rocking and then washed 4 times with TBS-T, this contained Tris (2.4 g/L), 
NaCl (8.8 g/L) and Tween-20 (0.1%). The secondary antibodies were goat anti-
rabbit HRP (Abcam) at a 1:5000 in 5 % BSA and anti-mouse HRP (Abcam) at 
1:1000 in 5 % milk protein. These were incubated with the membranes at room 
temperature for an hour. The membranes were then washed for ten minutes 4 
times and prepared for the enhanced chemiluminescence reaction. This reaction 
was performed using ECL prime western blotting detection media (GE 
Healthcare) and the blots developed in the dark room with the required 
exposure time. 
  
2.9 Statistical Analysis 
Data are represented as mean ± standard error of the mean (SEM). The graph 
plots and statistical analysis were performed using GraphPad Prism 5 software. 
Statistical significance (p < 0.05) was determined either by Student’s t test 
(paired or unpaired as appropriate) or by analysis of variance (ANOVA), (one or 
two way as appropriate), with the relevant post hoc tests. 
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Chapter 3: Analgesia and Tolerance 
  
75 
 
3.1 Introduction 
Morphine analgesia is mediated by MOP receptors. Morphine administration to 
MOP-/- mice does not cause analgesia (Matthes et al., 1996, Sora et al., 1997). 
There are a number of simple behavioural assays for assessing nociception and 
analgesia in mice (Wilson and Mogil, 2001, Le Bars et al., 2001, Barrot, 2012). 
These include nociceptive responses to heat, cold, mechanical stimuli and 
chemical stimuli. With regards to morphine analgesia there are several tests that 
are accepted as useful and reproducible. These include the tail flick test with 
radiant heat or immersion, paw withdrawal, the hot plate test and response to 
cold stimuli.  
 
The method that we have chosen here is tail withdrawal from hot water. This is a 
modification of D’Amour and Smith’s method (1941). The tail flick reflex is a 
spinal reflex that is generally regarded to reflect spinal analgesia (Kieffer, 1999). 
This is in contrast to the hotplate test that is subject to supraspinal influences 
and requires integration of a number of varying system inputs. The tail 
withdrawal assay is a simple and reproducible test that is highly responsive to 
opioid drugs (Wilson and Mogil, 2001, Barrot, 2012), but it does require restraint 
of the mouse which we perform using a plastic tube that is normally present in 
their cage. To minimise the stress associated with this the mice are habituated to 
the test room and handling for three days prior to the start of each test. The tail 
flick response can also be affected by the ambient temperature of the room 
(Tjølsen and Hole, 1993); we therefore maintain the test room at a temperature 
between 19 and 21°C. An advantage of this test is that due to the significant 
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surface area of the tail exposure there is a rapid increase in temperature of the 
tail and a spinal reflex response (Le Bars et al., 2001).  
 
It has been noted that there are significant strain differences in pain behaviour 
between different commonly used laboratory mouse strains (Brase et al., 1977, 
Mogil et al., 1999, Leo et al., 2008).  All of our mice are back crossed over many 
generations to the C57Bl/6J genetic background to allow comparison between 
groups and to a control population of C57Bl/6J mice. There are conflicting results 
reported with regard to gender differences in tail withdrawal time from hot 
water. Kest et al (1999) found an increase in baseline tail withdrawal time in 
male C57Bl/6J mice compared to females  but a subsequent study was not able 
to identify a gender difference using the same strain of mice and the identical 
nociceptive test (Kieffer et al., 1992). We have used balanced groups of male and 
female mice across all of behavioural experiments to avoid introducing bias by 
gender. 
 
Nociceptive stimuli are detected by a collection of peripheral nerve fibres 
termed nociceptors. Their cell bodies are located within the dorsal root ganglia 
(DRG). Binding of an opioid to MOP receptors leads to activation of inhibitory G 
proteins leading to several intracellular effects (Williams et al., 2001). This 
includes inhibition of Ca2+ entry through voltage-activated Ca2+ channels (VACCs) 
in primary afferent nociceptor DRG neurones.  The inhibition of presynaptic 
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VACCs gives rise to the opioid-mediated reduction of excitatory 
neurotransmission in the pain pathway (Heinke et al., 2011). 
 
As previously discussed opioid agonists do not produce analgesia in MOP-/- 
mice. However analgesia and a number of other opioid induced side effects 
including tolerance, locomotor activation (in rodents), constipation and 
respiratory depression are not solely MOP receptor mediated (Schmid and Bohn, 
2009). We know from previous studies that DOP receptors are not required for 
morphine-mediated analgesia, but their absence leads to blunted morphine 
analgesic tolerance (Zhu et al., 1999). In DRG neurones DOP receptors are 
required for the full functional expression of MOP receptors and inhibition of 
VACCs by DAMGO (Walwyn et al., 2009).  
 
MOP receptors in primary afferent neurones constitutively internalise, a process 
that is inhibited by either the absence of BAR2 or inhibition of c-Src (Walwyn et 
al., 2007). This implies that there is constitutive recruitment by MOP receptors 
of BAR2/c-Src in these neurones. BAR2 is a scaffolding protein that has been 
implicated in analgesia and tolerance. BAR2-/- mice appear phenotypically 
normal but develop negligible tolerance to opioid analgesia (Bohn et al., 1999, 
Bohn et al., 2000, Bohn et al., 2002). In addition the mouse’s endogenous opioid 
pain killing mechanism becomes persistently active without the requirement for 
drug administration. This occurs with no evidence of the hedonic effects typically 
associated with opioid drug taking (Lam et al., 2011). When expressed alone in 
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the absence of agonist Rozenfeld and Devi detected no co-localization between 
MOP receptors and BAR2 using confocal microscopy (Rozenfeld and Devi, 2007). 
However, co-expression of MOP and DOP receptors led to co-localization of all 
three proteins at the cell membrane; consistent with the idea that MOP/DOP 
receptor heterodimerisation is required for constitutive recruitment of BAR2.  
 
We confirmed a role for DOP receptors in the constitutive recruitment of BAR2 
using a protein complementation assay in which inactive fragments of β-
galactosidase are attached to MOP receptors and of BAR2 (Baptista-Hon et al., 
2013). The introduction of recombinant DOP receptors into cells expressing 
tagged MOP receptors and BAR2 led to enhanced agonist-independent β-
galactosidase activity. 
 
The basal analgesia observed in BAR2-/- mice is associated with constitutive 
MOP receptor coupling to VACCs in primary afferent neurones from these mice, 
a phenomenon that can be recapitulated in wild type neurones by directly 
inhibiting c-Src activity implicating tyrosine kinase-mediated phosphorylation 
(Walwyn et al., 2007). 
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Tolerance to opioids is a major problem particularly in the management of 
chronic pain including cancer pain, where to control symptoms escalating drug 
doses are often required (Rang et al., 2000). This then exposes patients to many 
other worsening drug side effects. Understanding the mechanisms of tolerance 
is therefore very important to allow alternative methods of drug design and 
administration.  
 
3.2 Analgesia 
3.2.1 The role of MOP receptors 
Female WT mice have a significantly shorter baseline tail withdrawal latency 
suggesting that they have a higher sensitivity to noxious stimuli compared to the 
male mice (Figure 3.1A). Morphine administration to wild type C57Bl/6J (WT) 
mice produces dose-dependent analgesia (Figure 3.1B). The latency for tail 
withdrawal from hot (48°C) water was established with a maximum exposure 
time of 15 s to prevent tail damage. The percentage of maximum possible effect 
(MPE) was then calculated using the formula; % MPE = 100*((drug latency – 
basal latency) / (15 s – basal latency)). ED50 values were established from logistic 
fits to the morphine dose-response relationships.  For WT mice ED50 = 1.2 ± 0.1 
mg/Kg morphine, n = 29 (Table 3.1). Despite the apparent gender difference in 
pain sensitivity, when the morphine ED50 values for male and female WT mice 
were compared there was no significant sex difference (ED50 male WT 1.1 ± 0.2 
mg/Kg, n = 14 and ED50 female WT 1.3 ± 0.1 mg/Kg morphine, n = 15, unpaired t 
test p = 0.2). 
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MOP+/- mice, in which one copy of the MOP receptor gene has been deleted, 
have a 50% reduction in MOP receptor number compared to WT mice (Sora et 
al., 2001). In these mice we observe a rightward shift in the dose-response curve 
indicating a reduction of morphine potency (ED50 MOP+/- = 6.2 ± 0.8 mg/Kg 
morphine, n = 15), without altered efficacy (Figure 3.1B and Table 3.1). It is not 
possible to compare sex differences across the genotypes at this time due to the 
small n numbers in the MOP+/- and MOP-/- groups. As future experiments are 
completed utilising these mice this will be addressed. 
 
MOP-/- mice, which lack MOP receptors, were unaffected by morphine (10 
mg/Kg) confirming the requirement for MOP receptors in opioid analgesia 
(Figure 3.1B). There was no significant difference in the basal tail withdrawal 
latencies between WT, MOP+/- and MOP-/- mice, one way ANOVA p = 0.1 
(Figure 3.1C).  This implies that there is no critical role for MOP receptors in the 
basal sensitivity of mouse tails to noxious heat. 
 
The inhibition of VACCs in primary afferent nociceptive DRG neurones plays an 
important role in morphine analgesia (Schroeder and McCleskey, 1993, Rusin 
and Moises, 1995, Heinke et al., 2011). DRG neurones were cultured from WT, 
MOP+/- and MOP-/- mice as described in the methods section. Whole-cell 
currents mediated by VACCs were activated by depolarising small diameter (<25 
μm) DRG neurones from -80 mV to +10 mV. Morphine caused an inhibition of 
Ca2+ currents recorded from WT DRG neurones (Figure 3.1D). In MOP+/- mice 
81 
 
there was a reduction in the ability of morphine to inhibit the VACC and in MOP-
/- it was absent, one way ANOVA p < 0.009, WT n = 4, MOP+/- n = 7, MOP-/- n = 
5. This confirms the importance of MOP receptors in morphine-evoked inhibition 
of VACC activity.  
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Figure 3.1: MOP receptors are required for morphine analgesia and inhibition 
of VACCs in DRG neurones. (A) Female WT mice have a significantly faster baseline 
tail withdrawal latency compared to the male mice. Male mice 3.4 ± 0.3 s, n = 39, female 
mice 2.4 ± 0.2 s, n = 46. Unpaired t test p = 0.006. (B) Dose response relationship for 
morphine analgesia in WT, MOP+/- and MOP-/- mice of mixed gender. ED50 WT = 1.2 ± 
0.1 mg/Kg morphine, n = 29, ED50 MOP+/- = 6.2 ± 0.8 mg/Kg morphine, n = 15. MOP-/- n 
= 10, no significant analgesia received from morphine sulphate. (C) Baseline tail 
withdrawal latencies for WT, MOP+/- and MOP-/- mice do not differ significantly (one 
way ANOVA). (D) Mean VACC inhibition in DRG neurones by morphine is reduced in a 
gene dependent manner compared to the WT neurones, one way ANOVA p < 0.001 post 
hoc Tukey results are shown on the graph, n = 4 - 7. For all figures the vertical lines 
represent ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001. 
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3.2.2 The Role of DOP receptors 
We established dose-response relationships for morphine in WT, DOP+/- and 
DOP-/- mice (Figure 3.2A and B). The ED50 for morphine analgesia differs 
between WT and DOP-/- mice (Figure 3.2C). There is also a reduction in the slope 
for morphine analgesia in DOP-/- mice compared to WT mice (Figure 3.2D and 
Table 3.1). Basal tail withdrawal times did not differ between WT, DOP+/- and 
DOP-/- mice (one way ANOVA) (Figure 3.2E). These data suggest that, while not 
necessary for morphine analgesia, DOP receptors are involved. This is consistent 
with previous work in DRG neurones demonstrating that the inhibition of VACCs 
is reduced in the absence of DOP receptors (Walwyn et al., 2009). The altered 
slope for morphine analgesia is evidence of an interaction between MOP and 
DOP receptors in the pain pathway.  
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Figure 3.2: Morphine is less potent as an analgesic in DOP-/- mice. (A) Morphine 
dose response relationship for WT and DOP+/- mice. The ED50 for DOP+/- mice is 1.4 ± 
0.2 mg/Kg, n = 14. This compares to the WT ED50 of 1.2 ± 0.1 mg/Kg, n = 29. The slope of 
the curve is not significantly different from that of the WT dose response curve, slope 
DOP+/- 6.8 ± 1.0 and slope WT 6.6 ± 1.2, unpaired t test p = 0.95. (B) Morphine dose 
response curve for WT and DOP-/- mice. The DOP-/- ED50 is 1.8 ± 0.3 mg/Kg, n = 14. (C) 
The DOP-/- mice show a significantly increased ED50 for morphine compared to the WT 
mice. Unpaired t test p < 0.02. (D) The morphine analgesia dose response relationship 
for DOP-/- mice also exhibited a significantly reduced slope (2.6 ± 0.4) compared to that 
for WT mice, unpaired t test p = 0.03. (E) DOP-/- mice do not show basal analgesia. 
Baseline tail withdrawal times are shown for WT, DOP+/- and DOP-/- mice, which do not 
differ significantly (one way ANOVA). Vertical lines represent ± SEM. * p < 0.05, ** p < 
0.01, *** p < 0.001. 
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3.2.3 The role of β-arrestin2 
We investigated morphine analgesia in BAR2+/- and BAR2-/- mice and compared 
this to WT mice. The BAR2-/- mice do not have a significantly different ED50 for 
morphine analgesia tested using the tail withdrawal assay (Figure 3.3A and Table 
3.1). As previously reported BAR2-/- mice exhibit a significantly longer basal tail 
withdrawal latency in a genotype dependent manner (one way ANOVA) (Figure 
3.3B).  
 
As described previously for WT, MOP+/- and MOP-/-, we recorded VACCs from 
DRG neurones to investigate the effects of morphine in the presence of these 
modifications. Morphine (3 μM) caused a 41 ± 8% inhibition of VACC recorded 
from WT DRG neurones, in the BAR2-/- neurones this inhibition was significantly 
reduced to 5.1 ± 2.0% (Figure 3.3C). This reduction in the ability of morphine to 
inhibit the VACC in BAR2-/- DRGs has been previously reported (Walwyn et al., 
2007). It is thought to be due to an increase in constitutive activity of MOP 
receptors in the absence of BAR2. This renders the receptor unavailable to the 
exogenous agonist and so the overall effect of the drug is reduced. 
 
In light of the evidence for an interaction between MOP and DOP receptors in 
the pain pathway we hypothesised that basal analgesia in the absence of BAR2 is 
caused by constitutively active MOP/DOP oligomers (Figure 1.4 Chapter 1).  
 
We tested this hypothesis by breeding mice that lack genes for both BAR2 and 
DOP receptors (BAR2-/-//DOP-/-). The rationale being that if MOP/DOP 
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oligomers are required for constitutive analgesia these double knockout mice 
should lack the phenomenon. The ED50 for the BAR2-/-//DOP-/- mice is not 
significantly different to that for the WT mice (Figure 3.4 and Table 3.1). These 
mice differ from WT mice by exhibiting basal analgesia, (unpaired t test p < 
0.0001, WT n = 110, BAR2-/-//DOP-/- n = 48), (Figure 3.4B). This suggests that 
DOP receptors are not required for the phenomenon of basal analgesia and 
constitutive opioid receptor signalling observed in mice lacking BAR2.  
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Figure 3.3: A lack of BAR2 has no significant effect on the dose-response 
relationship for morphine analgesia but causes basal analgesia. (A) Dose 
response relationships for morphine analgesia in BAR2-/- and WT mice. There is no 
difference in ED50 value for morphine analgesia between WT and BAR2-/- mice. ED50 WT 
= 1.2 ± 0.1 mg/Kg, ED50 BAR2-/- = 1.5 ± 0.4 mg/Kg morphine, WT n = 29, BAR2-/- n = 16. 
(B) BAR2-/- mice show basal analgesia. Their baseline tail withdrawal latencies are 
significantly prolonged compared to WT mice, (one way ANOVA p < 0.0001, post hoc 
Dunnett’s shown on graph, WT n= 110, BAR2+/- n= 30 and BAR2-/- n = 75). (C) Mean 
VACC inhibition by morphine is reduced in BAR2-/- neurones compared to the WT 
neurones, one way ANOVA with post hoc Dunnett’s, p < 0.01. Data points are averages 
of between 4 and 6 recordings. Vertical lines represent ± SEM. * p < 0.05, ** p < 0.01, 
*** p < 0.001. 
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Figure 3.4: Mice that lack DOP receptors and BAR2 exhibit basal analgesia. (A) 
Dose response relationships for morphine analgesia in WT and BAR2-/-//DOP-/- mice. 
WT ED50 = 1.2 ± 0.1 mg/Kg, n = 29 and BAR2-/-//DOP-/- ED50 = 1.4 ± 0.2 mg/Kg 
morphine, n = 16. (B) Like BAR2-/- mice, BAR2-/-//DOP-/- mice exhibit basal analgesia. 
One way ANOVA p < 0.0001 post hoc Dunnett’s shown on graph. WT n = 110, BAR2-/-
//DOP-/- n = 48, BAR2-/- n = 75. Vertical lines represent ± SEM. * p < 0.05, ** p < 0.01, 
*** p < 0.001.  
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3.3 Tolerance 
3.3.1 The role of MOP receptors 
Analgesic tolerance in WT mice leads to a reduction in opioid potency, observed 
as a rightward shift in the dose response relationship. The subcutaneous 
administration of 10 mg/Kg morphine once daily for 10 days, caused tolerance in 
WT mice as evidenced by a significant reduction in the tail withdrawal latency 
following morphine administration on day 10, one way ANOVA p < 0.0001, n = 16 
(Figure 3.5A).  
 
Compared to the WT mice, morphine analgesic tolerance developed significantly 
faster in MOP+/- mice. When these mice were given 10 mg/Kg morphine once 
daily for ten days there was a dramatic reduction in the analgesic effect of 
morphine, one way ANOVA p < 0.0001, n = 15 (Figure 3.5B). The mice show 
significant tolerance from day 4 onwards, despite starting with an analgesic 
effect of morphine that is not significantly different to WT mice. When compared 
directly to the WT mice (Figure 3.5C), there is a significant decrease in morphine 
analgesia in MOP+/- mice from day 4 onwards, (two way ANOVA, time p < 
0.0001, genotype p < 0.0001, n = 15 for MOP+/- mice and n = 16 for WT mice).  
 
As previously discussed, the morphine dose response relationship was 
established for naïve MOP+/- mice (Figure 3.1B), this revealed an ED50 of 6.3 ± 
0.8 mg/Kg morphine. We examined the dose-response relationship in MOP+/- 
mice that had received five days of 10 mg/Kg morphine. At this time point 
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MOP+/- mice exhibit tolerance to morphine analgesia (Figure 3.5B). The dose-
response relationship in these tolerant mice reveals both a further reduction in 
potency (rightward shift of the dose response curve) without an apparent 
reduction in the efficacy of morphine. The ED50 for morphine analgesia shifted 
from 6.3 ± 0.8 mg/Kg in naïve MOP+/- mice, to 43 ± 15 mg/Kg in tolerant MOP+/- 
mice, n = 7 (Figure 3.5D). 
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Figure 3.5: Development of morphine tolerance after repeated daily dosing in 
mice. For all figures analgesic effect of morphine has been measured using the tail 
immersion assay and expressed as %MPE, described in Chapter 2 (%MPE = 100*((drug 
latency – basal latency) / (15 s – basal latency))). (A) WT mice exhibit significant 
tolerance to morphine after 10 days of once daily subcutaneous administration. One 
way repeated measures ANOVA p < 0.0001, post hoc Tukey results vs day 1 shown on 
graph (n = 16). (B) Induction of tolerance in MOP+/- mice. One way repeated measures 
ANOVA p < 0.0001, post hoc Tukey vs day 1 shown on graph (n = 15). (C) Morphine 
tolerance develops significantly earlier and to a greater extent in MOP+/- mice 
compared to WT mice. Two way ANOVA, time p < 0.0001, genotype p < 0.0001, post hoc 
Bonferroni results are shown on graph. n = 15 for MOP+/- mice and n = 16 for WT mice. 
For all figures the black symbols represent WT mice and the open green symbols 
represent MOP+/- mice. (D) Effects of chronic morphine treatment on dose response for 
morphine analgesia in MOP+/- mice. ED50 analgesia for morphine naïve mice is 6.3 ± 0.8 
mg/Kg morphine. The ED50 following 5 days of morphine treatment in the MOP+/- mice 
is 43 ± 15 mg/Kg morphine, n = 7. The solid line represents opiate naïve MOP+/- mice 
and the dotted line tolerant MOP+/- mice. Vertical lines represent ± SEM. * p < 0.05, ** 
p < 0.01, *** p < 0.001. 
 
1 2 3 4 5 6 7 8 9 10
0
20
40
60
80
100
*
***
days
%
M
PE
1 2 3 4 5 6 7 8 9 10
0
20
40
60
80
100
**
***
***
***
***
***
***
days
%
M
PE
A B 
C D 
1 2 3 4 5 6 7 8 9 10
0
50
100
** ** ***
***
***
***
***
days
%
M
PE
0.01 0.1 1 10 100 1000
0
50
100
Morphine (mg/Kg)
%
M
PE
92 
 
 
3.3.2 A role for DOP receptors in morphine tolerance 
DOP+/- and DOP-/- mice also exhibit differences compared to WT mice in the 
development of tolerance to morphine. Significant morphine tolerance occurs by 
day 10 in DOP+/- and DOP-/- mice (DOP+/- mice one way ANOVA p < 0.0001, n = 
15. DOP-/- one way ANOVA DOP-/- p = 0.01, n = 16) (Figure 3.6A and B). While 
significant morphine tolerance does develop in the DOP+/- and DOP-/- mice, this 
is significantly reduced from that seen in the WT mice. On days 9 and 10 a 
significantly higher level of morphine analgesia remains in DOP-/- mice 
compared to the WT mice, two way ANOVA shows a significant difference in 
genotype compared to WT (p = 0.03), WT n = 16 and DOP-/- n = 16 (Figure 3.6C). 
The DOP receptor is important in the development of tolerance to morphine, 
removing the DOP receptor results in significantly reduced tolerance to 
morphine.  
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Figure 3.6: Mice lacking DOP receptors exhibit reduced morphine analgesic 
tolerance. (A) DOP+/- show significant morphine tolerance following 10 days of once 
daily morphine 10 mg/Kg. One way repeated measures ANOVA p < 0.0001, n = 15, post 
hoc Tukey results shown on the graph. (B) DOP-/- mice show reduced morphine 
tolerance over 10 days of once daily morphine administration. One way repeated 
measures ANOVA DOP-/- p = 0.01, n = 16. No post hoc significant differences were 
identified. (C) Morphine tolerance is significantly reduced in DOP+/- compared to WT 
mice. Two way ANOVA reveals a significant reduction in tolerance in the DOP+/- mice 
compared to WT mice (p < 0.01). Two way ANOVA comparing the WT and DOP-/- mice 
reveals a significant difference in genotype (p = 0.03), post hoc Bonferroni results shown 
on graph, WT n = 16 and DOP-/- n = 16. Vertical lines represent ± SEM. * p < 0.05, ** p < 
0.01, *** p < 0.001. 
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3.3.3 A role BAR2 in morphine tolerance 
BAR2 is also important in the development of tolerance to morphine analgesia. 
When the BAR2-/- mice were given morphine daily for the 10 day period they 
exhibited a blunted, but significant tolerance, one way ANOVA p = 0.02, n = 15 
(Figure 3.7B). Both the BAR2+/- and BAR2-/- mice exhibited a significant 
reduction in morphine tolerance during the 10 day protocol when compared to 
the WT mice, two way ANOVA, genotype p= 0.0007, WT n = 16, BAR2+/- n = 8, 
BAR2-/- n = 15, (Figure 3.7C).  
 
When the tolerance paradigm was performed in BAR2-/-//DOP-/- mice morphine 
caused no tolerance even after 10 days of exposure (Figure 3.8A). This was 
significantly different to the WT mice, two way ANOVA, time p = 0.0005, 
genotype p = 0.007, WT n = 16, BAR2-/-//DOP-/- n = 7, and also appears different 
to BAR2-/- and DOP-/- mice (Figure 3.8B and C). These data suggest that both 
BAR2 and DOP receptors are involved in the development of tolerance to the 
analgesic effects of morphine.  
 
 
 
95 
 
 
Figure 3.7: BAR2+/- and BAR2-/- mice exhibit reduced tolerance to morphine 
analgesia. (A) BAR+/- mice do not exhibit significant morphine analgesic tolerance 
following 10 days of once daily dosing, one way ANOVA ns. (B) Likewise, morphine 
tolerance in BAR2-/- mice is minimal at day 10, one way ANOVA p = 0.02 no significant 
differences were identified on post hoc testing, n = 15. (C) Both BAR2+/- and BAR2-/- 
mice show significantly less tolerance to morphine than WT mice, two way ANOVA, time 
p < 0.0001, genotype p = 0.0007, post hoc Bonferroni test results for BAR2-/- mice 
compared to day 1 are shown on the graph. BAR2+/- mice are significantly different 
from WT mice on days 9 and 10 (not shown). WT n = 16, BAR2+/- n = 8, BAR2-/- n = 15. 
Vertical lines represent ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001. 
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Figure 3.8: (A) BAR2-/-//DOP-/- mice do not become tolerant to morphine. 
Following 10 days of administration the level of morphine (10 mg/Kg) analgesia had not 
diminished. (B) BAR2-/-//DOP-/- mice exhibit significantly reduced tolerance compared 
to WT mice, two way ANOVA time p = 0.0005, genotype p = 0.007. Differences between 
WT and BAR2-/-//DOP-/- in post hoc Bonferroni tests are shown on the graph. WT n = 
16, BAR2-/-//DOP-/- n = 7. Vertical lines represent ± SEM. * p < 0.05, ** p < 0.01, *** p < 
0.001. (C) BAR2-/-//DOP-/- mice show less tolerance to morphine than the BAR2-/- 
mice.  
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3.4 Summary 
We have confirmed in MOP-/- mice that morphine (10 mg/Kg) does not cause 
analgesia in the absence of MOP receptors. Morphine also does not inhibit 
VACC’s in DRG neurones from MOP-/- mice. These observations are in keeping 
with previous findings (Matthes et al., 1996, Sora et al., 1997, Walwyn et al., 
2005). In MOP+/- mice we observe a reduced analgesic potency of morphine 
with a rightward shift in the dose response curve, there does not appear to be a 
change in efficacy of the drug in opioid naïve mice. This reduction in potency is 
significant, while the slope of the morphine dose response relationship remained 
unchanged (Table 3.1).  
 
While we identified a significant difference in the baseline tail withdrawal 
latency between male and female mice indicating a higher sensitivity of female 
mice to noxious heat, there were no significant differences between male and 
female mice in ED50 or development of morphine tolerance. However, the 
numbers in our groups are relatively small (a total of 29 mice in the analgesia 
experiment and a total of 16 mice in the tolerance experiment) and so it is likely 
that we would not be able to detect a subtle difference in morphine’s actions 
between genders. A gender difference in baseline sensitivity to noxious heat of 
C57Bl/6 mice has been reported previously (Kest et al., 1999) and other 
investigators using much larger cohorts of mice have demonstrated gender 
differences in morphine analgesia with male rodents receiving greater analgesia 
from morphine (Cicero et al., 1996) and the development of tolerance with 
increased tolerance to the morphine recorded in female mice (Kest et al., 2000, 
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Mogil and Chanda, 2005). To account for this within our results and attempt to 
avoid introducing bias by gender we kept the genders of all experimental groups 
balanced. 
 
MOP+/- mice exhibited a very rapid onset of tolerance following daily 
treatments with 10 mg/Kg morphine. They have significantly less analgesia at 
day 4 of the study protocol compared to day 1. This contrasts with WT mice in 
which there was no significant difference in morphine analgesia until day 9 of 
the protocol. MOP+/- mice also developed a significantly greater degree of 
tolerance to the analgesic effects of morphine by day 10 than that observed for 
WT mice. This suggests that MOP receptor number is important in the 
development of tolerance to morphine’s analgesic effects. MOP+/- mice have 
50% fewer MOP receptors than WT mice due to the deletion of one copy of the 
oprm1 gene (Sora et al., 1997). In WT mice the development of morphine 
tolerance appears to be limited by the existence of an excess of MOP receptors. 
The fact that morphine has a similar analgesic efficacy in naïve MOP+/- and WT 
mice suggests that the loss of 50% of the MOP receptors does not affect this and 
there are therefore spare receptors. The existence of spare receptors in WT mice 
presumably prevents a reduction in efficacy during morphine tolerance despite 
receptor down regulation.  
 
The potency of morphine is affected by an absence of DOP receptors, the ED50 is 
significantly increased in the DOP-/- mice compared to the WT mice (Table 3.1). 
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The slope of the morphine analgesia dose response relationship is also 
significantly reduced in the DOP-/- mice compared to the WT mice. This could be 
explained by a difference in the way that morphine interacts with MOP/DOP 
receptor oligomers compared to homomeric MOP receptors on nociceptive 
neurones. It is possible that binding of morphine to MOP receptors is influenced 
by occupancy of adjacent DOP receptors leading to cooperativity.  
 
While DOP-/- mice do develop tolerance to morphine this is significantly reduced 
compared to WT mice after 10 days of once daily dosing. This finding is 
consistent with work that has been previously published demonstrating the 
importance of DOP receptors in the development of tolerance (Zhu et al., 1999).  
 
BAR2-/- mice exhibited no significant alteration in ED50 value for morphine 
analgesia but did show basal analgesia as previously discussed (Bohn et al., 1999, 
Bohn et al., 2000, Bohn et al., 2002, Lam et al., 2011). Removal of BAR2 does not 
appear to affect binding of morphine as the ED50 and slope of the analgesic dose 
response curve to morphine are unaltered in the BAR2-/- mice.  
 
BAR2-/- mice did develop tolerance to morphine over the course of our 10 day 
protocol, but this was significantly reduced when compared to the WT mice. We 
then investigated the double knockout BAR2-/-//DOP-/- mice. These mice did 
not show any morphine tolerance during our 10 day test protocol. They have the 
same measurable analgesic effect of morphine on day 1 of the protocol as on 
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day 10. Removing both BAR2 and DOP receptors appears to have completely 
abolished tolerance to morphine.  
 
BAR2-/- mice show basal analgesia, their baseline tail withdrawal times, in the 
absence of exogenously administered drug, are significantly prolonged when 
compared to the WT mice. These data are consistent with previously reported 
studies that have also observed this phenomenon (Bohn et al., 1999, Bohn et al., 
2000, Bohn et al., 2002, Lam et al., 2011). We also observed a prolonged 
baseline tail withdrawal time in the BAR2-/-//DOP-/- mice. These mice show 
basal analgesia that is not significantly different to that observed in the BAR2-/- 
mice. DOP-/- mice baseline tail withdrawal times are not significantly prolonged 
when compared to those of the WT mice. It appears that the removal of BAR2 
allows constitutive signalling of MOP receptors to occur resulting in basal 
analgesia. There does not appear to be an involvement of DOP receptors in this 
process. However both BAR2 and DOP receptors are implicated in the 
development of tolerance to morphine. 
 
These results reveal the importance of MOP receptor number, DOP receptors 
and BAR2 in the development of tolerance to morphine. When there is a normal 
intact system, as in the WT mice, MOP and DOP receptors and BAR2 are all 
functioning, then there is an absence of basal analgesia and tolerance develops 
following repeated morphine administration. When DOP receptors are removed 
from this system (MOP receptors and BAR2 remain) morphine tolerance is 
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significantly reduced and there is no basal analgesia. When BAR2 is removed 
leaving MOP and DOP receptors alone this causes basal analgesia and a 
reduction in the development of morphine tolerance. When both BAR2 and DOP 
receptors are removed, leaving MOP receptors alone, basal analgesia occurs 
with no demonstrable tolerance to morphine (Figure 3.9). The significance of 
these findings will be discussed in the context of the entire project in Chapter 7. 
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Table 3.1: Summary of morphine ED50 (mg/Kg) and slope values for morphine 
analgesia in WT, MOP+/-, DOP+/-, DOP-/-, BAR2-/- and BAR2-/-//DOP-/- mice. * P < 0.05 
on Student’s t test compared to WT. 
 
Figure 3.9: The roles of MOP and DOP receptors and BAR2 in basal analgesia 
and the development of morphine tolerance. (A) WT mice do not exhibit basal 
analgesia and develop tolerance to the analgesic effects of morphine. (B) DOP-/- mice 
also do not exhibit basal analgesia, however they do develop significantly reduced 
morphine tolerance when compared to the WT mice. (C) BAR2-/- mice exhibit the 
development of significantly reduced tolerance to morphine analgesia, but they also 
have prolonged basal tail withdrawal times indicating basal analgesia. (D) In mice that 
lack both BAR2 and the DOP receptor we observe basal analgesia and they do not 
develop any significant tolerance to the analgesic effects of morphine over the 10 day 
test period. 
ED50 (mg/Kg morphine) slope n number
WT 1.2 ± 0.1 6.6 ± 1.2 29
MOP+/- 6.2 ± 0.8* 5.7 ± 1.1 15
DOP+/- 1.4 ± 0.2 6.8 ± 1.0 13
DOP-/- 1.8 ± 0.3* 2.6 ± 0.4* 14
BAR2-/- 1.5 ± 0.4 8.2 ± 2.7 16
BAR2-/-//DOP-/- 1.4 ± 0.2 3.3 ± 1.0 16
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Chapter 4: Psychomotor effects of morphine 
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4.1 Introduction 
Opioid receptors expressed throughout the reward pathway are involved in 
several natural (Agmo et al., 1993) and pharmacological rewards (Hall et al., 
2001). MOP receptors are required for the rewarding effects of opioid drugs. 
MOP-/- mice, which have the MOP receptor gene deleted, neither self-
administer opioids or exhibit opioid induced conditioned place preference 
(Matthes et al., 1996, Sora et al., 2001).   
 
We used conditioned place preference (CPP) to examine the reinforcing effects 
of morphine. Conditioned place preference is a Pavlovian behavioural paradigm 
that has been developed to allow the study of the reinforcing properties of drugs 
(Bardo and Bevins, 2000). In order for this test to function the animal must be 
able to associate the context that they are placed in with the drug effect. The 
associative reward learning required for the mice to perform CPP needs 
dopaminergic neurones located within the VTA. Rodents will learn to self-
administer opioid drugs directly into the VTA (Bozarth and Wise, 1984). These 
neurones are thought to encode the relationship between predictive cues and 
future events (Day et al., 2013). However, although the dopaminergic neurones 
of the VTA have been heavily implicated in rewarding processes, they can also be 
activated by aversive stimuli (Lammel et al., 2011). It is thought that they are 
crucial to decision making and so can respond to both rewarding or aversive 
stimuli and aid in the processing of an overall response. Dopamine D2 receptor 
knock-out mice do not self-administer opioid drugs (Elmer et al., 2002) and when 
they are conditioned with morphine in a CPP paradigm they do not exhibit 
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preference for the morphine paired chamber (Maldonado et al., 1997). However 
the D2 receptor knockout mice do retain the ability to demonstrate a preference 
for natural rewards suggesting that the reward processes for natural and drug 
induced effects may be instigated by separate mechanisms (Maldonado et al., 
1997). In dopamine deficient (Th-/-) mice it was still possible to demonstrate a 
preference for morphine in the CPP paradigm in all but the lowest doses of 
morphine that were tested (2.5 mg/Kg), suggesting that although dopaminergic 
systems are important in reward seeking it may not be the only system involved 
in this process (Hnasko et al., 2005). Further work investigating the dopamine D1 
receptor involvement in reward and locomotion following opioid administration 
has revealed that dopamine D1 receptors are not required for the mice to 
demonstrate a preference for morphine in the CPP paradigm but they are 
involved in the locomotor activation observed in rodents (Urs et al., 2011).  
 
Many drugs of abuse, including opioids, increase locomotor activation in mice 
following administration to drug naïve animals. The extent to which morphine 
stimulates locomotor activity is dependent on the genetic background of the 
mouse. C57Bl/6J mice, which are the genetic background of all knockout mice 
used in this study, exhibit a robust dose dependent increase in locomotor 
activity in response to morphine (Brase et al., 1977). This locomotor activation is 
important in the study of the rewarding effects of opioid drugs because 
increases in mesolimbic dopamine release have been implicated in both 
locomotor activation and drug seeking and reward related behaviours (Robinson 
and Berridge, 2000). The psychomotor stimulation theory of addiction proposed 
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by Wise and Bozarth (1987), suggests that forward locomotion is a necessary 
manifestation of the goal directed behaviours required for rewarding processes. 
 
Locomotor activity can be stimulated in rodents by direct administration of an 
opioid into the VTA (Kelley et al., 1980), implicating the VTA not only in reward 
related behaviour but also the observed locomotor activation. However, studies 
have failed to reliably correlate increased mesolimbic dopamine levels with 
locomotor activity following opioid administration (Murphy et al., 2001), 
suggesting that there may be both dopamine dependent and dopamine 
independent mechanisms that underlie the locomotor activation observed with 
opioid drugs. Studies in dopamine deficient mice reveal that Th-/- mice do not 
display a significant locomotor response to morphine compared to matched 
controls except at very high doses of drug (Hnasko et al., 2005). The remaining 
locomotor activation observed in these mice is only 5% of that observed in the 
control mice. So, although dopamine independent mechanisms exist, they 
appear to only play a small part in this process in rodents. 
 
The dopamine dependent component of locomotor activation is thought to be 
mediated via a dopamine D1 receptor mechanism. Activation of this pathway 
appears to recruit BAR2 and mitogen-activated protein kinase (MAPK). 
Phosphorylation and activation of MAPK requires the activity of mitogen-
activated protein kinase kinase (MEK). Systemic administration of the MEK 
inhibitor, SL327, to WT mice inhibits morphine induced locomotion in a dose 
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dependent manner (Urs et al., 2011).  SL327 has been shown to inhibit the 
activity of ERK in the brain (Beaulieu et al., 2006). This suggests that this pathway 
is important in the locomotor activation produced by morphine. 
 
Repeated administration of MOP receptor agonists causes an increased 
locomotor response. This increase in response when drugs are repeatedly 
administered is known as sensitisation. It is postulated that this behaviour may 
be indicative of a switch from voluntary to compulsive intake of the drug and 
therefore indicative of vulnerability to addiction (Charbogne et al., 2014). 
 
We measured locomotor activity during the conditioning phases of the CPP 
paradigm. This was done using a camera to track the position of the mouse 
within the apparatus based on a point coinciding with the position of the mid-
body. Immediately following injection of drug or vehicle mice were placed within 
the corresponding box and monitored for 30 minutes. Our test apparatus 
consisted of two compartments. One chamber had a wallcovering consisting of 
black and white horizontal stripes and the other black and white vertical stripes. 
The floors in each chamber both consisted of 1 cm square wire grid flooring 
material, however the direction of the bars was different in each chamber to 
match the stripe direction. Each test chamber measured 28 x 28 cm and was 19 
cm high. Two test arenas, each consisting of a two compartment apparatus, 
were contained within an operant box (Figure 2.1). These boxes are 
soundproofed and allow the light levels to be controlled at approximately 70 
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lumens; the temperature of the room was maintained between 21 and 23°C. The 
boxes also contain fans but we did not use them during the course of these 
experiments. 
 
4.2 Locomotor effects of morphine  
4.2.1 The role of MOP receptors 
WT mice do not exhibit locomotor activation following the administration of 
morphine (3 mg/Kg). There are no significant changes in either the distance 
travelled or their average speed of travel following morphine or saline injection 
(Figure 4.1A – 4.1D). On day 1 the distance travelled in the 30 minutes following 
saline injection was 20.8 ± 1.1 m and following morphine 3 mg/Kg injection the 
distance travelled was 23.8 ± 2.0 m. The speed of travel of the mice on day 1 
following saline injection was 0.012 ± 0.0007 m/s and following morphine 3 
mg/Kg injection their speed of travel was 0.013 ± 0.001 m/s. The speed of travel 
was not significantly increased following three days of morphine 3 mg/Kg 
injection (0.014 ± 0.002 m/s). 
 
However the WT mice did exhibit locomotor activation following administration 
of morphine (10 mg/Kg). Both their speed and the total distance travelled was 
significantly increased (Figure 4.1E – 4.1H). In this group of mice the distance 
travelled on day 1 in the 30 minutes following saline injection was 18.5 ± 1.4 m 
and following morphine 10 mg/Kg injection the distance travelled was 81.1 ± 7.0 
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m. Their average speed of travel for the 30 minutes was 0.01 ± 0.0008 m/s after 
saline injection and 0.045 ± 0.004 m/s after morphine 10 mg/Kg injection.  
 
The WT mice also developed sensitisation to the locomotor effects of morphine, 
on day 3 of conditioning they travelled significantly further than they had on day 
1 (118.6 ± 13.1 m) and their speed was similarly increased (0.07 ± 0.007 m/s) 
(Figure 4.1F and 4.1H). The distance travelled and the average speed following 
saline injection was unchanged on day 3 of the study (15.0 ± 2.0 m and 0.008 ± 
0.001 m/s respectively). 
 
MOP receptors have been implicated in the locomotor response to morphine 
(Matthes et al., 1996, Sora et al., 2001). Consistent with this, there was no 
significant locomotor activation following morphine administration to MOP-/- 
mice (Figure 4.2). Their distance travelled in the 30 minutes following saline 
injection on day 1 was 19.0 ± 1.6 m and their average speed of travel was 0.011 
± 0.0009 m/s. After an injection of morphine 10 mg/Kg the total distance 
travelled over the 30 minutes observation time was 16.9 ± 2.2 m and their 
average speed of travel was 0.009 ± 0.001 m/s.  
 
There was locomotor activation in MOP+/- mice treated with 10 mg/kg 
morphine, but not sensitisation (Figure 4.3). The total distance travelled by the 
MOP+/- mice after saline injection was 14.3 ± 2.0 m and their speed of travel 
was 0.008 ± 0.001 m/s. Following administration of morphine 10 mg/Kg the total 
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distance travelled was 26.2 ± 1.3 m and their speed of travel was 0.015 ± 0.0007 
m/s.  
 
By day 3 of conditioning the distance travelled was 33.5 ± 3.8 m after morphine 
10 mg/Kg injection; this was not a significant increase from day 1, p = 0.12. 
Furthermore, the locomotor response to morphine of the MOP+/- mice was 
significantly reduced compared to that of the WT mice. We investigated whether 
the reduced locomotor activation was due to a reduction in morphine potency in 
MOP+/- compared to WT mice. Consistent with this, 30 mg/Kg morphine caused 
a significant locomotor activation, which was increased compared to that 
observed after administration of 10 mg/Kg morphine (Figure 4.3). However, even 
at this increased dose of morphine there was no significant sensitisation of mice 
to the locomotor effects of morphine (30 mg/Kg).  The locomotor activation that 
we see for both the 10 and the 30 mg/Kg morphine, although significant, is 
reduced compared to WT mice (Figure 4.4).  
 
Consistent with previous observations these data demonstrate that morphine-
evoked locomotor activity is mediated through MOP receptors. As observed for 
morphine analgesia, the number of MOP receptors is important; MOP+/- mice 
exhibited reduced locomotor activation and also the absence of significant 
sensitisation to morphine.  
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Figure 4.1: Morphine causes a dose dependent locomotor activation in WT mice. WT 
mice do not show significant locomotor activation after 3 mg/kg morphine. (A) There is 
no significant alteration in distance travelled or sensitisation following injection of 
morphine 3 mg/Kg over the 3 days of conditioning, two way ANOVA (ns). (B) There is no 
significant alteration in distance travelled following 3 mg/kg morphine administration 
and no sensitisation. (C) There are no significant changes in speed following injection of 
morphine 3 mg/Kg, two way ANOVA (ns). (D) There is no significant alteration in speed 
of travel over the 3 day protocol following morphine 3 mg/Kg administration. (E) WT 
mice exhibit locomotor activation following morphine 10 mg/Kg administration and 
sensitisation with repeated exposure. Distance travelled following morphine 10 mg/Kg is 
significantly increased compared to saline treatment, two way repeated measures 
ANOVA, time p = 0.0002 and morphine treatment p < 0.0001, n = 8. (F) WT mice show 
sensitisation to the locomotor effects of morphine. They travel a significantly increased 
distance on day 3 of conditioning compared to day 1. The saline injection does not 
affect locomotion and there is no significant change in the distance travelled in the 
saline compartment between day 1 and day 3. (G) Speed of travel is significantly 
increased following morphine 10 mg/Kg, two way repeated measures ANOVA, time p = 
0.0002 and morphine treatment p < 0.0001, n = 8. (H) WT mice exhibited a significant 
increase in the speed of travel following morphine treatment. They also exhibit 
sensitisation to this effect with a significant increase in speed on day 3 compared to day 
1. Bar graphs – white represents saline and black represents morphine. Line graphs – 
red square symbols represent morphine and black circle symbols represent saline. Open 
symbols are day 1 and closed symbols are day 3 of the study. 
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Figure 4.2: MOP-/- mice do not exhibit locomotor activation or sensitisation to 
morphine. (A) Distance travelled is not significantly different following morphine 10 
mg/kg administration or saline injection, two way repeated measures ANOVA (ns), n = 8. 
(B) MOP-/- mice show no changes in speed of travel following conditioning with 10 
mg/Kg morphine, two way repeated measures ANOVA (ns), n = 8. (C) MOP-/- mice did 
not exhibit sensitisation to the effects of morphine 10 mg/Kg over the conditioning 
period. The distance travelled was not significantly different to that of saline treated 
mice. (D) They did not exhibit a significant change in speed following administration of 
10 mg/Kg morphine compared to the saline treated mice. 
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Figure 4.3: MOP+/- mice show a significant dose-dependent locomotor activation by 
morphine without sensitisation. (A) MOP+/- mice administered 10 mg/Kg morphine 
travelled significantly further than saline treated mice, two way repeated measures 
ANOVA, time (ns) and morphine treatment p < 0.0001, n = 8. (B) MOP+/- mice exhibited 
an increase in speed following conditioning with 10 mg/Kg morphine but no 
sensitisation to this effect over the three day conditioning period. Two way repeated 
measures ANOVA, time (ns), morphine treatment p < 0.0001, n = 8. (C) MOP+/- mice 
treated with 10mg/kg morphine do not show sensitisation over the three day 
conditioning period. There are no significant differences in their distance travelled 
between day 1 and day 3. (D) There are also no significant differences in the speed of 
travel between days 1 and 3 of morphine 10 mg/Kg treatment. MOP+/- treated with 
30mg/kg morphine show locomotor activation to morphine but do not sensitise. (E) 
There is significant locomotor activation following administration of 30 mg/kg morphine 
to MOP+/- mice, two way repeated measures ANOVA, time (ns), morphine treatment p 
< 0.0001, n = 8. (F) There is a corresponding significant increase in the speed of travel 
following administration of morphine 10 mg/Kg, two way repeated measures ANOVA 
time (ns), morphine treatment p < 0.0001, n = 8. (G) MOP+/- mice treated with 30mg/kg 
morphine do not show sensitisation to locomotor activation. There is no significant 
increase in the distance travelled between day 1 and day 3. (H) No significant increase in 
speed is seen on day 3 compared to day 1, confirming that there is no sensitisation over 
this time period. Bar graphs – white represents saline and black represents morphine. 
Line graphs – red square symbols represent morphine and black circle symbols 
represent saline. Open symbols are day 1 and closed symbols are day 3 of the study. 
Vertical lines represent ± SEM.  
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Figure 4.4: Locomotor activation by morphine is dependent on the MOP receptors. 
One way ANOVA distance travelled following saline injection (ns, p = 0.21). When 
distance travelled in the saline conditioning session is compared to the morphine 10 
mg/Kg session for each genotype using a paired t test we observe locomotor activation 
in all groups except the MOP-/-, WT p < 0.0001, MOP+/- (10) p = 0.0004, MOP+/- (30) p 
< 0.0001, MOP-/- p = 0.47 (ns), all groups n = 8. One way ANOVA of the morphine 
treated group is significantly different, p < 0.0001. All are significantly reduced 
compared to WT (post hoc Tukey results are shown on the graph). There are also 
significant differences between MOP+/- (10) and MOP+/- (30) (**). MOP+/- (30) and 
MOP-/- (***). There is no significant difference between MOP+/- (10) and MOP-/-. Two 
way repeated measures ANOVA interaction, genotype and drug are all significant (p < 
0.0001). Post hoc Bonferroni results compared to saline are shown on graph 
(immediately above bars). Vertical lines represent ± SEM. *, p < 0.05, **, p < 0.01, ***, p 
< 0.001. 
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4.2.2 The role of DOP receptors 
The DOP receptor influences morphine analgesia and tolerance (Chapter 4). As 
described previously, WT mice do not show significant locomotor activation 
following morphine 3 mg/Kg administration (Figure 4.1A-D). By contrast, 
administration of 3 mg/Kg morphine to DOP-/- mice caused significant 
locomotor activation (Figure 4.5). The distance that DOP-/- mice travelled during 
the 30 minutes following saline injection was 21.3 ± 2.6 m and after morphine 3 
mg/Kg this distance was 28.7 ± 3.1 m. Their average speed of travel following 
saline injection was 0.012 ± 0.001 m/s and after morphine 3 mg/Kg was 0.016 ± 
0.002 m/s. They did not exhibit the development of significant sensitisation to 
morphine’s locomotor effects following three days once daily administration of 3 
mg/kg morphine. The total distance travelled on day 3 of morphine 3 mg/Kg was 
29.0 ± 4.3 and their average speed was 0.016 ± 0.002 m/s. These data suggest 
that DOP-/- mice show increased sensitivity to the locomotor activation 
produced by morphine.  
 
When the mice receive 10 mg/Kg morphine the DOP+/- and the DOP-/- mice 
show a significant locomotor activation which was similar to that observed in WT 
mice (Figure 4.5 and 4.6 compared to Figure 4.1). For the DOP+/- mice the 
distance travelled in the 30 minutes after saline injection was 25.2 ± 3.8 m and 
their average speed was 0.014 ± 0.002 m/s. When morphine 10 mg/Kg was 
administered the distance travelled significantly increased to 63.8 ± 4.5 m 
(Figure 4.6) and their speed of travel was also significantly increased at 0.035 ± 
0.003 m/s (data not shown). The DOP+/- mice also sensitised to the locomotor 
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effects of morphine as on day 3 of the conditioning phase their total distance 
travelled following morphine 10 mg/Kg administration was 95.9 ± 3.3 m and 
their average speed was 0.053 ± 0.002 m/s.  
 
The DOP-/- mice also exhibited significant locomotor activation and sensitisation 
following the administration of morphine 10 mg/Kg. Their distance travelled in 
the 30 minutes following saline injection was 16.3 ± 1.5 m and their speed of 
travel was 0.009 ± 0.0008 m/s. After morphine 10 mg/Kg injection their total 
distance travelled in the 30 minutes was 74.1 ± 3.8 m and their average speed 
was 0.041 ± 0.002 m/s. They also sensitised to the locomotor effects of 
morphine following the administration of the 10 mg/Kg dose, their total distance 
travelled on day 3 of conditioning was 107.5 ± 7.4 m and their average speed 
was 0.06 ± 0.004 m/s (Figure 4.5 and 4.6). 
 
Overall these results suggest that DOP receptors are not required for locomotor 
activation but influence the potency of morphine in this respect. 
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Figure 4.5: DOP-/- mice show significant locomotor activation following both 3 mg/kg 
and 10 mg/Kg morphine. (A) DOP-/- mice administered 3 mg/Kg morphine travelled 
significantly further than saline treated mice, two way repeated measures ANOVA, time 
(ns), morphine treatment p < 0.01. (B) The DOP-/- mice do not display sensitisation to 
the effects of 3 mg/kg morphine over the three days of conditioning, the distance that 
they travel on day 3 is not significantly different to that travelled on day 1. (C) DOP-/- 
mice displayed significant locomotor activation following the administration of 3 mg/kg 
morphine, paired t test p = 0.006. (D) The average speed of travel of DOP-/- mice is 
increased following administration of 3 mg/Kg morphine. (E) The DOP-/- mice do not 
sensitise to the effects of morphine 3 mg/Kg over the three days of conditioning, the 
speed they travel on day 3 is not significantly different from that on day 1. DOP-/- mice 
do not exhibit significantly altered locomotor activation following morphine 10 mg/Kg 
administration when compared to WT mice. (F) DOP-/- mice show locomotor activation 
following 10 mg/kg morphine injection, two way repeated measures ANOVA, time p < 
0.0001, drug p < 0.0001, n = 8. (G) DOP-/- mice show sensitisation in speed of travel 
over the three day conditioning period. They travel significantly faster following 
treatment with 10 mg/ kg morphine on day 3 compared to day 1, two way repeated 
measures ANOVA, time p < 0.0001, drug p < 0.0001, n = 8. (H) DOP-/- mice travel 
significantly further following three days of morphine 10 mg/kg compared to day 1, n = 
8. (I) DOP-/- mice travel significantly faster on day 3 of conditioning compared to day 1, 
n = 8. Bar graphs – white represents saline and black represents morphine. Line graphs – 
red square symbols represent morphine and black circle symbols represent saline. Open 
symbols are day 1 and closed symbols are day 3 of the study. Vertical lines represent ± 
SEM. 
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Figure 4.6: The absence of DOP receptors does not affect locomotor activation 
following morphine 10 mg/Kg. All mice (WT, DOP+/- and DOP-/-) show significant 
locomotor activation with morphine on day 1 of conditioning as shown on graph. WT p < 
0.0001, DOP+/- p = 0.0002, DOP-/- p < 0.0001 (paired t test). There are no significant 
differences in baseline locomotion with saline (one way ANOVA). There were also no 
significant differences in locomotor activation observed following morphine treatment, 
one way ANOVA p = 0.1. Vertical lines represent ± SEM. *, p < 0.05, **, p < 0.01, ***, p < 
0.001. 
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4.2.3 The role of β-arrestin2 
A previous study has implicated BAR2 in the morphine-evoked locomotor 
response (Bohn et al., 1999). In keeping with WT mice (Figure 4.1) BAR2-/- mice 
in the present study did not exhibit locomotor activation following the 
administration of morphine at 3 mg/Kg (Figure 4.7A-4.7D). The distance travelled 
in the 30 minutes following saline administration on day 1 of conditioning was 
11.4 ± 0.9 m and after morphine 3 mg/Kg the distance travelled was 15.3 ± 2.1 
m. The average speed of travel after saline was 0.006 ± 0.0005 m/s and after 
morphine 3 mg/Kg was 0.008 ± 0.001 m/s. In addition, BAR2-/- mice did not 
sensitise to the locomotor effects of morphine during the three days of 
conditioning, on day 3 the distance travelled after morphine 3 mg/Kg was 15.6 ± 
2.9 m and their average speed of travel was 0.009 ± 0.002 m/s. 
 
However, BAR2-/- mice exhibited locomotor activation and sensitisation to 
morphine following administration of 10 mg/Kg (Figure 4.7E-H). The distance 
travelled in the 30 minutes following the saline injection on day 1 was 15.6 ± 1.7 
m and the distance travelled following the morphine 10 mg/Kg injection was 
50.8 ± 6.6 m. Their average speed of travel was 0.009 ± 0.0009 m/s after the 
saline injection and 0.028 ± 0.004 m/s after the morphine 10 mg/Kg injection.  
 
By day 3 of the conditioning period the distance travelled after the morphine 10 
mg/Kg was significantly increased (75.6 ± 12.0 m) and their average speed of 
travel had also increased (0.042 ± 0.007 m/s).  
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BAR2-/-//DOP-/- mice also did not exhibit locomotor activation or sensitisation 
after administration of morphine 3 mg/Kg. Their distance travelled in the 30 
minutes following injection of saline on day 1 was 24.6 ± 0.5 m and their average 
speed of travel was 0.014 ± 0.0002 m/s. After morphine 3 mg/Kg injection their 
total distance travelled over the 30 minutes was 23.5 ± 3.3 m and their average 
speed was 0.013 ± 0.002 m/s. On day 3 of the conditioning period there were no 
significant differences compared to day 1 in either total distance travelled after 
morphine 3 mg/Kg (27.2 ± 6.7 m) or their average speed of travel (0.015 ± 0.004 
m/s) (Figure 4.8A-D).  
 
After morphine 10 mg/Kg administration BAR2-/-//DOP-/- mice also exhibited 
significant locomotor activation and sensitisation to morphine (Figure 4.8E-H). 
The distance travelled by the BAR2-/-//DOP-/- mice in the 30 minutes following 
saline injection was 17.1 ± 1.6 m and after morphine 10 mg/Kg injection the 
distance travelled was 42.5 ± 2.7 m. Their average speed after the saline 
injection was 0.009 ± 0.0009 m/s and after the morphine 10 mg/Kg injection was 
0.024 ± 0.002 m/s. On day 3 of the conditioning period the total distance 
travelled following morphine 10 mg/Kg had significantly increased to 73.1 ± 5.0 
m and their average speed of travel was 0.041 ± 0.003 m/s.  
 
Consistent with the previous report (Bohn et al., 1999), locomotor activation by 
morphine (10 mg/Kg) in BAR2-/- mice was significantly reduced compared to WT 
mice (Figure 4.9).  As discussed previously morphine (10 mg/Kg) produced 
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locomotor activation in the BAR2-/-//DOP-/- mice but this was also significantly 
reduced when compared to the WT mice (Figure 4.9). There was no significant 
difference in locomotor activation by morphine when the BAR2-/- and the BAR2-
/-//DOP-/- mice were compared.  
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Figure 4.7: BAR2-/- mice exhibit locomotor activation by morphine. (A) BAR2-/- mice 
exhibit no significant alteration in distance travelled following the administration of 3 
mg/Kg morphine. (B) BAR2-/- mice do not exhibit locomotor sensitisation following 
morphine 3 mg/KG, there are no significant differences in the distance travelled 
between day 1 and day 3. (C) BAR2-/- mice exhibit no significant differences in average 
speed of travel following administration of morphine 3 mg/Kg. (D) BAR2-/- mice exhibit 
no significant alterations in speed of travel following morphine 3 mg/Kg administration. 
Morphine 10 mg/Kg produces significant locomotor activation and sensitisation in BAR2-
/- mice. (E) The distance travelled was significantly increased following morphine 
administration, two way repeated measures ANOVA, time p = 0.004, morphine p < 
0.0001. (F) The mice exhibit locomotor activation to morphine and sensitise to its 
locomotor activating effects over the conditioning period. The distance travelled on day 
3 was significantly greater than that on day 1. (G) The speed of travel is also significantly 
increased, two way repeated measures ANOVA, time p = 0.005, morphine p < 0.0001. 
(H) The speed travelled on day 3 was significantly greater than on day 1. Bar graphs – 
white represents saline and black represents morphine. Line graphs – red square 
symbols represent morphine and black circle symbols represent saline. Open symbols 
are day 1 and closed symbols are day 3 of the study. Vertical lines represent ± SEM. 
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Figure 4.8: BAR2-/-//DOP-/- mice exhibit locomotor activation following morphine 
administration. (A) There are no significant differences in the distance travelled 
following saline or morphine 3 mg/Kg injection in the BAR2-/-//DOP-/- mice. (B) BAR2-/-
//DOP-/- mice also show no sensitisation to the locomotor effects of morphine 3mg/Kg. 
The distance travelled is not significantly different between day 1 and day 3. (C) The 
average speed of travel is not significantly different between the saline and morphine 3 
mg/Kg injections. (D) Again the BAR2-/-//DOP-/- mice do not exhibit sensitisation, their 
speed of travel is not significantly different from day 1 to day 3. BAR2-/-//DOP-/- mice 
do show significant locomotor activation and sensitisation to morphine 10 mg/Kg. (E) 
Locomotor activation over the conditioning sessions is intact, two way ANOVA time p < 
0.0001, morphine p < 0.0001. (F) The mice show locomotor activation to morphine and 
sensitise to its locomotor activating effects over the conditioning period. (G) The BAR2-
/-//DOP-/- mice exhibit a significant increase in speed following morphine 10 mg/Kg 
administration, two way ANOVA time p < 0.0001, morphine p < 0.0001.  (H) There is also 
significant sensitisation to morphine between day 1 and day 3. The mice travel 
significantly faster by day 3. Line graphs – red square symbols represent morphine and 
black circle symbols represent saline. Open symbols are day 1 and closed symbols are 
day 3 of the study. Vertical lines represent ± SEM. 
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Figure 4.9: Removing β-arrestin2 significantly reduced locomotor activation following 
morphine 10 mg/Kg administration. This is true for the BAR2-/- mice and the BAR2-/-
//DOP-/- mice. There are no significant differences in locomotor activity between these 
mice (unpaired t test p = 0.3), suggesting that the DOP receptor is not involved in this 
aspect of behaviour. Two way ANOVA reveals significant locomotor activation by 
morphine 10 mg/Kg in WT, BAR2-/- and BAR2-/-//DOP-/- mice, p < 0.001, post hoc 
Bonferroni results are shown on the graph. Vertical lines represent ± SEM. *, p < 0.05, 
**, p < 0.01, ***, p < 0.001. 
 
 
 
 
 
  
WT
BA
R2
-/-/
/D
OP
-/-
BA
R2
-/- WT
BA
R2
-/-/
/D
OP
-/-
BA
R2
-/-
0
20
40
60
80
100
Saline
Morphine
***
***
***
*** **
D
is
ta
nc
e 
tr
av
el
le
d 
(m
)
125 
 
4.3 Conditioned place preference 
4.3.1 The role of MOP receptors in reinforcement 
The experiments described above for establishing the locomotor effects of 
morphine were conducted during the conditioning phase of the CPP experiments 
described here. Prior to the conditioning phase mice showed no preference for 
either of the compartments which were distinguishable on the basis of 
differences in the wallcoverings and floor orientation. As previously described 
one chamber had a wallcovering consisting of black and white horizontal stripes 
and the other black and white vertical stripes. As discussed previously, Chapter 
2, the floors in each chamber both consisted of 1 cm square wire grid flooring 
material. The grid direction of this material differs depending on its orientation. 
We utilised this property to provide a difference in the floor between each 
chamber. The direction of the grid matched the wall stripe direction in each 
chamber. The mice investigated both chambers equally as shown by the fact that 
there was no significant difference in time spent in each chamber during the 
habituation phase of the experiment, time spent in saline paired chamber was 
455.7 ± 21.8 s and the time spent in the morphine paired chamber was 444.3 ± 
21.8 s (Figure 4.10A). Morphine administered at 3 mg/Kg to WT mice did not 
cause CPP and the time spent in the saline and morphine chambers was 
consistent throughout the test period (Figure 4.10B and C). The time spent in 
saline paired chamber was 412.9 ± 31.6 s and the time spent in the morphine 3 
mg/Kg paired chamber was 487.1 ± 31.6 s (Figure 4.10B). By contrast, WT mice 
showed a significant preference for the 10 mg/Kg morphine paired chamber 
following three days of conditioning. Time spent in the saline paired chamber 
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was 353.3 ± 11.5 s and the time spent in the morphine 10 mg/Kg paired chamber 
was 546.8 ± 11.5 s (Figure 4.10D). Mice spent a significantly longer time in the 
morphine-paired chamber, p<0.0001. Furthermore, the time spent in the 
morphine paired chamber compared to the saline paired chamber was 
consistent throughout the test period suggesting that there was no extinction 
during this observation period (Figure 4.10E).  
 
The development of morphine preference in MOP+/- and MOP-/- mice was 
investigated using the same conditioning protocol. MOP-/- mice did not show a 
preference for morphine. The time spent in saline paired chamber was 441.4 ± 
20.2 s and the time spent in morphine 10 mg/Kg chamber was 458 ± 20.2 s 
(Figure 4.10F), confirming the importance of MOP receptors in reinforcement. 
Importantly, there was no initial chamber bias during habituation, the time spent 
in the saline paired chamber was 445.1 ± 23.0 s and the time spent in the 
morphine paired chamber was 454.9 ± 23.0 s (data not shown). There was also 
no significant difference in the time spent in the saline and morphine paired 
chambers throughout the test period (Figure 4.10G). 
  
The MOP+/- mice did not show a significant preference for the morphine paired 
chamber following conditioning with 10 mg/Kg morphine. The time spent in the 
saline paired chamber was 419.8 ± 25.0 s and the time spent in the morphine 10 
mg/Kg paired chamber was 480.2 ± 25.0 s (Figure 4.11A). Closer examination of 
the data reveals that MOP+/- mice initially exhibited a preference for the 
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morphine paired chamber but this preference was extinguished during the test 
period (Figure 4.11B and C). The MOP+/- mice show a significant reduction in 
preference score for 10 mg/Kg morphine compared to WT mice, 60.3 ± 49.9 
compared to 193.5 ± 23.0 for the WT mice (Figure 4.11D).  
 
The reduced preference of MOP+/- mice for morphine in this paradigm appears 
to be caused by reduced drug potency. When the conditioning dose of morphine 
was increased to 30 mg/Kg the MOP+/- mice exhibited a preference for the 
morphine paired chamber over the saline paired chamber. The time spent in the 
saline paired chamber was 371.0 ± 25.8 s and the time spent in the morphine 
paired chamber was 529.0 ± 25.8 s. The preference score for the morphine 
paired chamber was 157.9 ± 51.6 (Figure 4.11E). The MOP+/- mice no longer 
exhibited extinction of the morphine preference during the testing period when 
conditioned with morphine 30 mg/Kg (Figure 4.11F). There was no initial 
chamber bias for the MOP+/- mice during habituation, time spent in the saline 
paired chamber was 453.9 ± 28.1 s and the time spent in the morphine paired 
chamber was 446.1 ± 28.1 s (data not shown). 
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Figure 4.10: MOP receptors are required for the reinforcing effect of morphine. (A) WT 
mice show no chamber preference during the habituation phase of conditioned place 
preference (CPP). Student’s t test p = 0.8, n = 8. (B) WT mice exhibit no preference for 
the morphine paired chamber following conditioning with morphine 3 mg/Kg, paired t 
test p = 0.3, n = 8. (C) Time spent by the WT mice in the saline and morphine paired 
chambers by segment of test following conditioning with morphine 3 mg/Kg. Two way 
ANOVA ns, n = 8. (D) WT mice do show significant preference for the morphine paired 
chamber after three days of conditioning with morphine 10 mg/Kg, paired t test p < 
0.0001, n = 8. (E) Time spent in each chamber on test day. WT mice demonstrated a 
continued preference for the morphine paired chamber throughout the test period, 
with no sign of extinction within the test period of 900 s. (F) MOP-/- mice exhibit no 
preference for morphine following conditioning with morphine 10 mg/ Kg for three 
days, paired t test (ns) p = 0.7, n = 7. (G) The time that the MOP-/- mice spent in the 
saline and morphine paired chambers is not significantly different throughout the test 
period. Two way ANOVA ns, n = 7. Vertical lines represent ± SEM. *, p < 0.05, **, p < 
0.01, ***, p < 0.001. 
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Figure 4.11: Morphine has a lower potency for reinforcement in MOP+/- mice. (A) 
MOP+/- mice do not show a significant preference for the morphine paired chamber 
following conditioning with 10 mg/Kg morphine, n = 8 t test p = 0.27. (B) MOP+/- mice 
show a reduction in morphine preference over time during the test period compared 
with the WT mice. (C) MOP+/- mice show extinction of morphine preference during the 
test period following conditioning with 10 mg/kg morphine. During the first 300 s of the 
test period there are no significant differences between the MOP+/- and WT mice, 
suggesting that the MOP+/- mice are at this point showing a preference, unpaired t test 
p = 0.4, n = 8. During the last 300s of the test period (Segment 600-900 s) there is now a 
significant difference in the time spent in the drug paired chamber between the WT and 
MOP+/- mice. This suggests extinction of preference in the MOP+/- mice, unpaired t test 
p = 0.04. (D) The MOP+/- mice show a significant reduction in preference score for 
morphine 10 mg/Kg compared to WT mice, unpaired t test p = 0.03. (E) MOP+/- mice 
conditioned with 30 mg/Kg morphine exhibit significant morphine preference, paired t 
test p = 0.02, n = 8. (F) Morphine has reduced reinforcement potency in MOP+/- mice 
compared to WT mice. Time in morphine paired chamber shown for WT mice, MOP+/- 
mice (10 mg/kg) and MOP+/- mice (30 mg/kg). This is restored following conditioning 
with 30 mg/Kg. Vertical lines represent ± SEM. *, p < 0.05, **, p < 0.01, ***, p < 0.001. 
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4.3.2 The role of DOP receptors in reinforcement 
The DOP+/- and DOP-/- mice did not display any initial chamber preference on 
the habituation day. The DOP+/- mice spent 452.3 ± 15.1 s in the saline paired 
chamber and 447.7 ± 15.1 s in the morphine paired chamber. The DOP-/- mice 
spent 451.3 ± 13.7 s in the saline paired chamber and 448.7 ± 13.7 s in the 
morphine paired chamber (data not shown). DOP-/- mice did not exhibit a 
significant preference for the morphine paired chamber following conditioning 
with morphine 3 mg/Kg. The time spent in the saline paired chamber was 433.3 
± 12.2 s and the time spent in the morphine 3 mg/Kg paired chamber was 466.7 
± 12.1 s resulting in a preference score of 33.3 ± 24.3 (Figure 4.12A).  
 
During CPP both strains exhibited a significant preference for the morphine 10 
mg/Kg paired chambers on test day. DOP+/- mice spent 380.5 ± 16.8 s in the 
saline paired chamber and 519.5 ± 16.8 s in the morphine paired chamber 
(preference score 138.9 ± 33.7) (data not shown) and the DOP-/- mice spent 
370.8 ± 21.7 s in the saline paired chamber and 529.3 ± 21.7 s in the morphine 
10 mg/Kg paired chamber (preference score 158.5 ± 43.5) (Figure 4.12B). There 
was no significant difference in the preference scores between these genotypes 
(Figure 4.12E).  
 
Conditioning with 10 mg/Kg morphine is significantly more reinforcing in the 
DOP-/- mice compared to conditioning with morphine 3 mg/Kg (Figure 4.12C). 
There was no significant difference in the time that the DOP-/- mice spent in the 
morphine and saline chambers over the duration of the test (Figure 4.12D). The 
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DOP-/- mice do not exhibit extinction of morphine preference during the test 
period.  
 
These data suggest that the removal of DOP receptors does not significantly 
affect morphine reinforcement in our model. Using this paradigm and dose of 
morphine there were no significant differences between WT, DOP+/- and DOP-/- 
mice (Figure 4.12E). 
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Figure 4.12: DOP receptors are not required for morphine reinforcement. (A) DOP-/- 
mice do not exhibit a morphine preference following conditioning with morphine 3 
mg/Kg, paired t test p = 0.2 n = 8. (B) DOP+/- and DOP-/- show a significant preference 
for morphine 10 mg/Kg. DOP+/- mice exhibited a significant preference for morphine 
following conditioning with 10 mg/Kg, paired t test p = 0.004, n = 8 (data not shown). 
DOP-/- mice showed a significant preference for morphine following conditioning with 
morphine 10 mg/Kg, paired t test p = 0.008, n = 8. (C) There is significantly more 
preference for the morphine paired chamber when the DOP-/- mice are conditioned 
with 10 mg/Kg morphine, p = 0.02 n = 8. (D) Time spent in the saline and morphine 
paired chambers during the test period by the DOP-/- mice reveals a lack of extinction of 
morphine preference during the test period. (E) DOP-/- and DOP+/- mice show no 
difference in morphine preference for 10 mg/Kg morphine compared to WT mice, one 
way ANOVA ns, n = 8. Vertical lines represent ± SEM. *, p < 0.05, **, p < 0.01, ***, p < 
0.001. 
 
 
 
 
 
Saline Morphine
0
200
400
600
Ti
m
e 
(s
) i
n 
dr
ug
-p
ai
re
d 
ch
am
be
r
3 10
0
100
200
300
400
*
Morphine (mg/Kg)
Pr
ef
er
en
ce
 s
co
re
 (s
)
Saline Morphine
0
200
400
600 **
Ti
m
e 
(s
) i
n 
dr
ug
-p
ai
re
d 
ch
am
be
r
0-300 300-600 600-900
0
50
100
150
200
250
Saline
Morphine
segment of test (s)
Ti
m
e 
(s
) i
n 
dr
ug
-p
ai
re
d 
ch
am
be
r
WT DOP+/- DOP-/-
0
100
200
300
400
Pr
ef
er
en
ce
 s
co
re
 (s
)
A B C 
D E 
133 
 
4.3.3 The role of β-arrestin2 in reinforcement 
It has previously been demonstrated that BAR2-/- mice show an increased 
preference for morphine compared to WT mice in the CPP paradigm (Bohn et al., 
2003). Therefore mice were tested with 3 mg/Kg morphine, a dose that was 
without effect in WT mice (Figure 4.10B). By contrast to WT mice, BAR2-/- mice 
exhibited a significant preference for morphine following three days of 
conditioning to 3 mg/Kg. The time spent in the saline paired chamber was 330.7 
± 19.2 s and the time spent in the morphine 3 mg/Kg paired chamber was 569.3 
± 19.2 s (the preference score for 3 mg/Kg morphine was 238.6 ± 38.4) (Figure 
4.13A).  
 
When the BAR2-/- mice were conditioned and tested with morphine 10 mg/Kg 
there was also significant morphine CPP. The time spent in the saline paired 
chamber was 326.8 ± 41.4 s and the time spent in the chamber paired with 
morphine 10 mg/Kg was 573.2 ± 41.4 s (Figure 4.13B). The preference of BAR2-/- 
and WT mice for 10 mg/Kg morphine was not significantly different. WT 
preference score for 10 mg/Kg morphine was 193.5 ± 23.0 and the BAR2-/- 
preference score was 246.5 ± 82.7 (Figure 4.13C). As the preference was 
maintained throughout the test period (Figure 4.13D), BAR2-/- mice did not 
demonstrate significant extinction.  
 
There was no initial preference for either chamber. On habituation day the 
BAR2-/- mice spent 450.0 ± 22.4 s in the saline paired chamber and 450.0 ± 22.4 
s in the morphine paired chamber (data not shown). There was no significant 
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difference between the preference scores for 3 and 10 mg/Kg morphine in BAR2-
/- mice suggesting that these doses lie at the top of the morphine dose-response 
relationship for reinforcement. These data suggest that there is a considerable 
increase in the potency of morphine reinforcement in BAR2-/- mice. 
 
The BAR2-/-//DOP-/- mice did not show a significantly increased preference for 
the morphine paired chamber following conditioning with 3 mg/Kg morphine, 
although there was a trend towards a preference (p = 0.07). The time that they 
spent in the saline paired chamber on the test day was 391.2 ± 27.2 s and the 
time that they spent in the chamber paired with morphine 3 mg/Kg was 508.8 ± 
27.2 s, this gave a preference score of 117.6 ± 54.6 for the morphine 3 mg/Kg 
paired chamber (Figure 4.14A).  
 
Like WT and BAR2-/- mice, BAR2-/-//DOP-/- mice also showed a significant 
preference for morphine following conditioning with 10 mg/Kg. The time spent 
in the saline paired chamber was 380.1 ± 18.0 s and the time spent in the 
morphine 10 mg/Kg paired chamber was 520.0 ± 18.0 s, resulting in a preference 
score of 139.9 ± 36.0 for the morphine (10 mg/Kg) paired chamber (Figure 
4.14B). Again these mice did not show any extinction of this preference during 
the test period (Figure 4.14D). Their preference scores for the morphine paired 
chambers were not significantly different from either that of the WT mice or the 
BAR2-/- mice (Figure 4.14C). There was no significant initial chamber bias during 
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habituation, time spent in the saline paired chamber was 469.0 ± 19.1 s and time 
spent in the morphine paired chamber was 431.0 ± 19.1 s (data not shown). 
 
When the preference scores are compared across the genotypes we observed a 
trend for a dose response relationship in the WT and DOP-/- mice. However in 
the BAR2-/- and BAR2-/-//DOP-/- mice both 3 mg/Kg and 10 mg/Kg morphine 
appear to be at the top of the dose response relationship. This suggests that the 
BAR2-/- and BAR2-/-//DOP-/- mice are more sensitive to the conditioned 
reinforcing properties of morphine. 
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Figure 4.13: BAR2-/- mice exhibit increased sensitivity to morphine reinforcement. (A) 
3 mg/Kg morphine is reinforcing in BAR2-/- mice. BAR2-/- mice show a preference for 
morphine following conditioning with 3mg/Kg morphine, paired t test p = 0.0004 n = 8. 
(B) BAR2-/- mice show morphine preference following 3 days of conditioning to 10 
mg/Kg morphine, t test p = 0.0009, n = 8. (C) BAR2-/- show a significantly increased 
preference for morphine compared to WT mice following conditioning with 3 mg/Kg 
morphine, t test p = 0.04 n = 8. There is no difference in preference score between 3 
mg/Kg and 10 mg/Kg for BAR2-/- mice, t test ns, p = 0.9 n = 8. At 10 mg/Kg there is no 
significant difference in morphine preference between the WT and BAR2-/- mice, t test 
p = 0.55, n = 8. (D) BAR2-/- mice show continued preference for the morphine 10 mg/Kg 
paired chamber during the entire test period, similar to the WT mice they do not show 
extinction of the preference, two way ANOVA ns, n = 8. Vertical lines represent ± SEM. 
*, p < 0.05, **, p < 0.01, ***, p < 0.001. 
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Figure 4.14: BAR2-/-//DOP-/- mice exhibit morphine reinforcement. (A) BAR2-/-//DOP-
/- mice appear to spend more time in the morphine 3 mg/Kg paired chamber on test 
day but this is not significant, paired t test p = 0.07 n = 8. (B) BAR2-/-//DOP-/- mice do 
exhibit a significant preference for the 10 mg/Kg morphine chamber on test day, paired 
t test p = 0.006, n = 8. (C) There is no significant difference in the preference score of 
these mice for morphine when we compare the measured preference at 3 mg/Kg and 
10 mg/Kg morphine, p = 0.7 n = 8. (D) Time spent in morphine 10 mg/Kg chamber on 
test day is not significantly different from WT mice, two way ANOVA ns. The BAR2-/-
//DOP-/- mice do not show extinction of preference over the test period. Vertical lines 
represent ± SEM. *, p < 0.05, **, p < 0.01, ***, p < 0.001. 
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4.4 Summary 
WT mice exhibited a robust dose dependent locomotor activation by morphine 
and they sensitised to these effects, this is consistent with work previously 
published (Brase et al., 1977). They also exhibited a dose dependent relationship 
in the preference that they express for morphine in the CPP paradigm. None of 
the mice tested exhibited a significant preference for either chamber on the 
habituation day. The distance travelled in the 30 minutes after saline injection 
on day 1 was not significantly different across the genotypes tested. 
 
Locomotor activation following morphine administration requires MOP 
receptors, it does not occur in the MOP-/- mice. MOP receptors are also required 
for the reinforcing effects of morphine. The MOP-/- mice expressed no 
preference for the morphine paired chamber during CPP. These results are 
consistent with previously published work (Matthes et al., 1996, Sora et al., 
2001).  
 
The MOP+/- mice reveal that, as demonstrated for analgesic response (Chapter 
4), there is a reduction in the potency of morphine for both locomotor activation 
and reinforcement. Locomotor activation in these mice is significantly reduced 
compared to WT mice. Even when the locomotor activation produced by the 
highest dose tested in the MOP+/- mice (morphine 30 mg/Kg) is compared to 
that produced by morphine (10 mg/Kg) in the WT mice we still observe a 
significant reduction in the locomotor activation produced by morphine. MOP+/- 
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mice do not show any sensitisation to the locomotor activating effects of 
morphine even at a dose of 30 mg/Kg. This suggests that MOP receptor number 
is critical for the process of sensitisation.  
 
In the MOP+/- we observed a dose dependency in the development of morphine 
preference, with no significant preference at 10 mg/Kg but a restored preference 
when the mice are conditioned with 30 mg/Kg morphine. Interestingly, the 
MOP+/- mice displayed a preference for the 10 mg/Kg morphine paired chamber 
during the first 300 s of the test period but this was extinguished by the last 300 
s (segment 600 – 900 s). This suggests a reduction in potency of morphine in 
these mice as we have observed for the analgesic and locomotor effects 
previously. This pattern of extinction observed in the MOP+/- mice conditioned 
with morphine (10 mg/Kg) did not occur in the other groups of mice tested. WT 
mice do not display a preference for the morphine paired chamber following 
conditioning with morphine 3 mg/Kg at any of the time points. There are no 
significant differences in the time spent in each chamber across the test period. 
This is also the case for the MOP-/- mice conditioned with morphine (10 mg/Kg). 
These data suggest that MOP receptors alone are responsible for this effect and 
that receptor number may have a role in this process. 
 
The DOP-/- mice exhibited no significant alteration in locomotor activation at 10 
mg/Kg morphine compared to the WT mice but interestingly did demonstrate 
increased sensitivity to its locomotor activating effects. They exhibited significant 
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locomotor activation at the 3 mg/Kg dose which the WT mice do not. This 
implies that the DOP receptor may be involved in limiting the sensitivity of the 
locomotor system to activation by morphine. Utilizing a different morphine dose 
and test protocol it has been previously reported that DOP-/- mice exhibit a 
greater degree of locomotor activation to morphine when compared to WT mice 
and also sensitise to this effect at a faster rate (Chefer and Shippenberg, 2009). 
We have only tested our mice over the three day conditioning period for CPP 
and so we are not able to determine if this occurs in our study. 
 
The DOP-/- mice exhibited no significant alteration in morphine preference 
compared to the WT mice at either the 3 mg/Kg or 10 mg/Kg morphine doses, 
suggesting that DOP receptors are not involved in morphine reinforcement. The 
results obtained here for morphine CPP differ in some respects from findings 
previously published. One study demonstrated that the DOP-/- mice developed a 
morphine preference only when paired with a previously non-preferred chamber 
and not when paired with a preferred chamber (Chefer and Shippenberg, 2009). 
This is hard to interpret when compared to our results as we commenced the 
conditioning phase with no initial chamber bias. They also maintained the CPP 
apparatus in darkness whereas we use controlled low light levels. The study does 
not state whether the mice were tested in their normal light phase as ours were. 
The only difference between their chambers was floor texture whereas we use 
both a pattern and floor difference to provide cues to the mice that the 
chambers are different. Other groups have suggested that the acquisition of 
morphine CPP in the DOP-/- mice is state dependent, testing with no drug 
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resulted in no preference and testing with drug present revealed a preference 
for the previously paired chamber (Le Merrer et al., 2011). Further work has 
suggested that it is the drug-context association that is important in the 
acquisition of morphine CPP in these mice, giving a time, sound or drug cue 
restored morphine CPP (Le Merrer et al., 2012).  
 
Our experimental protocol was the same for all genotypes, it involved an AM 
saline injection and a PM morphine injection separated by a 4 hour interval, 
testing took place at a time point midway between the administration points. It 
is conceivable that this protocol constituted enough of a circadian cue to allow 
our DOP-/- mice to develop morphine preference. 
 
BAR2-/- mice exhibited a significant reduction in locomotor activation following 
the administration of 10 mg/Kg morphine as has previously been reported (Bohn 
et al., 2003). We could observe no significant locomotor activation following the 
administration of morphine 3 mg/Kg in either the BAR2-/- or WT mice. The 
BAR2-/- mice also did not demonstrate any sensitisation to the locomotor 
activating effects of morphine at the 10 mg/Kg dose, this is significantly different 
from the behaviour of the WT mice. The BAR2-/- mice exhibited a marked 
preference for the morphine paired chamber at both 3 and 10 mg/Kg morphine. 
While the WT and DOP-/- mice demonstrate a dose response relationship in the 
development of morphine preference, this is lost in the BAR2-/- mice. The 
preference score for morphine at 3 and 10 mg/Kg are not significantly different. 
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This is likely because these doses lie at the top of the dose response relationship 
for morphine preference in these mice and reveal a significant increase in the 
potency of morphine to produce reinforcement when BAR2 is absent. 
 
BAR2-/-//DOP-/- mice also exhibited significantly reduced locomotor activation 
following administration of morphine 10 mg/Kg compared to WT mice. This is 
not significantly different to that observed in the BAR2-/- mice. These mice do 
not exhibit a significant preference for morphine following conditioning with 
morphine 3 mg/Kg, although there is a trend towards significance. They do 
demonstrate a preference for the morphine paired chamber following 
conditioning with morphine 10 mg/Kg. They exhibited no extinction of 
preference during the test period at either dose and their preference scores for 
morphine are not significantly different from those of the BAR2-/- mice. 
 
MOP-/- mice do not exhibit morphine preference confirming that the MOP 
receptor is required for the development of preference for opioid. By contrast, 
there were no significant differences between WT mice and DOP-/- mice in the 
development of morphine preference. This conflicts to some extent with 
previously published work but may be due to differences in our experimental 
protocol. Removing β-arrestin2 increases the sensitivity of the mice to the 
reinforcing effects of morphine and suggests that the potency of morphine to 
produce a preference is increased in this circumstance.  
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The role of opioid receptors and BAR2 in the psychomotor effects of morphine 
will be discussed further in the context of analgesia in the final discussion 
(Chapter 7). 
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Chapter 5: Opioid receptor signalling within the VTA 
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5.1 Introduction 
The VTA in the midbrain is important for a number of behaviours but particularly 
in the development of reward and goal directed behaviour (Ungless and Grace, 
2012). Although dopaminergic (DA) cells only make up <1% of the total brain 
neuronal population (Arias-Carrion et al., 2010), three areas in the midbrain 
(retrorubal field, substantia nigra pars compacta (SNc) and the VTA) contain 70-
75% of them (Grillner and Mercuri, 2002).  
 
Within the VTA differing cell populations have been reported. Ungless et al 
(2012) suggest that the composition is 70% DA cells, 30% GABAergic and 2-3% 
glutamatergic, which is similar to that suggested by Chieng et al (2011). 
However, Margolis et al (2012) have reported that 22% VTA neurons are neither 
GABAergic nor dopaminergic when assessed using immunostaining. These 
differences may be due to species differences between rat and mouse or to the 
precise location assessed within the VTA as it appears that this is a 
heterogeneous area.  
 
Johnson and North (Johnson and North, 1992b, Johnson and North, 1992a) 
suggested that cells could be distinguished into two groups in the rat VTA, 
principal cells and secondary cells as in the SNc reported by Lacey et al (1989). 
They suggested that tyrosine hydroxylase (TH) positive, spontaneously active 
(1.7 +/- 0.1 Hz) principal cells were dopaminergic with a long duration AP (half 
peak amplitude 0.92 +/- 0.02 ms) and hyperpolarised to dopamine but not met-
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enkephalin. In contrast, TH negative secondary cells were usually quiescent with 
short duration APs (0.50 +/- 0.03 ms), were hyperpolarised by met-enkephalin, 
but not dopamine (Johnson and North, 1992b).  
 
Margolis et al (2006) looked at a variety of parameters within rat brain slices to 
attempt to distinguish cell type. It was noted that there were differences in cell 
morphology between TH(+) and GAD67-GFP(+) cells. Most elliptical neurones 
were TH(+) and most multipolar neurones were GAD67-GFP(+) but no 
morphology was exclusive to a single cell type. No differences were observed in 
the cell cross sectional area. Furthermore no differences were found in whole 
cell action potential duration between the cell types, (Ih(+) TH(+) cells 2.4 +/- 0.1 
ms, Ih(-) 2.3 +/- 0.3 ms and Ih(+) TH(-) 2.1 +/- 0.2 ms). They found overall that 
none of the following: Ih magnitude, Rinput, or dopamine D2 receptor agonist 
inhibition could be used to differentiate DA neurones from non-DA neurones in 
the VTA (Margolis et al., 2006).  
 
Chieng et al (2011) utilised GAD67-GFP mice to investigate differences between 
cell types, they studied both cell attached and whole cell recording 
configurations. In cell attached mode the GAD67-GFP(+) cells had shorter AP 
durations (0.43 +/- 0.02 ms) and higher spontaneous AP frequencies (3.6 +/- 0.8 
Hz) than did negative cells (AP duration: 1.49 +/- 0.04 ms and firing frequency: 
1.6 +/- 0.2 Hz). There was no overlap between these cell groups and so they 
could be distinguished using these parameters. This was not the case in whole 
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cell recording, where there was considerable overlap between the cell types. The 
AP duration was generally less in GAD67-GFP positive cells but could not be used 
to reliably distinguish cell type. They also looked at cell size, GFP(+) cells were 
generally smaller than other cells, but there was again considerable overlap 
between groups. 
  
In mouse VTA, Hnasko et al (2012) found Ih to be an unreliable marker of cell 
phenotype. They also found that AP durations between DA and glutamatergic 
cells were not significantly different. Despite these inconsistencies, a variety of 
people have used Ih as a marker of DA neurones (Madhavan et al., 2010, Zhang 
et al., 2010). Zhang et al (2010) found that the magnitude of Ih varies according 
to the projection target of the individual neurone and its anatomical location 
within the VTA. This heterogeneity has been increasingly appreciated as the role 
of this brain area and influence on behaviour has been investigated (Lammel et 
al., 2011, Lammel et al., 2012, Lammel et al., 2014). Both the GABAergic and the 
dopaminergic neurones of the VTA receive inputs from several different areas of 
the brain. These inputs can produce excitatory, modulatory or inhibitory effects. 
It is becoming increasingly apparent that neuronal subpopulations exist within 
the VTA and these subpopulations belong to different circuits that produce 
differing behavioural responses (Beier et al., 2015). A number of different 
GABAergic inputs synapse onto VTA neurones, these originate from either local 
interneurones, NA or RMTg (Barrot et al., 2012, Cui et al., 2014, Matsui et al., 
2014). Matsui et al (2014) demonstrated in rat brain slices that opioid inhibition 
of GABAergic IPSCs within the VTA was projection specific, with a significant 
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input from terminals arising in the RMTg. Differences in cell type distribution and 
function have also been identified across the anterior/ posterior sections of the 
VTA (Sanchez-Catalan et al., 2014).  
 
DA neurones from the VTA project mainly to the nucleus accumbens (NA) within 
the ventral striatum as well as the pallidum, prefrontal cortex, amygdala and 
hippocampus. Together these projections form the mesocorticolimbic dopamine 
system (Korotkova et al., 2004). Recent optogenetic studies support a role for DA 
neurones within the VTA in reinforcement. Rats and mice will learn a 
conditioned response in order to receive a photostimulation that selectively 
excites the DA neurones within the VTA (Tsai et al., 2009). Photostimulation of 
the VTA DA neurones using this method produces CPP in a manner similar to 
that of natural rewards (Kim et al., 2012). 
 
MOP receptor agonists produce analgesia in part by reducing Ca2+ entry through 
VACCs on primary afferent neurones, reducing the frequency of excitatory 
postsynaptic currents (EPSCs) in dorsal horn (DH) neurones of the spinal cord 
(Heinke et al., 2011). By contrast, MOP receptor agonists reduce the frequency 
of GABAergic inhibitory postsynaptic currents (IPSCs) in the VTA disinhibiting 
dopaminergic neurones, increasing dopamine release and stimulating reward 
(Johnson and North, 1992b, Matsui and Williams, 2011, Fields and Margolis, 
2015, Xi and Stein, 2002). The mechanism by which opioid drugs mediate the 
observed inhibition of IPSC frequency in the VTA remains unknown (Williams et 
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al., 2013). There appear to be significant differences in the behaviour of MOP 
receptors following agonist binding depending on their location within the 
neurone (Lowe and Bailey, 2015).  
 
There is conflicting evidence regarding the expression of DOP receptors within 
the VTA. It has been proposed that GABAergic neurones of the VTA express MOP 
receptors but not DOP receptors (Matsui and Williams, 2011). This would 
suggest that in these neurones there may be an absence of MOP/DOP receptor 
heterodimers and consequently a lack of basal recruitment of BAR2 (Rozenfeld 
and Devi, 2007). However, further studies have identified neuronal expression of 
DOP receptors within the VTA (Erbs et al., 2015, Erbs et al., 2014) and It has been 
suggested that DOP receptors are involved in addiction behaviours (Gendron et 
al., 2015). Rats will learn to self-administer both MOP receptor agonists and 
DPDPE directly into the VTA (Devine and Wise, 1994) and both MOP and DOP 
agonists cause an increase in the striatal dopamine levels following VTA injection 
(Devine et al., 1993a). We have investigated the role of DOP receptors in CPP 
and locomotor activation produced by morphine (Chapter 4). No difference in 
morphine preference could be identified between the WT and DOP-/- mice.  
 
We examined the involvement of MOP, DOP receptor and BAR2 in opioid-
mediated signalling within the VTA. To do this brain slices were taken from WT 
mice and mice that lack one or both copies of the MOP, DOP or BAR2 genes.  
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5.2 VTA cell type identification 
Horizontal brain slices of 250 μm thickness were used to study the 
electrophysiological consequences of activating opioid receptors within the VTA. 
Slices were labelled with a tyrosine hydroxylase antibody and a secondary 
antibody conjugated to Alexa Fluor 594 to reveal dopaminergic cells (Figure 5.1). 
During whole-cell recording biocytin 1% was used within the intracellular 
solution. This was allowed to dialyse into the cell. Slices were subsequently 
exposed to streptavidin-Alexa Flour 488 secondary antibody. Slices were then 
imaged using confocal microscopy (Figure 5.1C and D).  
 
The protocol worked reliably for labelling with the TH antibody and 
dopaminergic cells of the VTA were routinely identified within brain slices used 
for recording. Labelling with intracellular biocytin during whole cell recording 
was considerably less reliable. There are many possible reasons for the 
unreliable nature of the approach. These include washout of the biocytin during 
long recordings performed particularly for the concentration response curves. 
Inability to locate the biocytin labelled cell within the slice due to rotation of the 
slice during fixation and staining and potential leakage of biocytin from the cell 
during removal of pipette, fixation and/or staining. An example of a successfully 
biocytin labelled TH positive cell is provided in Figure 5.1C and D. 
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Figure 5.1: The identification of dopaminergic cells within the VTA. (A) Area of interest 
(i.e. the VTA) is labelled PBP (parabrachial pigmented nucleus) in the brain atlas (Paxinos 
and Franklin, 2013). (B) Confocal microscopy image at 10x magnification of a brain slice 
stained with antibody to tyrosine hydroxylase (TH) primary and secondary antibody 
conjugated to Alex Fluor 594. Revealing TH stained neurones within the VTA. (C) This is a 
40x magnification image of a cell labelled with a tyrosine hydroxylase primary antibody 
and a secondary antibody conjugated to Alexa Fluor 594, this labelling process allows 
the identification of dopaminergic cells. (D) Biocytin labelled cell identified by a 
streptovidin secondary antibody conjugated to Alexa Fluor 488. As can be appreciated 
from panel C, the biocytin labelled cell is also dopaminergic. 
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The electrophysiological parameters of the neurones within the VTA were 
examined using whole cell current clamp recordings to study action potentials 
(APs) and their response to morphine. All of the recordings were performed on 
slices at 36°C with continuous perfusion of oxygenated saline (see Methods 
Chapter 2). After a control recording period morphine (10 μM) was bath applied. 
The drug effects observed allowed the neurones to be grouped into either 
responders to morphine (i.e. the spontaneous action potential frequency was 
inhibited by morphine) or  non-responders (i.e. the action potential frequency 
was not inhibited by morphine) (Figure 5.2). On the basis of previous reports 
using MOP receptor agonists, these two groups likely represent recordings from 
presynaptic GABAergic neurones and postsynaptic DA neurones, respectively 
(Johnson and North, 1992a). On the basis of this we analysed the responders and 
non-responders for differences in baseline frequency of firing, action potential 
duration, threshold potential, peak amplitude or rise time. We could identify no 
significant differences in these parameters between these groups. There was a 
trend towards a reduction in both rise time, (p = 0.36 unpaired t test), and peak 
amplitude (p = 0.56 unpaired t test) and an increase in the baseline firing 
frequency, (p = 0.25 unpaired t test), in the cells which demonstrated inhibition 
of AP firing following morphine exposure (Table 5.1). We may not have been 
able to identify any significant differences in these parameters due to the small n 
numbers. Power analysis indicates that a minimum of 18 experiments would be 
required to identify a possible difference in the baseline frequency of firing, 112 
to identify a difference in the peak amplitude and 47 to identify a difference in 
the event rise time.   
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Figure 5.2: Current clamp recordings from WT VTA neurones in the presence of 
morphine (10 μM) and naloxone (10 μM). (A) An example trace from a WT VTA 
neurone in which morphine (10 μM) did not result in inhibition of spontaneous action 
potential frequency. (B) There were a second group of cells in whom morphine (10 μM) 
application resulted in a reduction in the frequency of spontaneous action potential 
firing. 
 
 
 
Table 5.1: Characteristics of action potentials recorded from spontaneously firing WT 
VTA neurones in current clamp mode. The neurones were grouped according to the 
response to the application of morphine (10 μM). The * represents p < 0.05 on Student’s 
t test. The distinguishing feature between these groups is the response to morphine. 
 
 
 
Morphine Naloxone 
15 mV 
50 s
Control
15 mV 
50 s
Control Morphine Naloxone A B
Non-Responders
n = 4
Responders
n = 3
Action potential duration (ms) 2.5 ± 0.3 2.3 ± 0.2
Threshold potential (mV) -49.3 ± 5.8 -39.3 ± 2.4
Peak amplitude (mV) 58.7 ± 12.7 49.2 ± 2.7
Rise time (ms) 1.2 ± 0.4 0.72 ± 0.06
Baseline frequency 7.4 ± 4.5 15.9 ± 4.4
Frequency with morphine (10 μM) 12.1 ± 6.9 0.62 ± 0.5*
154 
 
5.3 The influence of opioid drugs on IPSC events within the VTA 
Recordings of spontaneous IPSCs from WT VTA neurones within  horizontal brain 
slices in voltage clamp mode at -60 mV and 36°C reveal a baseline event 
frequency of 2.2 ± 0.2 Hz, n = 64.  These events were inhibited by the GABAA 
receptor antagonist bicuculline (30 µM), confirming that they are GABAA 
receptor mediated IPSCs (Figure 5.3). 
     
Morphine inhibited the frequency of sIPSC events in a concentration dependent 
manner (Figures 5.4 and 5.6). The application of TTX (500 nM) to the recording 
solution did not significantly affect the baseline IPSC event frequency. In the 
absence of TTX the baseline IPSC frequency was 2.2 ± 0.3 Hz and in the presence 
of TTX (500 nM) the frequency of IPSC events was 2.7 ± 0.7 Hz (Table 5.2). No 
significant difference in the degree of inhibition with morphine (10 μM) was 
identified, for the sIPSC recordings there was an inhibition of 58.2 ± 3.7% and for 
the mIPSC recordings the inhibition was of 49.6 ± 4.3% (Figure 5.5).  
 
The kinetic parameters, which include peak amplitude, rise time, T70 and the 
decay time constant (Tω) were not significantly different for the sIPSC events 
compared to the mIPSC events and the application of morphine (10 μM) did not 
significantly alter these parameters (Table 5.2). These observations suggest that 
events recorded in the absence of TTX are mono-synaptic in nature.  
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As previously discussed morphine inhibits the frequency of sIPSC events in WT 
neurones within the VTA in a concentration dependent manner. The MOP 
receptor is required for the effects of opioid drugs on sIPSC frequency within the 
VTA, there was no significant inhibition of sIPSC frequency in neurones from 
MOP-/- mice, paired t test p = 0.08 n = 5 (Figure 5.6A-C). Morphine (100 μM) 
caused a significant reduction in the ability of morphine to inhibit sIPSC 
frequency in WT and MOP+/- neurones but no significant inhibition of sIPSC 
frequency in MOP-/- neurones (Figure 5.6B).  
 
Receptor number is also important in the ability of morphine to produce this 
effect as removing 50% of MOP receptors, as is the case in MOP+/- mouse (Sora 
et al., 1997, Sora et al., 2001), caused a reduction in the potency of morphine. 
This is indicated by the rightward shift in the concentration response relationship 
for morphine (Figure 5.6A). The ability of morphine (100 µM) to inhibit sIPSC 
frequency in MOP+/- neurones was significantly reduced compared to WT 
neurones (Figure 5.6B). 
 
There was a trend towards baseline inhibition of sIPSC frequency even with low 
concentrations of morphine (25.4 ± 5.2% with 0.03 μM morphine) in WT 
neurones, although this was not significant (paired t test p 0.06, n = 5), but it is 
likely that this will reach significance with additional experiments (Figure 5.6A). 
Although not significant, as stated earlier, there was also a trend towards 
inhibition in MOP-/- neurones (14.4 ± 5.0%, p < 0.08, n = 6). Additional 
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experiments are needed to establish whether this is in fact a small but significant 
MOP receptor independent inhibitory effect of morphine. Interestingly there 
was no trend towards inhibition when recordings were performed with DAMGO 
(Figure 5.8).  
 
It has previously been reported that morphine is an antagonist at the 5-HT3 
receptor (Baptista-Hon et al., 2012) and 5-HT receptors are present within the 
VTA (Cameron et al., 1997, Rodd et al., 2007). The 5HT3 receptor antagonist 
ondansetron was used to test the possibility of an involvement of 5-HT3. 
Consistent with a role for 5-HT3 receptors in the release of GABA from 
presynaptic neurones in the VTA, ondansetron alone caused a significant 
inhibition of sIPSC frequency in WT neurones (Figure 5.7A) by 23.1 ± 6.2%. When 
applied with morphine the effects of ondansetron were additive. The inhibition 
of sIPSC frequency with morphine (10 μM) alone is 58.2 ± 3.6% and in the 
presence of ondansetron (100 nM) is 79.7 ± 10.2%. However, the level of sIPSC 
inhibition observed in the presence of ondansetron is not significantly different 
from when morphine was applied alone (Figure 5.7C). Taken together these data 
suggest that if morphine is inhibiting 5-HT3 receptors within the VTA this is a 
minor effect compared to the inhibition mediated by MOP receptors.  
 
DAMGO, a selective MOP receptor agonist, also inhibited sIPSC frequency in a 
concentration dependent manner in WT neurones (Figure 5.8). The EC50 of 
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DAMGO was 0.25 µM in the WT neurones. The potent inhibition of sIPSC 
frequency observed with morphine was not evident with DAMGO.  
 
It appears that morphine causes a small high potency inhibition of sIPSC 
frequency that is not replicated by the selective agonist DAMGO. While 
negligible this inhibition by morphine appears to remain in slices from MOP-/- 
neurones. The observation that ondansetron and morphine are additive in their 
combined inhibition of sIPSC frequency suggests that the 5-HT3 receptor is not 
the target of this action. Morphine can activate DOP receptors. DOP-/- mice 
were used to establish a possible role for DOP receptors in the actions of 
morphine.   
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Figure 5.3: sIPSC events within the VTA are GABAA receptor mediated. The above 
example trace reveals inhibition of the sIPSC events following the addition of the GABAA 
receptor antagonist bicuculline (30 μM) to the recording solution. 
 
 
Figure 5.4: Morphine inhibits sIPSC activity in a concentration dependent manner in 
WT neurones. sIPSCs were recorded from voltage-clamped VTA neurones before and 
during the application of increasing concentrations of morphine. 
 
    60 pA  40 s 
Bicuculline 30 µM 
   125 pA  
10 s 
Morphine 100 μM 
Control 
Morphine 10 μM 
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Figure 5.5: TTX does not affect IPSC frequency or inhibition by morphine. (A) There is 
no difference in IPSC frequency in the presence or absence of TTX (500 nM). Control 
frequency, sIPSC n = 10, mIPSC n= 4, unpaired t test p = 0.8. (B) TTX does not affect the 
degree of inhibition of IPSC frequency observed in the presence of morphine (10 μM), 
sIPSC n = 7, mIPSC n = 12, unpaired t test p = 0.2. Vertical lines represent ± SEM.  
 
 
 
Table 5.2: TTX does not significantly affect IPSC parameters within the VTA. Morphine 
inhibits IPSC frequency but does not alter the kinetics of the events. There are no 
significant changes in the kinetic parameters of the IPSC events in the presence of TTX 
(500 nM) or morphine (10 μM). The frequency of events is significantly decreased 
following morphine exposure; this is unchanged in the presence of TTX. For the sIPSC 
recordings n = 8 and for the mIPSC recordings n = 12, * represents p < 0.05 on Student’s 
t test. 
 
sIPSC mIPSC
Control Morphine 10 μM Control Morphine 10 μM
Peak Amplitude (pA) -83.7 ± 6.8 -94.8 ± 13.6 -81.1 ± 8.9 -86.6 ± 9.3
Rise time (ms) 0.64 ± 0.02 0.65 ± 0.04 0.64 ± 0.03 0.67 ± 0.03
T70 (ms) 7.5 ± 0.4 7.6 ± 0.6 7.4 ± 0.7 8.1 ± 0.8
Tau ω (ms) 6.5 ± 0.4 6.8 ± 0.7 7.0 ± 1.0 6.8 ± 0.7
Frequency (Hz) 2.2 ± 0.3 1.0 ± 0.3 * 2.7 ± 0.7 1.2 ± 0.3 *
Control sIPSC Control mIPSC
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Figure 5.6: Morphine inhibits sIPSCs in a concentration dependent manner in WT and 
MOP+/- neurones; it does not cause significant inhibition in MOP-/- neurones. (A) 
Concentration response curve for morphine inhibition of sIPSC frequency within the 
VTA. WT neurones EC50 2 µM n = 5 – 10, MOP+/- neurones EC50 81.2 µM n = 4 – 6, and 
MOP-/- neurones n = 5. (B) Inhibition of sIPSC frequency by 100 µM morphine. There is 
a significant reduction in the ability of morphine to inhibit sIPSC frequency in the 
MOP+/- and MOP-/- neurones compared to the WT neurones. One way ANOVA p < 
0.001, post hoc Tukey test results are shown on the graph. Vertical lines represent ± 
SEM. *, p < 0.05, **, p < 0.01, ***, p < 0.001. (C) Morphine had a negligible effect on 
sIPSC frequency in MOP-/- neurones. 
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Figure 5.7: Addition of the 5-HT3 receptor antagonist ondansetron results in inhibition 
of sIPSC frequency within the VTA. It does not affect the ability of morphine to inhibit 
sIPSC frequency. (A) Ondansetron (100 nM) significantly inhibits sIPSC frequency in WT 
VTA neurones, t test p = 0.04 n = 6. (B) Morphine (10 μM) significantly inhibits sIPSC 
frequency in WT neurones in the presence of ondansetron (100 nM), t test p = 0.01 n = 
3. (C) The presence of ondansetron does not affect the ability of morphine to inhibit 
sIPSC frequency in WT neurones within the VTA, one way ANOVA p < 0.0001 post hoc 
Tukey results are shown on the graph, ondansetron alone n = 6, ondansetron plus 
morphine n = 3, morphine alone n = 7. Vertical lines represent ± SEM. *, p < 0.05, **, p < 
0.01, ***, p < 0.001. 
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Figure 5.8: DAMGO inhibits sIPSC frequency in a concentration dependent manner in 
WT neurones within the VTA. (A) DAMGO (1 μM) inhibits sIPSC frequency in a WT 
neurone. (B) Concentration response curve for inhibition of sIPSC frequency by DAMGO 
in WT neurones, n = 3 – 7, EC50 DAMGO 0.25 µM. Vertical lines represent ± SEM.  
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5.4 DOP receptors within the VTA 
DPDPE (1 µM) significantly inhibited sIPSC frequency in WT neurones (37.3 ± 
7.4% n = 6; paired t test p = 0.001). The inhibition observed was not significantly 
different in MOP-/- neurones suggesting that the response is mediated by DOP 
receptors. In confirmation of this DPDPE (1 μM) has no significant effect on sIPSC 
frequency when applied to DOP-/- neurones (Figure 5.9). This confirms the 
presence of DOP receptors within the VTA and suggests that they can function 
independently of MOP receptors. 
 
The inhibition by morphine (10 μM) of sIPSC frequency within the VTA was 
significantly reduced in the DOP+/- and DOP-/- neurones (Figure 5.10). While 
DOP receptors appear to be required for the full inhibitory effect of morphine on 
IPSCs the inhibition of IPSC frequency by DAMGO was not significantly different 
in the WT and DOP-/- VTA neurones (Figure 5.11).  
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Figure 5.9: DOP receptors are functional and can signal independently of MOP 
receptors within the VTA. (A) In WT neurones we observe inhibition of sIPSC activity in 
the presence of DPDPE 1 µM, (37.3 ± 7.4%). In MOP-/- neurones there is no significant 
difference in the ability of DPDPE to inhibit sIPSC frequency (34.0 ± 2.2%), unpaired t 
test p = 0.7. DPDPE is selective for the DOP receptor, there are no significant changes in 
sIPSC frequency in response to DPDPE exposure in DOP-/- neurones (7.0 ± 5.2%), one 
way ANOVA p = 0.0032, post hoc Tukey results shown on graph. WT n = 6, MOP-/- n = 5, 
DOP-/- n = 6. Vertical lines represent ± SEM. *, p < 0.05, **, p < 0.01, ***, p < 0.001. (B) 
DPDPE inhibits sIPSC frequency in WT neurones. (C) DPDPE inhibits sIPSC frequency in 
MOP-/- neurones. (D) DPDPE does not inhibit sIPSC frequency in DOP-/- neurones. 
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Figure 5.10: The absence of DOP receptors in the VTA significantly reduces the ability 
of morphine to inhibit sIPSC frequency. (A) The ability of morphine (10 μM) to inhibit 
sIPSC frequency is reduced in DOP+/- neurones (33.1 ± 5.8 %) compared to WT 
neurones (64.6 ± 4.9 %), unpaired t test p = 0.001, WT n = 10, DOP+/- n = 6. (B) The 
ability of morphine (10 μM) to inhibit sIPSC frequency is reduced in DOP-/- neurones 
(44.1 ± 4.3 %) compared to WT neurones, unpaired t test p = 0.009, WT n = 10, DOP-/- n 
= 7. Vertical lines represent ± SEM. *, p < 0.05, **, p < 0.01, ***, p < 0.001. (C) Inhibition 
of sIPSC events by morphine in a DOP-/- neurone within the VTA. 
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Figure 5.11: DOP receptors are not involved in signalling within the VTA in response to 
DAMGO. (A) The inhibtion by DAMGO (1 μM) of sIPSC frequency in DOP-/- neurones 
(47.4 ± 10.8 %) is not significantly different to that seen in WT neurones (54.7 ± 4.0 %), 
unpaired t test p = 0.54, WT n = 7, DOP-/- n = 7. Vertical lines represent ± SEM. (B) 
DAMGO (1 μM) exposure results in significant inhibition of sIPSC’s in DOP-/- neurones. 
Vertical lines represent ± SEM. 
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5.5 The role of β-arrestin2 in signalling within the VTA 
BAR2 is involved in the analgesic and psychomotor effects of morphine (see 
Chapter 4). However, the role of BAR2 in opioid receptor mediated inhibition of 
IPSCs in the VTA is unknown. Surprisingly, there was a significant decrease in the 
ability of morphine (10 µM) to inhibit sIPSC frequency in BAR2-/- VTA neurones 
compared to WT VTA neurones (Figure 5.12A). Increasing the concentration of 
morphine (from 10 to 100 μM) increased the inhibition suggesting that the 
absence of BAR2 leads to a reduction in morphine potency (Figure 5.12B). This 
effect appears not to be specific to morphine as the inhibition of sIPSC frequency 
by DAMGO in the BAR2-/- neurones was also less than in WT neurones (Figure 
5.12C). 
 
There was also a significant decrease in the inhibition of sIPSC frequency by 
morphine (37.0 ± 6.6 %) in BAR2-/-//DOP-/- neurones compared to WT neurones 
(Figure 5.13). Overall there is a decrease in the ability of morphine to inhibit 
sIPSC frequency in the DOP-/-, BAR2-/- and the BAR2-/-//DOP-/- neurones 
(Figure 5.13). There are no significant differences in the level of inhibition 
observed between these genotypes. This suggests that both BAR2 and DOP 
receptors are involved in signalling in response to morphine within the VTA. 
 
While an absence of BAR2 led to reduced inhibition of sIPSC frequency by 
DAMGO (Figure 5.12C) the absence of DOP receptors had no effect (Figure 5.11). 
This suggests that DOP receptors are not involved in signalling in response to 
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DAMGO within the VTA but that BAR2 is. Together these data provide evidence 
that different opioid drugs may utilise differing combinations of opioid receptor 
subtypes to achieve inhibition of sIPSC frequency in the VTA. This may have 
important implications regarding their tendency to initiate tolerance and 
dependence. 
 
While there were differences in the degree of inhibition of sIPSC frequency in 
response to agonist stimulation, there were no significant differences in baseline 
sIPSC frequency across the genotypes (Figure 5.14). WT VTA neurones have a 
baseline sIPSC frequency of 2.2 ± 0.2 Hz, MOP+/- neurones: 2.0 ± 0.5 Hz, MOP-/- 
neurones: 1.8 ± 0.3 Hz, DOP-/- neurones: 1.4 ± 0.3 Hz, BAR2-/- neurones: 1.6 
±0.3 Hz and BAR2-/-//DOP-/- neurones: 2.0 ± 0.3 Hz.  This implies that there is 
little basal MOP or DOP mediated inhibition of sIPSCs, because the absence of 
these receptors (or their signalling pathway) would otherwise be expected to 
result in enhanced tonic sIPSC frequency. 
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Figure 5.12: The absence of BAR2 reduces inhibition of the frequency of sIPSC events 
in the VTA by opioid drugs. (A) There is a genotype dependent reduction in the ability of 
morphine to inhibit the frequency of sIPSCs within the VTA WT 64.6 ± 4.9 % n = 10, 
BAR2+/- 34 ± 4 % n = 4, BAR2-/- 23.3 ± 4.4 % n = 5. (B) The inhibition of sIPSC in BAR2-/- 
neurones is concentration dependent. The difference in the ability of morphine to 
inhibit sIPSC frequency in the presence of 10 and 100 µM morphine in WT and BAR2-/- 
neurones, unpaired t test (100 µM morphine) p = 0.0085, WT n = 7, BAR2-/- n = 5. (C) 
The ability of DAMGO 1 µM to inhibit sIPSC frequency within the VTA was also 
significantly reduced in the BAR2-/- neurones, unpaired t test p = 0.03, WT 54.7 ± 4 % n 
= 7, BAR2-/- 37.1 ± 5.6 % n = 8. Vertical lines represent ± SEM. *, p < 0.05, **, p < 0.01, 
***, p < 0.001. 
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Figure 5.13: BAR2 and the DOP receptor are involved in the response of VTA neurones 
to morphine. The ability of morphine 10 μM to inhibit sIPSC frequency within the VTA is 
significantly reduced in DOP-/-, BAR2-/- and BAR2-/-//DOP-/- neurones compared to WT 
neurones, one way ANOVA p < 0.0001, post hoc Tukey results are shown on graph. WT n 
= 10, DOP-/- n = 7, BAR2-/- n = 5 and BAR2-/-//DOP-/- n = 4. Vertical lines represent ± 
SEM. *, p < 0.05, **, p < 0.01, ***, p < 0.001.  
 
  
Figure 5.14: Deletion of MOP receptors, DOP receptors or BAR2 does not affect the 
sIPSC frequency in the absence of drug. One way ANOVA p = 0.4 post hoc Dunnett’s 
tests were ns. WT n = 64, MOP+/- n = 19, MOP-/- n = 18, DOP-/- n = 27, BAR2-/- n = 18 
and BAR2-/-//DOP-/- n = 12. Vertical lines represent ± SEM.  
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5.6 Effects of naloxone on sIPSC frequency within the VTA 
Naloxone competitively antagonises the actions of agonists at MOP receptors 
and causes conditioned place aversion when administered to morphine 
dependent mice (Shoblock and Maidment, 2006). Systemic naloxone is also 
somewhat aversive in morphine naive mice. This effect is mediated through 
MOP receptors as it does not occur in MOP-/- mice (Skoubis et al., 2001). 
Surprisingly, MOP receptor antagonists administered into the VTA cause 
increased DA release in the NA (Devine et al., 1993b). We examined whether 
naloxone affects basal IPSC frequency recorded from VTA neurones. Naloxone 
(10 μM) consistently inhibited sIPSC frequency recorded from WT VTA neurones. 
The inhibition was independent of MOP receptors as it was not significantly 
different in recordings from WT and MOP+/- or MOP-/- neurones (Figure 5.15).  
 
In DOP-/- neurones there was no significant difference between the sIPSC 
frequency under control conditions or during naloxone (10 μM) application. The 
sIPSC frequency with naloxone added was 96.2 ± 6.4% of control, paired t test 
(ns) p = 0.5, n = 6. Interestingly, naloxone caused a small enhancement of sIPSC 
frequency in BAR2-/- neurones in which sIPSC frequency in the presence of 
naloxone was 115.7 ± 12.7% of control frequency (paired t test p = 0.3, n = 5). 
 
This facilitation was not observed in BAR2-/-//DOP-/- neurones, in which the 
sIPSC frequency in the presence of naloxone was 92.9 ± 11.6 % of control (paired 
t test was p = 0.3, n = 6) (Figure 5.16). These data suggest that the inhibition of 
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sIPSC frequency by naloxone involves both BAR2 and DOP receptors. The small 
facilitatory effect of naloxone in the absence of BAR2 appears to require DOP 
receptor expression (Figure 5.16). 
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Figure 5.15: Naloxone causes an inhibition of IPSC frequency that is independent of 
MOP receptors. Inhibition of sIPSC frequency by naloxone in WT neurones is 23.4 ± 
6.9%, n = 5 paired t test versus control p = 0.03. One way ANOVA of inhibition of sIPSc 
frequency by naloxone in WT, MOP+/- and MOP-/- is not significantly different, p = 0.96. 
MOP+/- inhibition of sIPSC events is 24.0 ± 4.5 % n = 5, MOP-/- inhibition is 25.7 ± 5.8 % 
n = 8. Vertical lines represent ± SEM.  
 
Figure 5.16: Naloxone does not cause significant inhibition of sIPSC events in DOP-/-, 
BAR2-/- or BAR2-/-//DOP-/- neurones. One way ANOVA p = 0.1, post hoc Dunnett’s 
results shown on graph. Vertical lines represent ± SEM. *, p < 0.05. This suggests that 
the inhibition of sIPSC frequency by naloxone involves both BAR2 and DOP receptors. 
The small facilitatory effect of naloxone in the absence of BAR2 appears to require DOP 
receptor expression. 
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5.7 Summary 
Identifying cell type within the VTA using electrophysiological techniques is 
currently controversial as previously discussed. The IHC protocol used to label 
brain slices revealed nuclei of TH positive cells corresponding to the VTA. The 
identification of biocytin labelled TH positive cells following whole-cell recording 
demonstrates that the postsynaptic DA neurones were effectively targeted in 
these cases, however, this approach was not routine and in future studies the 
reliability of cell identification will need to be improved. Nevertheless, the vast 
majority of cells targeted for whole-cell voltage-clamp recording exhibited a 
reduction in sIPSC frequency upon application of either DAMGO or morphine 
indicating their likely identification as DA neurones postsynaptic to GABAergic 
inhibitory neurones.  
 
Other investigators have suggested that the response to MOP receptor agonists 
is a reliable marker of cell type (Johnson and North, 1992b, Johnson and North, 
1992a, Cameron et al., 1997, Chieng et al., 2011, Ford et al., 2006).  The cells 
that exhibit a reduced AP frequency with opioids are likely to be presynaptic 
GABAergic neurones, while those that do not are likely to be post-synaptic DA 
neurones. Therefore the neurones identified in current-clamp recordings as 
morphine responders are likely to be the GABAergic neurones and the non-
responders are dopaminergic neurones. We could detect no significant 
differences between action potential (AP) duration, amplitude, threshold 
potential or rise time in current clamp recordings from VTA neurones. The AP 
duration in cells that exhibited inhibition of AP frequency upon morphine 
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application did not differ significantly from those published previously (Margolis 
et al., 2006). There was a trend for an increase in the baseline frequency in the 
neurones that were responders to morphine (i.e. morphine inhibited AP 
frequency) but this was not significant.  
 
This corresponds to previously published work that suggests that the firing 
frequency is increased in non-dopaminergic neurones when compared to 
dopaminergic neurones (Margolis et al., 2006, Johnson and North, 1992a). The 
T70 of our sIPSC events in WT neurones was 7.5 ± 0.4 ms, this is similar to a 
previously reported T75 for dopaminergic cells within the VTA of 7.55 ms but 
significantly different from the T75 reported for GABAergic neurones within the 
VTA of 3.16 ms (Tan et al., 2010). Together these findings suggest that DA 
neurones were effectively targeted for voltage-clamp recordings of IPSCs. 
However, further work will be required to further identify postsynaptic neurones 
and the source of their inhibitory input. 
 
The addition of bicuculline to the recording solution abolished the sIPSC events 
in the VTA confirming that these are GABAergic events. Bicuclline did not 
produce any alteration in the baseline current suggesting that tonic GABAergic 
receptor activity is not present in this region under these recoding conditions.  
 
We could identify no significant differences in baseline frequency, kinetics or 
effects of morphine between mIPSCs and sIPSCs. Recordings of sIPSC events 
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were used subsequently for the remainder of the study. In recordings performed 
in the VTA of guinea pig brain slices mIPSC frequency was 2.4 ± 1.3 Hz (Bonci and 
Williams, 1997) and in VTA containing mouse brain slices the mIPSC frequency 
was 1.5 Hz in a study published by Meye et al (2012). These results are similar to 
the event frequency observed here.  
 
Previously published studies of MOP receptor activation in the VTA 
predominately used DAMGO and reported inhibition in responding cells at single 
concentration points for each drug. One study by Lecca et al (2012) bath applied 
morphine (1 μM) to rat brain slices while recording from DA cells in the VTA and 
reported an inhibition of sIPSC frequency of 42 ± 4%. This is similar to the 
inhibition that we observe with morphine (1 μM) in WT mouse VTA neurones (43 
± 7%). With DAMGO (1 μM) the inhibition of mIPSC frequency has been reported 
as 57.5 ± 9.9% (Bergevin et al., 2002) in cultured VTA neurones and 56.94 ± 
9.53% and 75.35 ± 9.94% respectively in VTA neurones within mouse brain slices 
(Meye et al., 2012, Madhavan et al., 2010). I observed an inhibition of 54.7 ± 
4.0% (n = 7) with DAMGO (1 μM) in WT VTA neurones, which is not dissimilar 
from these results. Unlike previous studies, the current study examined full 
concentration response relationships for morphine and DAMGO. The addition of 
increasing concentrations of DAMGO, a selective MOP receptor agonist, or 
morphine resulted in a concentration dependent inhibition of sIPSC events in the 
VTA.  
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In the MOP+/- neurones we observed a rightward shift in the concentration 
response relationship indicating a reduction in potency of morphine in these 
neurones. There was no apparent change in morphine’s efficacy. These data are 
similar to results in MOP+/- mice for analgesia (Chapter 3) and psychomotor 
assays (Chapter 4) in which a higher dose of morphine was required for 
analgesia, for the development of a preference to morphine and also for 
significant locomotor activation. In the MOP-/- neurones there is no significant 
inhibition of sIPSC frequency following exposure to morphine. This is consistent 
with the previous demonstration that these mice do not show a preference for 
morphine (Chapter 4). However, there is a trend towards inhibition which may 
be caused by an action of morphine on DOP receptors. 
 
Even very low concentrations of morphine inhibit sIPSC frequency in WT 
neurones, although this is not significant in sample of neurones tested (25.4 ± 
5.2%, paired t test p = 0.06 n = 5). There was no such trend in the presence of 
DAMGO. Morphine is not entirely selective for MOP receptors and therefore 
may be having off target effects that could contribute to this high potency 
inhibition of sIPSCs. There are 5-HT3 receptors within the VTA (Cameron et al., 
1997, Rodd et al., 2007) and morphine potently inhibits this ligand-gated ion 
channel (Baptista-Hon et al., 2012). 5-HT3 antagonists can also decrease 
morphine self-administration in rats (Hui et al., 1993), modulate tolerance and 
opioid induced hyperalgesia in mice (Hui et al., 1996, Liang et al., 2011) and 
prevent morphine CPP (Carboni et al., 1989). Ondansetron alone produced a 
significant inhibition of sIPSC frequency and, when applied together, the actions 
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of ondansetron and morphine appear to be additive. These data suggest that 
there are 5-HT3 receptors within the VTA, but these are not responsible for the 
inhibitory effect of morphine. 
 
The ability of morphine to inhibit sIPSC frequency was reduced in DOP-/-, BAR2-
/- and BAR2-/-//DOP-/- neurones. These findings suggest that both DOP 
receptors and BAR2 are involved in signalling within the VTA in response to 
morphine. With regard to DOP receptors, we observed a significant reduction in 
the ability of morphine to inhibit sIPSC frequency even after the deletion of one 
copy of the oprd1 gene in the DOP+/- neurones. However in the DOP-/- 
neurones inhibition with DAMGO was not changed compared to the WT 
neurones. By contrast, BAR2-/- neurones exhibited a reduction in the inhibition 
of sIPSC frequency by both morphine and DAMGO. This suggests that differing 
opioid drugs may signal through differing opioid receptor combinations. The 
observation that the selective DOP receptor agonist DPDPE also inhibits sIPSC 
frequency in the WT VTA neurones, but not DOP-/- neurones suggests that the 
DOP receptors can function independently of MOP receptors.  
 
In BAR2-/- neurones there is a gene dependent reduction in the ability of 
morphine to inhibit sIPSC frequency. In these neurones DAMGO is also less 
effective at producing inhibition of sIPSC frequency. These data support the role 
of BAR2 in signalling in response to different opioid drugs within the VTA.  
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The results of CPP in the BAR2-/- mice suggest that these mice are more 
sensitive to the reinforcing effects of morphine and are more likely to develop a 
preference at lower doses than the WT mice (Chapter 4). The fact that we 
observe a reduction in the ability of morphine to inhibit sIPSC frequency and 
therefore higher concentrations of drug are required to produce inhibition in 
BAR2-/- neurones suggests that this synapse may not be involved in the 
reinforcing effects of morphine.  
 
The reduction in the ability of morphine to inhibit sIPSC events is also observed 
in the BAR2-/-//DOP-/- neurones. Overall our data suggest that both DOP 
receptors and BAR2 are important in signalling within the VTA their involvement 
is dependent on the agonist used.  
 
Surprisingly exposure to naloxone caused a small but significant decrease in the 
frequency of sIPSC events in the WT neurones. It had been anticipated that there 
would either be no change in frequency or an increase in frequency if there was 
tonic inhibition of sIPSC frequency mediated by the opioid receptors. This effect 
persisted in the MOP+/- and MOP-/- neurones and is therefore independent of 
MOP receptors. The inhibition in sIPSC frequency was absent in both the DOP-/- 
and BAR2-/- neurones, revealing that this action is occurring through DOP 
receptors perhaps coupled to BAR2. Interestingly, naloxone caused a small 
facilitation of sIPSC frequency in BAR2-/- VTA neurones which was not seen in 
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BAR2-/-//DOP-/- neurones suggesting that this effect, unmasked by the absence 
of BAR2, is mediated through DOP receptors. 
 
Overall these results confirm that MOP receptors are required for the actions of 
morphine and DAMGO within the VTA. There are functional DOP and 5-HT3 
receptors within the VTA. The former, but not the latter appear to be important 
for the full inhibition of sIPSC frequency by morphine. BAR2 is also involved in 
the response to DAMGO suggesting that it may have a wider role in VTA 
signalling in response to opioid drugs.  This is the most surprising finding of this 
study implicating the BAR2 pathway in the control of vesicular release. The next 
chapter explores a possible role for c-Src in this and other consequences of MOP 
receptor activation mediated through the BAR2 signalling pathway. 
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Chapter 6: The effects of c-Src on opioid receptor signalling 
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6.1 Introduction 
BAR2-/- mice exhibit decreased sensitivity to noxious heat and a marked 
reduction in analgesic tolerance to morphine (Chapter 3). These findings are in 
line with previous reports suggesting that the BAR2 signalling system impairs 
MOP receptor mediated analgesia (Bohn et al., 1999, Lam et al., 2011). The 
absence of BAR2 enhances MOP receptor constitutive activity leading to tonic 
inhibition of VACCs in primary afferent neurones (Walwyn et al., 2007). 
Inhibition of c-Src activity in DRG neurones of WT mice also enhanced 
constitutive MOP receptor inhibitory coupling to VACCs suggesting that tyrosine 
kinase mediated phosphorylation may attenuate opioid analgesia. This study 
utilised PP2, a selective inhibitor of the Src family tyrosine kinases and compared 
its actions to those of an inactive chemical analogue called PP3, used as a 
negative control. This work raises the possibility that sustained MOP receptor 
mediated analgesia might be produced by inhibiting c-Src (Walwyn et al., 2007). 
Furthermore, the basal analgesia and reduced morphine tolerance observed in 
BAR2-/- mice might be caused by uncoupling of MOP receptors from c-Src. 
Therefore, a primary goal of this study was to examine whether inhibition of c-
Src in mice causes sustained MOP receptor mediated analgesia.   
 
A previous study in rats has suggested that a tyrosine kinase inhibitor used in the 
treatment of leukaemia (imatinib) can abolish morphine analgesic tolerance 
(Wang et al., 2012). For this study the drug had been modified to allow it cross 
the blood brain barrier as the normal clinically administered drug cannot do this. 
One of the targets of imatinib is the PDGFRβ receptor and this study focused on 
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this receptor as a target strategy to reduce morphine tolerance (Wang et al., 
2012). There are a number of other anti-cancer drugs related to imatinib that 
inhibit tyrosine kinases. These include dasatinib, a drug also licensed for clinical 
use to treat leukaemia. It is thought that it may be a useful treatment for other 
cancers, including colorectal cancer as an adjunct to existing therapies (Sharma 
et al., 2012). Dasatinib has the capability to cross the blood brain barrier without 
any alterations to its structure/ pharmacology (Lagas et al., 2009, Porkka et al., 
2008). Dasatinib is a potent c-Src inhibitor that is normally administered orally to 
patients. However, the oral bioavailability is low (14 – 34%), after oral dosing it 
reaches a peak plasma concentration between 30 minutes and 3 hours, it has a 
high volume of distribution (> 3 l/Kg) and high serum protein binding (> 90%) 
(Kamath et al., 2008).  
 
We used this drug for its capacity to inhibit c-Src in mice. When oral and IP 
dosing has been compared in mice there are no significant differences in brain 
accumulation at six hours when either 10 mg/Kg is administered orally or 5 
mg/Kg is administered via the IP route. The Cbrain after oral dosing was 6.5 ± 2.1 
ng/g and after IP dosing was 5.5 ± 0.4 ng/g. These corresponded to plasma levels 
(Cmax) of 0.37 ± 0.08 mg/L for oral dosing and 0.94 ± 0.07 mg/L for IP dosing 
(Lagas et al., 2009). We chose to use a dose of 5 mg/Kg via the IP route for ease 
of administration at a defined time point.  
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It is important to establish whether approaches developed to modify opioid 
receptor signalling, in an attempt to reduce tolerance and enable persistent 
analgesia, affect reward. We have demonstrated that an absence of BAR2 causes 
persistent analgesia and an increase in the sensitivity of BAR2-/- mice to the 
reinforcing effects of morphine (Chapters 3 and 4). We know from the animal 
studies that dasatinib can cross the blood brain barrier (Lagas et al., 2009, Porkka 
et al., 2008). We examined whether c-Src affects the psychomotor effects of 
morphine.  
 
6.2 PP2 and Dasatinib inhibit c-Src in vitro and in vivo 
As previously discussed, in Chapter 1 (Section 1.21), PP2 is a tyrosine kinase 
inhibitor that is selective for c-Src (Bain et al., 2007, Uitdehaag et al., 2012). This 
contrasts with dasatinib that affects several different tyrosine kinases but which 
is a potent inhibitor of c-Src with a Kd of 0.21 nM (Karaman et al., 2008). PP2 has 
been widely used in vitro but it is rarely administered in vivo, however, dasatinib 
is a clinically used drug that has been widely tested in vivo. PP3 is an inactive 
chemical analogue of PP2 that provides a control for studies utilising PP2 
(Tocris). 
 
Both PP2 and dasatinib inhibit the phosphorylation of c-Src in SW620 cells 
following a 24 hour exposure to the drug at a concentration of 10 μM (Figure 
6.1A). The presence of phosphorylated c-Src was confirmed in samples only 
exposed to DMSO or PP3. A modified protocol was performed on DRG neurones 
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obtained post mortem from mice treated with either vehicle control, PP2 (5 
mg/Kg), PP3 (5 mg/Kg) or dasatinib (5 mg/Kg). The samples obtained from the 
mice treated with dasatinib (5 mg/Kg) exhibited a marked reduction in the 
phosphorylation of c-Src compared to the control vehicle treated sample. 
However, there was no detectable difference in the level of phosphorylated c-Src 
between the PP2 and the PP3 treated mice (Figure 6.1B). 
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Figure 6.1: PP2 and dasatinib inhibit the phosphorylation of c-Src. (A) Western blot 
demonstrating that PP2 and dasatinib inhibit the phosphorylation of c-Src in SW620 
cells. SW620 cells were incubated with PP2, dasatinib and PP3 (10 μM) and DMSO 
control for 24 hours prior to collection. Primary antibodies were used against actin 
(loading control) total c-Src and phosphorylated c-Src (pc-Src) Both PP2 and dasatinib 
reduced pc-Src with DMSO and PP3 having no effect. (B) c-Src inhibition in DRG 
neurones following systemic administration of PP2 and dasatinib. Dasatinib but not PP2 
exhibits a reduction in pc-Src in DRG neurones collected post mortem from drug treated 
WT mice. GAPDH was used as a loading control for these experiments. 
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6.3 The role of c-Src in morphine tolerance 
As previously discussed (Chapter 3), WT mice exhibit tolerance to morphine 
following repeated administration (Figure 3.5). Tolerance was markedly reduced 
in BAR2+/- and -/- mice (Figure 3.7). Previous work has implicated c-Src in BAR2-
mediated signalling in the pain pathway (Walwyn et al., 2007). Therefore, we 
hypothesised that c-Src may participate in tolerance. We investigated the effects 
of administering dasatinib (5 mg/Kg) or vehicle via the IP route, 30 minutes prior 
to the SC injection of morphine (10 mg/Kg) in WT mice for 10 days, n = 8 in each 
group. The baseline tail withdrawal latencies of the two groups were not 
significantly different, the vehicle treated mice had a baseline tail withdrawal 
latency of 2.3 ± 0.1 s and the dasatinib treated group had a baseline tail 
withdrawal latency of 2.3 ± 0.4 s on day 1 of the protocol.  
 
Morphine was administered 30 minutes after the IP injection, immediately prior 
to this a repeat tail withdrawal assay was performed. On day 1 the vehicle 
treated mice had an average tail withdrawal time of 2.7 ± 0.4 s and the dasatinib 
treated mice had an average tail withdrawal time of 3.6 ± 0.3 at this point. This 
was not significantly different (t test p = 0.08) (data shown as %MPE, Figure 
6.2A). The baseline tail withdrawal times expressed as MPE at this time point 
were also not significantly different between the groups. The vehicle treated 
group had an MPE of 3.0 ± 4.0% and the dasatinib treated group had an MPE of 
10.1 ± 4.8% (Figure 6.2A). There were also no significant changes in tail 
withdrawal times or equivalent values expressed as %MPE for analgesia between 
the vehicle treated and dasatinib treated mice prior to morphine administration 
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over the ten days of the protocol two way repeated measures ANOVA time p = 
0.2 and treatment p = 0.8 (Figure 6.2D). These data suggest that dasatinib 
administration did not produce consistent basal analgesia when administered to 
WT mice.  
 
Baseline tail withdrawal times were also investigated in the MOP+/- mice, which 
exhibited latencies of 2.5 ± 0.3 s for the vehicle allocated group and 2.1 ± 0.2 s 
for the dasatinib allocated group, n = 8 in each group. After either vehicle or 
dasatinib injection a tail withdrawal assay was repeated. At this point the vehicle 
treated group had a tail withdrawal time of 3.1 ± 0.3 s (MPE of 3.3 ± 0.52%) and 
the dasatinib treated group a time of 4.2 ± 2.2 s (MPE of 9.4 ± 3.5%)(Figure 
6.3A). These times were not significantly different between the groups and the 
mice did not exhibit any significant differences over the 5 days of testing (data 
not shown). These data demonstrate that dasatinib administration did not 
produce basal analgesia in the MOP+/- mice.  
 
Mice (MOP+/-) treated with either PP3 (5mg/Kg) or PP2 (5mg/Kg) IP 30 minutes 
prior to morphine also did not exhibit any significant differences in baseline tail 
withdrawal times (Figure 6.3B). For these groups the average baseline tail 
withdrawal times for the PP3 allocated group were 3.3 ± 0.4 s and for the PP2 
allocated group they were 3.4 ± 0.2 s.  
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Following PP3/ PP2 administration the tail withdrawal times were 4.0 ± 0.3 s (5.1 
± 1.6% MPE) and 3.8 ± 0.3 s (3.8 ± 2.2% MPE) respectively, n = 8 in each group. 
When these results were compared over the 5 days of the experiment there 
were no significant differences between the PP3 and the PP2 treated MOP+/- 
mice (data not shown). PP2 administration did not produce basal analgesia in the 
MOP+/- mice. 
 
Having investigated the actions of c-Src inhibition on baseline sensitivity to 
noxious heat the effect of dasatinib and PP2 were examined against morphine 
analgesic tolerance. Interestingly, dasatinib treated WT mice did not develop 
significant tolerance to the analgesic effects of morphine (10 mg/Kg) over the 
ten day test period (Figure 6.2B). On day 10 vehicle treated mice exhibited a 
decline in morphine analgesia to 57.6 ± 11.4% of the MPE. By contrast, dasatinib 
treated mice maintained morphine (10 mg/Kg) analgesia at 99.3 ± 0.7% of MPE. 
The difference between dastinib and vehicle treated groups was significant on 
day 10, t test p = 0.003 (Figure 6.2C). 
 
MOP+/- mice develop a more rapid and profound morphine analgesic tolerance 
than do WT mice (Chapter 3, Figure 3.5). This provides an additional model in 
which to investigate the capacity of c-Src inhibition to affect the development 
and maintenance of tolerance. Either vehicle or dasatinib (5 mg/Kg) were 
injected IP, 30 minutes prior to morphine (10 mg/Kg) administration, n = 8 for 
each group. On day 5 the tail withdrawal latency for control mice treated with 
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morphine was 32.0 ± 9.2% of MPE, while dasatinib treated mice exhibited a 
significantly increased analgesic effect of morphine with an MPE of 88.1 ± 7.9% 
(Figure 6.3C).   
 
The effect of the c-Src inhibitor, PP2, on the development of morphine analgesic 
tolerance in MOP+/- mice was also investigated. For this experiment mice 
received either the inactive analogue, PP3 (10 mg/Kg), or PP2 (10 mg/Kg) 
injected IP, 30 minutes prior to SC morphine (10 mg/Kg), n = 12 in each group. 
Like dasatinib, PP2 administration also significantly reduced the development of 
analgesic tolerance in the MOP+/- mice. On day 5 the PP3 treated mice had a 
MPE of 17.0 ± 4.1% for morphine and the PP2 treated mice had a significantly 
larger analgesic response to morphine with an MPE of 87.4 ± 4.7% (Figure 6.3D). 
 
Dasatinib was applied next using a paradigm to determine whether the drug 
affects morphine tolerance after the process had already developed. MOP+/- 
mice received morphine (10 mg/Kg) for three days, n = 8 in each group. Tail 
withdrawal latencies were established 30 minutes after morphine 
administration. As previously observed a significant reduction in the morphine 
analgesia developed in both groups of mice. The group that subsequently 
received IP vehicle treatment exhibited an MPE of 64.8 ± 12.7% following the 
administration of morphine (10 mg/Kg). The other group that subsequently 
received dasatinib exhibited a morphine analgesic MPE of 69.8 ± 12.7%. On days 
4 and 5 one group received a vehicle injection IP, 30 minutes prior to the 
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administration of morphine (10 mg/Kg) and the other group received dasatinib 
(5 mg/Kg) IP, 30 minutes prior to morphine (10 mg/Kg) administration. Not only 
was there no further development of analgesic tolerance, in the dasatinib 
treated group, the previously existing analgesic tolerance appears to have 
reversed.  
 
On day 5 the vehicle treated group had an MPE of 30.3 ± 17.3% following the 
administration of morphine, indicating a significant morphine analgesic 
tolerance. By contrast, the dasatinib treated group had an MPE of 88.9 ± 5.8% 
following the administration of morphine. In addition to being significantly 
different from the vehicle treated group, the analgesic effect of morphine in the 
mice treated with dasatinib on day 4 was significantly greater than that observed 
on the previous day (t test p = 0.04)(Figure 6.3E). 
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Figure 6.2: The c-Src inhibitor dasatinib inhibits the development of morphine 
tolerance in WT mice. (A) Dasatinib does not significantly alter baseline tail withdrawal 
when compared to vehicle injection on day 1, t test p = 0.14, n = 8 in each group. (B) 
Administration of dasatinib (5 mg/Kg) prior to the administration of morphine (10 
mg/Kg) prevented the development of tolerance in WT mice, two way repeated 
measures ANOVA time p = 0.009, dasatinib administration p = 0.002, the post hoc 
Bonferroni results are shown on graph. (C) WT mice treated with dasatinib prior to 
morphine administration exhibited significantly more analgesia on day 10 compared to 
the vehicle treated mice, unpaired t test p = 0.003, n = 8 in each group. (D) Dasatinib 
administration did not produce persistent analgesia in WT mice over a 10 day 
administration period, two way repeated measures ANOVA, time p = 0.2, treatment p = 
0.8. Vertical lines represent ± SEM. *, p < 0.05, **, p < 0.01, ***, p < 0.001. 
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Figure 6.3: c-Src inhibition inhibits morphine tolerance in MOP+/- mice. (A) Dasatinib 
does not cause basal analgesia in MOP+/- mice. Tail withdrawal times (not shown) and 
MPE 30 minutes after either vehicle or dasatinib injection were not significantly 
different, t test p = 0.11 n = 8 in each group. (B)PP2 does not cause basal analgesia in 
MOP+/- mice. The tail withdrawal times (not shown) and MPE are not significantly 
different for the PP2 treated mice when compared to those that have received PP3, t 
test p = 0.64, n = 12 in each group. (C) Dasatinib (5 mg/kg) administered 30 minutes 
prior to morphine (10 mg/Kg) prevented the development of significant morphine 
tolerance in MOP+/- mice, two way repeated measures ANOVA, time p < 0.0001, 
dasatinib treatment p = 0.0005, post hoc Bonferroni results are shown on the graph, n = 
8 in each group. (D) PP2 also inhibits the development of morphine tolerance. PP2 (5 
mg/Kg) administered IP 30 minutes prior to subcutaneous morphine (10 mg/Kg) 
administration prevented the morphine tolerance observed in the PP3 (5 mg/Kg IP) 
treated mice, two way repeated measures ANOVA, time p < 0.0001, drug difference p < 
0.0001, post hoc Bonferrroni results are shown on the graph. Each treatment group was 
n = 12, (5 female and 7 male). (E) Dasatinib reversed the development of tolerance in 
MOP+/- mice. 16 mice (5 male and 3 female in each group) were treated with morphine 
(10 mg/Kg) daily for three days, on days 4 and 5 one group received dasatinib (5 mg/Kg 
IP) 30 minutes prior to subcutaneous morphine administration and the other group 
received a vehicle injection at the equivalent time. The mice that received dasatinib 
exhibited a significantly greater morphine analgesia compared to the vehicle treated 
mice; two way repeated measures ANOVA revealed a significant difference between the 
two groups on days 4 and 5. The post hoc Bonferroni test results are shown on graph. 
Vertical lines represent ± SEM. *, p < 0.05, **, p < 0.01, ***, p < 0.001. 
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6.4 The effects of c-Src inhibition on locomotor activation by morphine 
As described previously (Chapter 4, Figure 4.1), morphine (10 mg/Kg) 
administration causes locomotor activation and sensitisation in WT mice. Before 
investigating the effects of dasatinib on the locomotor activating effects of 
morphine we investigated whether administration of dasatinib alone produced 
any locomotor effects. The two chamber CPP apparatus, was used to establish 
locomotor responses (see Methods, Chapter 2), n = 8 for each experiment. Saline 
was administered in both compartments but one compartment was paired with 
a vehicle injection and the other dasatinib (5 mg/Kg) injection 30 minutes prior 
to the saline administration. There were no significant differences in distance 
travelled following vehicle or dasatinib administration (Figure 6.4A). There were 
also no significant differences in distance travelled or speed of travel over the 
three days of conditioning (Figure 6.4B). On day 1 of conditioning the saline 
alone treated mice travelled 16.2 ± 2.2 m with an average speed of 0.009 ± 0.001 
m/s and the dasatinib and saline treated mice travelled 14.2 ± 1.9 m with an 
average speed of 0.008 ± 0.001 m/s during the 30 minute time period. 
 
To determine whether administering an IP injection 30 minutes prior to 
conditioning with morphine affects the CPP protocol and to control for the other 
aspects of the IP injection a vehicle was administered 30 minutes prior to 
morphine (10 mg/Kg) administration.  
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On day 1 of conditioning these mice travelled 21.5 ± 1.2 m with an average 
speed of 0.012 ± 0.0007 m/s following saline administration and 57.1 ± 2.5 m 
with an average speed of 0.03 ± 0.001 m/s following vehicle and morphine (10 
mg/Kg) administration (Figure 6.4E). WT mice administered a vehicle injection IP 
prior to morphine exhibited both locomotor activation following morphine 10 
mg/Kg administration and also sensitisation to its affects (Figure 6.4F). However, 
the locomotor activation observed following morphine administration was 
significantly reduced compared to the WT mice that received morphine alone 
which travelled 81.1 ± 7.0 m following morphine administration (data not 
shown), suggesting that the administration of the vehicle injection affected the 
morphine-evoked locomotor activation. 
 
Morphine (3 mg/Kg) administered 30 minutes after an IP injection of dasatinib (5 
mg/Kg) to WT mice did not produce significant locomotor activation or 
sensitisation (Figures 6.4C and D). After saline injection the mice travelled 23.2 ± 
2.2 m and after dasatinib and morphine injection they travelled 26.0 ± 1.5 m. 
This is not different to the effect observed when morphine (3 mg/Kg) is 
administered alone to WT mice (Chapter 4, Figure 4.1).  
 
Dasatinib (5 mg/Kg) administered 30 minutes prior to morphine (10 mg/Kg) had 
the same effect as vehicle injection. On day 1 the distance travelled following 
saline injection was 18.5 ± 1.7 m with an average speed of 0.01 ± 0.0009 m/s and 
the distance travelled following dasatinib and morphine administration was 61.1 
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± 6.1 m with an average speed of 0.03 ± 0.003 m/s (Figure 6.4G). This was not 
significantly different to that observed in the vehicle and morphine treated mice. 
However, similar to vehicle treated mice the distance travelled was significantly 
reduced compared to the morphine alone group (data not shown).   
 
By contrast to vehicle treated mice, which exhibited significant sensitisation to 
the locomotor effects of morphine (10 mg/ Kg; Figure 6.4F), mice that received 
dasatinib prior to the administration of morphine did not. The distance that they 
travelled on day 3 was not significantly increased compared to the distance 
travelled on day 1 of the conditioning phase (Figure 6.4H).    
 
However, when day 3 conditioning distances are directly compared there were 
no significant differences in the distance travelled following administration of 
morphine 10 mg/Kg in the WT alone (118.6 ± 13.1 m), WT vehicle treated (88.5 ± 
3.0 m) and WT dasatinib treated (87.9 ± 11.6 m), one way ANOVA p = 0.08 (data 
not shown). The difference observed between the vehicle treated and dasatinib 
treated mice may be due to the increased variability in the distance travelled on 
day 3 in the dasatinib treated mice compared to the vehicle treated mice. The 
range of distances travelled in the last 300 s of the morphine conditioning phase 
on day 3 were 18.1 to 24.7 m for the vehicle treated and 10.3 to 30.8 m for the 
dasatinib treated mice. Overall this suggests that the absence of significant 
sensitisation observed in the dasatinib treated mice is likely to increased 
variability rather than a systematic reduction caused by dasatinib. 
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On day 1 of conditioning WT mice treated with either vehicle or dasatinib alone 
do not exhibit locomotor activation (Figure 6.5). Furthermore, the mean distance 
travelled after morphine (10 mg/Kg) was similar in vehicle and dasatinib treated 
mice, suggesting that c-Src inhibition does not affect the locomotor activation 
produced by morphine (Figure 6.5).  
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Figure 6.4: Dasatinib has no consistent effect on locomotor activation by morphine. 
(A) Dasatinib (5 mg/Kg IP) does not affect locomotion, two way repeated measures 
ANOVA ns, n = 8 in each group. White bars represent vehicle treatment, grey bars 
represent dasatinib treatment.  (B) Dasatinib alone does not cause locomotor activation 
or sensitisation following repeated dosing. The distance travelled on day 3 is not greater 
than the distance travelled on day 1. The grey squares represent dasatinib and the black 
circles represent vehicle, open symbols are day 1 and closed symbols are day 3.  (C) WT 
mice treated with dasatinib (5 mg/Kg) prior to conditioning with morphine (3 mg/Kg) do 
not exhibit significant locomotor activation, two way ANOVA ns, n = 8. (D) Mice treated 
with dasatinib prior to morphine (3 mg/Kg) do not exhibit locomotor sensitisation, two 
way ANOVA ns. (E) WT mice injected with vehicle 30 minutes prior to morphine (10 
mg/Kg) conditioning exhibit locomotor activation, two way repeated measures ANOVA 
time p < 0.0001, n = 8 in each group. (F) WT mice sensitise to the locomotor effects of 
morphine when injected with vehicle prior to morphine conditioning, the distance 
travelled on day 3 following morphine injection was significantly further than on day 1. 
(G) Dasatinib pre-treatment did not affect locomotor activation with morphine. The WT 
mice exhibit significant locomotor activation, two way repeated measures ANOVA, 
morphine effect p < 0.0001. (H) WT mice treated with dasatinib prior to morphine do 
not exhibit significant sensitisation to morphine over the three days of conditioning, two 
way repeated measures ANOVA time p = 0.2 (ns). White bars represent saline 
administration and the black bars morphine administration, while on the line graphs red 
squares represent morphine administration and the black circles represent saline 
administration, open symbols are day 1 and the closed symbols are day 3.  
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Figure 6.5: Dasatinib has no direct locomotor effect and does not differ from vehicle in 
its effect of locomotor stimulation by morphine. The distance travelled by the WT mice 
was not significantly different following saline treatment on day 1 of conditioning for 
the dasatinib alone or the mice treated with vehicle or dasatinib prior to morphine (10 
mg/Kg), one way ANOVA ns (p = 0.6). Dasatinib administered alone did not produce 
significant locomotor activation. WT mice administered vehicle then morphine (10 
mg/Kg) exhibit significant locomotor activation on day 1 of conditioning, WT mice 
treated dasatinib prior to morphine (10 mg/Kg) administration also exhibit significant 
locomotor activation, two way repeated measures ANOVA post hoc Bonferroni results 
are shown on the graph.  Vertical lines represent ± SEM. *, p < 0.05, **, p < 0.01, ***, p 
< 0.001. 
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6.5 The effects of c-Src inhibition on conditioned place preference to morphine 
Dasatinib (5 mg/Kg) administered alone is not rewarding or aversive to WT mice 
(Figure 6.6A). The mice spent 464.6 ± 302 s in the saline alone paired chamber 
and 435.4 ± 30.2 s in the dasatinib and saline paired chamber, t test p = 0.6. 
When WT mice were conditioned to saline or dasatinib (5 mg/Kg) and morphine 
(3 mg/Kg) they did not exhibit a significant preference for the morphine paired 
chamber (Figure 6.6B). The mice spent 411.6 ± 17.5 s in the saline paired 
chamber and 488.2 ± 17.6 s in the chamber paired with dasatinib and morphine 
(3 mg/Kg). there were no significant differences in the preference score for the 
morphine paired chamber between mice administered dasatinib prior to 
morphine and those that received morphine alone, t test p = 0.97. The 
preference score for the morphine (3 mg/Kg) paired chamber was 76.6 ± 35.1 s, 
this compares to 74.2 ± 63.1 s for WT mice administered morphine (3 mg/Kg) 
alone (Figure 6.6C). 
 
The mice that received a vehicle injection prior to morphine (10 mg/Kg) during 
the conditioning phase exhibited a preference for the morphine paired chamber 
on test day (Figure 6.6D). The time spent in the saline paired chamber was 402.3 
± 20.4 s and the time spent in the vehicle and morphine paired chamber was 
497.7 ± 20.4 s. There were no significant differences in chamber preference on 
habituation day (data not shown). 
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When WT mice received dasatinib (5 mg/Kg) prior to morphine (10 mg/Kg) 
during the conditioning phase of the experiment the mice demonstrated a 
preference for the morphine paired chamber on test day (Figure 6.6E). The time 
spent in the saline paired chamber was 375.2 ± 15.6 s and the time spent in the 
dasatinib and morphine paired chamber was 524.8 ± 15.6 s. There was no 
significant difference in preference score for the morphine (10 mg/Kg) between 
the vehicle treated mice and the dasatinib treated mice (Figure 6.6F). The vehicle 
treated mice had a preference score of 95.5 ± 40.8 s and the dasatinib treated 
mice had a preference score of 149.7 ± 31.2 s.  
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Figure 6.6: Dasatinib does not affect morphine conditioned place preference. (A) Saline 
both sessions, but 30 minutes prior to second session all mice received dasatinib (5 
mg/kg IP). Mice did not show a preference for, or aversion to, dasatinib alone, t test ns p 
= 0.6, n = 8. (B) WT mice treated with dasatinib prior to morphine (3 mg/Kg) did not 
exhibit a significant preference for the morphine paired chamber on test day, t test p = 
0.07 n = 8. (C) The preference score for morphine (3 mg/Kg) was not significantly 
different between WT mice treated with morphine alone and those that received 
dasatinib prior to morphine , t test p = 0.97 n = 8. (D) WT mice that received vehicle 
treatment 30 minutes prior to morphine (10 mg/Kg) conditioning exhibited a significant 
morphine preference, t test p = 0.005. (E) WT mice administered dasatinib (5 mg/Kg) 30 
minutes prior to the morphine (10 mg/Kg) conditioning session exhibited a preference 
for the morphine paired chamber, t test p < 0.0001. (F) There was no significant 
difference in preference score for the morphine paired chamber between vehicle 
treated and dasatinib treated mice subsequently conditioned with morphine (10 
mg/Kg), t test p = 0.3. Vertical lines represent ± SEM. *, p < 0.05, **, p < 0.01, ***, p < 
0.001. 
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6.6 The effects of c-Src inhibition on sIPSC frequency in the VTA 
PP2 mimics the effects of the absence of BAR2 in DRG neurones by increasing 
the constitutive inhibitory coupling of MOP receptors to voltage-activated Ca2+ 
channels (Walwyn et al., 2007). We investigated whether inhibition of c-Src 
affects neurones within the VTA. PP2 (10 μM) alone had no effect on the sIPSC 
frequency of WT neurones (Figure 6.7B), the control sIPSC frequency was 1.6 ± 
0.3 Hz and the sIPSC frequency following PP2 (10 μM) exposure was 1.4 ± 0.2 Hz, 
n = 6. PP3, the inactive chemical analogue of PP2, also had no effect on sIPSC 
frequency of WT neurones within the VTA when applied alone (Figure 6.7C), 
control sIPSC frequency was 2.1 ± 1.3 Hz and the sIPSC frequency following PP3 
(10 μM) exposure was 1.8 ± 1.0 Hz, n = 5. Exemplar recordings from WT 
neurones of the VTA exposed to both PP2 and morphine are provided in Figure 
6.7A. 
 
As described in Chapter 5, morphine inhibits sIPSC frequency in VTA neurones 
(Figure 5.6) and this effect was diminished in BAR2-/- mice (Figure 5.12). PP2 and 
PP3 were applied with morphine to determine whether c-Src plays a role in the 
inhibition of sIPSCs by morphine. There was a significant reduction in the 
inhibition of sIPSC frequency in VTA neurones that received morphine (10 μM) in 
the presence of PP2 (10 μM) (25.5 ± 3.1%) compared to those that received 
morphine in the presence of PP3 (10 μM) (52.2 ± 4.5%). In this respect neurones 
exposed to PP2 resembled BAR2-/- neurones, which exhibited a 23.3 ± 4.4% 
inhibition of sIPSC frequency by morphine (10 μM).  
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The inhibition of sIPSC frequency produced by exposure of the neurones to 
morphine was not significantly different in the presence or absence of PP3 
(Figure 6.7D). These results, together with the effects of the BAR2 knockout, 
suggest that BAR2 and c-Src are important in the response of VTA neurones to 
morphine.  
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Figure 6.7: PP2 significantly reduces the inhibition of sIPSC frequency in VTA neurones 
by morphine. (A) This is an exemplar recording from a WT neurone in the presence of 
PP2 (10 μM) and PP2 plus morphine (10 μM). (B) PP2 (10 μM) alone does not 
significantly affect sIPSC frequency, t test ns p = 0.2, n = 6. (C) PP3 (10 μM) alone does 
not significantly alter sIPSC frequency within the VTA, t test ns p = 0.3, n = 5. (D)The 
ability of morphine 10 μM to inhibit sIPSC frequency is significantly reduced in the 
presence of PP2 10 μM and unchanged in the presence of PP3 10 μM. One way ANOVA 
p < 0.0001, the post hoc Tukey results are shown on the graph. WT n = 10, WT + PP2 + 
morphine n = 5, WT + PP3 + morphine n = 5. Vertical lines represent ± SEM. *, p < 0.05, 
**, p < 0.01, ***, p < 0.001. 
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6.7 The effects of MEK inhibition on sIPSC frequency within the VTA 
BAR2-/- mice exhibit a reduced locomotor activation compared to WT mice 
following the administration of morphine (10 mg/Kg). As previously discussed 
the dopamine dependent component of locomotor activation is thought to be 
mediated via a dopamine D1 receptor mechanism. Activation of this pathway 
recruits the BAR2/MAPK complex. Phosphorylation and activation of MAPK 
requires the activity of MEK. Systemic administration of the MEK inhibitor, 
SL327, to WT mice inhibits locomotion in a dose dependent manner (Urs et al., 
2011).  The effect of SL327 on morphine induced locomotor activation in BAR2-/- 
mice has not yet been investigated. SL327 has been shown to inhibit 
phosphorylation of ERK in the striatal brain regions of the mouse (Beaulieu et al., 
2006). This suggests that the BAR2-MEK-ERK pathway is important in the 
locomotor activation by morphine. It is possible that the MEK-ERK pathway is 
also involved in the inhibition of sIPSC frequency by morphine. To test this, WT 
neurones within the VTA were treated with the MEK inhibitor, SL327 (Figure 
6.8). Control sIPSC frequency was 3.0 ± 1.6 Hz in the absence and 3.0 ± 1.7 Hz in 
the presence of SL327 (1 μM). Morphine (10 μM) significantly inhibited sIPSC 
frequency in the presence of SL327 (1 μM) (51.8 ± 7.4%) (Figure 6.8C). This was 
not significantly different to the inhibition of sIPSC frequency observed in the WT 
neurones exposed to morphine 10 μM alone (64.6 ± 4.9%). In contrast, the 
presence of PP2 significantly reduces the ability of morphine to inhibit sIPSC 
frequency.  
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The inhibition of sIPSC frequency observed in the presence of PP2 was not 
significantly different to that recorded in the BAR2-/- neurones. These data 
suggest that the MEK-ERK pathway does not contribute to the inhibitory effect 
of morphine on sIPSC frequency in VTA neurones but that c-Src is involved in this 
process. 
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Figure 6.8: MEK inhibition by SL327 has no significant effect on morphine inhibition of 
sIPSC frequency within the VTA. (A) Example of a recording from a neurone exposed to 
SL327 (1μM) and morphine (10μM). (B) SL 327 (1 μM) alone had no significant effect on 
sIPSC frequency, t test, p = 0.8, n = 6. C) SL327 (1 μM) has no significant effect on the 
ability of morphine (10 μM) to inhibit sIPSC frequency in WT neurones within the VTA, t 
test p = 0.15, WT n = 10, WT + SL327 n = 6. This is significantly different to the reduction 
in sIPSC inhibition observed in response to morphine (10 μM) exposure in the BAR2-/- 
neurones and when PP2 is present, one way ANOVA p <0.0001 the post hoc Tukey 
results are shown on the graph. Vertical lines represent ± SEM. *, p < 0.05, **, p < 0.01, 
***, p < 0.001. 
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6.8 Summary 
Dasatinib, administered prior to morphine, prevents the development of 
significant morphine tolerance in both WT and MOP+/- mice. It does not 
significantly alter basal tail withdrawal latency, this is interesting because BAR2-
/- mice exhibit prolonged basal tail withdrawal latencies and this suggests that 
another signalling pathway may be responsible for this aspect of behaviour. PP2 
also inhibits the development of morphine analgesic tolerance; this inhibition is 
not significantly different from that observed following the administration of 
dasatinib. Dasatinib also reversed the analgesic tolerance that had already 
developed to morphine in the MOP+/- mice. The observed reversal and return to 
almost full analgesia suggests that these effects can be rapidly reversed and 
implicated c-Src in these processes. 
 
Dasatinib had no psychomotor effects when administered alone. Mice 
administered either vehicle or dasatinib injections prior to morphine exhibited a 
reduced locomotor response. This may be due to an effect of the components of 
the vehicle injection (DMSO / Kolliphor EL) on locomotor activity or a 
behavioural effect due to a further period of restraint and injection. Further 
experiments will be required to determine whether either of these play a role in 
locomotor activation following morphine administration. Our data suggested 
that dasatinib may inhibit sensitisation to the locomotor effects of morphine, 
however, on closer inspection the average distances travelled by WT alone, 
vehicle treated and dasatinib treated mice administered morphine are not 
significantly different. The reason that there appears to be a difference is due to 
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an increase in the variability of response in the dasatinib treated mice, which is 
not present in the vehicle treated mice or mice treated with morphine alone.  To 
explore this effect further more experiments will be required to diminish the 
variance in the dasatinib data and to investigate whether dasatinib is affecting 
locomotor sensitisation. 
 
Inhibition of c-Src does not produce reinforcement or aversion in the absence of 
morphine. Furthermore, when mice were treated with either vehicle or dasatinib 
prior to morphine during the conditioning phase of CPP there was no significant 
differences in the preference for the morphine paired chamber on test day. 
Dasatinib does not appear to affect morphine reinforcement. This contrasts with 
the differences that we have observed in the BAR2-/- mice, which exhibit an 
increased sensitivity to morphine reinforcement compared to the WT mice. 
BAR2-/- mice exhibited a significant preference for morphine following 
conditioning with morphine at both 3 and 10 mg/Kg. This was not the case for 
WT mice or for WT mice administered dasatinib prior to morphine. In these mice 
reinforcement was only exhibited following conditioning with morphine (10 
mg/Kg) not the lower dose. This suggests that c-Src is not implicated in this 
process of sensitisation to the reinforcing effects of morphine.  
 
The c-Src inhibitor, PP2, reduced the ability of morphine to inhibit sIPSC 
frequency in VTA neurones. The diminished sIPSC inhibition by morphine in the 
presence of PP2 was similar to that observed in recordings from BAR2-/- 
211 
 
neurones. By contrast, PP3, an inactive chemical analogue of PP2, did not 
significantly alter the ability of morphine to inhibit sIPSC frequency compared to 
the WT neurones exposed to morphine alone. This suggests that BAR2 and c-Src 
are important components of the signalling pathway within the VTA in response 
to morphine.   
 
Systemic administration of the MEK inhibitor SL 327 has been demonstrated to 
inhibit locomotion in a dose dependent manner that involves D1 dopamine 
receptors in WT mice, the effect in BAR2-/- mice has not been investigated. By 
contrast, MEK inhibition was without effect on morphine evoked CPP (Urs et al., 
2011). We investigated whether inhibition of the MEK/ERK pathway using SL327 
would affect the ability of morphine to inhibit sIPSC frequency within the VTA. 
There were no significant differences in the ability of morphine to inhibit sIPSC 
frequency in WT VTA neurones treated with morphine alone or WT VTA 
neurones treated with SL327 and morphine. This suggests that the inhibition by 
morphine of vesicular release of GABA from presynaptic GABAergic neurones in 
the VTA does not involve the BAR2-MEK-ERK signalling pathway. 
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Chapter 7: Discussion and Conclusions 
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7.1 Discussion 
This study in mice confirms that morphine causes analgesia, analgesic tolerance, 
and has psychomotor effects leading to enhanced locomotion and conditioned 
reinforcement. In VTA neurones morphine and the selective MOP receptor 
agonist DAMGO caused concentration-dependent inhibition of the frequency of 
IPSCs. All these actions of morphine were absent from MOP-/- mice that lack 
MOP receptors. The absence of 50% of MOP receptors (in MOP+/- mice) reduced 
the potency of morphine in all of these actions, with no evidence of reduced 
efficacy, and greatly accelerated the development of analgesic tolerance. Even 
after the development of profound tolerance the dose-response relationship in 
MOP+/- mice for analgesia suggests that morphine maintains its efficacy. Taken 
together these observations suggest that there is a remarkable surplus of MOP 
receptors.  
 
A lack of DOP receptors resulted in a significant decrease in morphine analgesia 
and in the development of analgesic tolerance compared to the WT mice. 
However, these mice still displayed significant tolerance to the analgesic effects 
of morphine. DOP receptors are not required for the locomotor activation 
produced by morphine, but they do contribute to this effect as demonstrated by 
the increased locomotor activation produced in DOP-/- mice by a low dose of 
morphine when compared to WT mice. They are not involved in the 
development of sensitisation to the locomotor activating effects of morphine 
and are not required for the development of the reinforcing effect of morphine 
as the absence of DOP receptors did not alter morphine CPP. Interestingly, DOP 
214 
 
receptors are required for the full inhibitory effect of morphine on sIPSC 
frequency within the VTA. This is not the case for DAMGO, as its inhibition of 
sIPSC frequency in the DOP-/- VTA neurones was not different to that observed 
in the WT neurones. There was no difference in the effects on morphine function 
of a lack of a single or both copies of the Oprd1 gene (i.e. DOP+/- and DOP-/- 
mice, respectively). This suggests that in contrast to MOP receptors there is not a 
large receptor reserve as the loss of 50% of the receptors in the DOP+/- mouse 
creates the full phenotype seen in the KO animals. 
 
A lack of BAR2 does not significantly affect morphine analgesia, but these mice 
display basal analgesia. They also exhibit significantly reduced tolerance to 
morphine compared to the WT mice, although the analgesia that they receive 
from morphine is itself significantly reduced by day 10 of the tolerance protocol. 
This demonstrates that the absence of BAR2 alone does not completely abolish 
morphine analgesic tolerance and that other signalling mechanisms may be 
involved. BAR2 is also involved in the locomotor activating effects of morphine 
as BAR2-/- mice exhibit significantly reduced locomotor activation after the 
administration of morphine when compared to WT mice. They do still sensitise 
to this effect over the conditioning period suggesting that BAR2 is not involved in 
the process of sensitisation. The BAR2-/- mice exhibit an increased sensitivity to 
the rewarding aspects of morphine as they have an increased preference for the 
morphine paired chamber at lower doses of drug when compared to WT mice. 
However, unexpectedly we found that the ability of morphine to inhibit sIPSC 
frequency within the VTA of BAR2-/- mice was significantly decreased. This was 
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also the case when we used DAMGO, suggesting that BAR2 is involved in the 
response to both morphine and DAMGO within the VTA. 
 
In most cases the combined lack of DOP receptors and BAR2 had no additional 
phenotypic effects. The double KO mice replicated the effects seen in mice 
lacking either DOP receptors or BAR2. The exception to this was for analgesic 
tolerance. Mice lacking both genes exhibited a complete absence of tolerance, 
which while negligible, was still detectable in DOP-/- and BAR2-/- mice.  
 
Similar to the effect of the absence of DOP receptors and/or BAR2, inhibition of 
c-Src activity by dasatinib or PP2 also reduced morphine analgesic tolerance. 
Furthermore, similar to VTA neurones from BAR2-/- mice, WT VTA neurones 
treated with PP2 exhibited reduced morphine inhibition of sIPSC frequency. 
Dasatinib alone was neither rewarding nor aversive to WT mice and IP 
administration did not significantly alter the psychomotor effects (reinforcement 
or locomotion) of morphine.  
 
In contrast to our original hypothesis that DOP receptors are absent from the 
VTA leading to a lack of MOP/DOP oligomers, the evidence suggests that DOP 
receptors are present and functional in this brain region. They appear to be 
involved in the locomotor activating effects of morphine and their absence 
results in an increased sensitivity to this effect. They do not appear to be 
involved in the development of morphine preference although their presence is 
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required for the full inhibitory effect of morphine on sIPSC frequency within the 
VTA. BAR2 also appears to be involved in the rewarding effects of morphine. Its 
absence results in an increase in morphine preference and a decrease in the 
ability of morphine to produce locomotor activation. It, like DOP receptors, is 
required for the full inhibitory effect of morphine on sIPSC frequency within the 
VTA. Inhibition of c-Src resulted in a reproduction of this effect implicating both 
BAR2 and c-Src in VTA signalling in response to morphine. This raises a number 
of questions about the role of BAR2 and c-Src in the VTA. It would be very 
interesting to investigate whether c-Src inhibition has an effect on sIPSC 
frequency and the ability of morphine to inhibit these events in BAR2-/- slices. It 
will also be important to determine whether inhibitors of c-Src administered via 
the IP route inhibit the activity of c-Src within the VTA. The lack of psychomotor 
effects of systemically administered dasatinib might simply reflect a failure to 
reach a concentration in the VTA sufficient to inhibit c-Src activation. 
 
In the pain pathway it appears that both DOP receptors and BAR2 are involved in 
the development of morphine analgesic tolerance. The absence of either 
component reduced tolerance but when both were removed in the BAR2-/-
//DOP-/- mice then tolerance to the analgesic effect of morphine was abolished. 
Inhibition of c-Src also significantly reduced the development of tolerance but 
did not produce basal analgesia. This suggests that a reduction in morphine 
tolerance can be produced without altering basal MOP receptor signalling. These 
findings are summarised in Figure 7.1. 
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Figure 7.1: The role of MOP and DOP receptors, BAR2 and c-Src in opioid receptor 
signalling in the pain and reward pathway. In the diagrams MOP and DOP receptors are 
depicted as physically interacting in the form of dimers. This is based on reports of 
heterodimerisation and the recent crystal structure of MOP receptors which reveals the 
existence of dimers (Manglik et al., 2012). (A) When expressed recombinantly MOP 
receptors, DOP receptors and BAR2 colocalise (Rozenfeld and Devi, 2007). This is 
depicted as the hypothetical scenario in WT neurones. The absence of DOP receptors 
(B), BAR2 (C), both DOP receptors and BAR2 (D), or the inhibition of c-Src (E) have the 
consequences summarised in each case. In each case the scenario is represented 
schematically.   
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7.2 Analgesia and Tolerance 
7.2.1 MOP receptors in analgesia and tolerance 
Work with MOP-/- mice confirms previously published data that MOP receptors 
are required for the analgesic effect of morphine (Matthes et al., 1996, Sora et 
al., 1997, Tian et al., 1997, Schuller et al., 1999, Becker et al., 2000). MOP-/- 
neurones in slices of VTA and from DRGs harvested from these mice do not 
respond to drugs that act as selective agonists at MOP receptors. Small DRG 
neurones are largely primary afferent nociceptors and a loss of opioid inhibition 
of VACCs here is likely to contribute to the absence of morphine analgesia. The 
VTA has also been implicated in the analgesic activity of opioids (Niikura et al., 
2010, Schifirnet et al., 2014) and a lack of opioid inhibition of sIPSCs recorded 
from dopaminergic neurones is also likely to contribute to the analgesic deficit. 
Dissection of the contribution of these two neuronal populations to the 
analgesic actions of morphine will require conditional MOP knockouts and/or 
neurone specific reintroduction of MOP receptors into MOP-/- mice.  
 
We could not identify any alteration in baseline tail withdrawal times in MOP-/- 
mice implying that basal sensitivity to noxious heat is not affected by tonic MOP 
receptor mediated activity in the mouse. This is consistent with previously 
published work (Matthes et al., 1996). We did however identify differences in 
the baseline tail withdrawal latency between male and female WT mice, 
indicating a higher sensitivity of female mice to noxious heat. A gender 
difference in baseline sensitivity to noxious heat of C57Bl/6J mice has been 
reported previously (Kest et al., 1999) and other investigators using much larger 
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cohorts of mice have demonstrated gender differences in morphine analgesia 
with male rodents receiving greater analgesia from morphine (Cicero et al., 
1996) and the development of tolerance with increased tolerance to the 
morphine recorded in female mice (Kest et al., 2000, Mogil and Chanda, 2005). 
Additional experiments using MOP-/- mice will be required to determine 
whether this difference relates to a sex difference in the contribution of MOP 
receptors to thermal nociception. 
 
Mice lacking one copy of the Oprm1 gene, MOP+/- mice, have 50% less MOP 
receptors than WT mice (Sora et al., 2001). The analgesic potency of morphine 
was reduced in these mice as observed by a rightward shift in the dose response 
curve. This occurred without any significant change in the efficacy of morphine. 
They also exhibit a very rapid onset of tolerance to the analgesic effects of 
morphine. This is significantly different from the development of tolerance in WT 
mice. Interestingly, there appears to be no loss of analgesic efficacy in MOP+/- 
mice, even after 5 days of morphine daily exposure, a time point at which these 
mice exhibit profound morphine analgesic tolerance. This suggests that MOP 
receptor number in WT animals massively exceeds that required for maximum 
analgesia. This has been described previously as spare receptors and receptor 
reserve (Chavkin and Goldstein, 1984). A number of investigators have examined 
MOP receptor reserve and attempted to identify changes following opioid 
exposure. In cell and tissue models there are demonstrable effects of decreasing 
MOP receptor reserve (Chavkin and Goldstein, 1984, Adams et al., 1990). A 
previous study using MOP+/- mice revealed a decreased locomotor activation, 
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decreased self-administration and an increased lethal dose of morphine in these 
mice (Sora et al., 2001). MOP+/- mice in this study also developed morphine 
analgesic tolerance following repeated dosing, which appears to be greater than 
in WT mice but was not directly compared (Sora et al., 2001). They did not 
comment on the pattern of development of tolerance in the differing genotypes. 
The mice that were used for this study were also a different genetic background 
as they were maintained on a C57/129 base. The rapid development of 
morphine analgesic tolerance observed in the MOP+/- mice reveals the 
importance of MOP receptor number in this process. A recently published study 
using a genetically modified mouse that expresses humanised MOP receptors 
with the A118G mutation, which decreases receptor expression, demonstrates 
the importance of receptor reserve in the response to morphine (Robinson et al., 
2015). 
 
Morphine is a low efficacy partial agonist at MOP receptors but causes tolerance 
whereas fentanyl is a high efficacy full agonist at the receptor that appears to 
cause little tolerance in comparison to morphine (Duttaroy and Yoburn, 1995). 
This has led to the concept that receptor internalisation/ desensitisation and 
endocytosis are important in this process (Alvarez et al., 2002, Koch et al., 2005, 
Johnson et al., 2006). Consistent with this is the demonstration that morphine is 
poor at initiating receptor internalisation compared to other MOP agonists such 
as DAMGO and methadone (Keith et al., 1996, Keith et al., 1998, Koch et al., 
2005, Walwyn et al., 2006). Initial studies suggested that the degree of 
internalisation produced by agonists at MOP receptors correlated with their 
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ability to cause endocytosis (Alvarez et al., 2002). However subsequent work 
suggests that receptor internalisation is inversely correlated with desensitisation 
leading to the RAVE hypothesis (Whistler et al., 1999, Finn and Whistler, 2001). 
In this hypothesis the ratio of receptor activation versus endocytosis is 
considered to be the key determinant of desensitisation/tolerance. Endocytosis 
is considered to be a requirement for receptor resensitisation. This is further 
complicated by the fact that morphine will internalise MOP receptors in striatal 
and DRG neurones (Haberstock-Debic et al., 2005, Walwyn et al., 2006). This 
suggests that the internalisation of receptors produced by morphine differs 
across cell types and locations. It would be very interesting to look at DRG 
neurones from these mice stained for MOP receptors and investigate the effects 
of exposure to morphine and the differences from WT cells. It would also be 
informative to establish the level of receptor endocytosis/recycling in these 
neurones.  
 
7.2.2 DOP receptors in analgesia and tolerance 
DOP-/- mice exhibit slightly reduced analgesic potency of morphine, with an 
increased ED50. This corresponds with previously published data (Zhu et al., 
1999) and suggests that both MOP and DOP receptors are involved in the 
antinociceptive effects of morphine. While MOP receptors must be present for 
any analgesic effect it appears that DOP receptors also play a role. This is 
possibly in the binding of morphine to the receptor as the slope of the analgesia 
dose response curve is altered in DOP-/- mice and suggests a reduced 
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cooperativity of agonist binding. DOP-/- mice also exhibit reduced morphine 
tolerance confirming previous reports of this effect (Zhu et al., 1999). These mice 
do not exhibit any alteration in baseline tail withdrawal time compared to the 
WT mice. 
 
There is evidence for opioid receptor dimerisation, this was first evident for DOP 
receptors in recombinant models (Cvejic and Devi, 1997, Jordan and Devi, 1999) 
and subsequently for MOP receptors with DOP receptors (George et al., 2000) 
and also with other GPCRs (Fujita et al., 2014). The potential for the opioid 
receptors to dimerise has been supported by the publication of the structural 
models for the receptors, in particular that of MOP receptors (Manglik et al., 
2012). From further work it is known that DOP receptors are required for the 
complete inhibitory response on VACCs in DRGs by morphine (Walwyn et al., 
2009). Disruption of the MOP/DOP association results in  decreased analgesic 
tolerance (He et al., 2011) and the exposure of DRGs and brainstem neurones to 
chronic morphine results in an increase in MOP/DOP receptor antibody staining 
(Gupta et al., 2010, Costantino et al., 2012). Interestingly the presence of DOP 
receptors appears to increase the ability of morphine to induce internalisation 
(Whistler et al., 1999, Haberstock-Debic et al., 2003, Walwyn et al., 2006). This 
suggests that morphine would produce a greater degree of tolerance when only 
MOP receptor homomers are present when compared to a mixed population 
including MOP/DOP heteromers. This occurs as these heteromers exhibit an 
increased degree of internalisation with morphine (Walwyn et al., 2006, Finn and 
Whistler, 2001). Although we observe decreased morphine tolerance in DOP-/- 
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mice and the presence of MOP/DOP heteromers in the cell membrane is 
increased after chronic morphine treatment (Gupta et al., 2010, Costantino et 
al., 2012), this is thought to reduce the analgesic effects of opioid drugs (Milan-
Lobo et al., 2013). This is contradictory and requires further investigation, it is 
also interesting that the compensatory increases in several second messenger 
systems associated with the detrimental long term adaptations that occur with 
chronic opioid exposure, for example increases in cAMP and MAPK kinase 
signalling, occur to a greater extent with agents that produce more 
internalisation (Koch et al., 2005, Walwyn et al., 2006). Dual labelling for DOP 
and MOP receptors would allow the study of whether decreased receptor 
number, (as in the MOP+/- mice), affects the ability of these two opioid 
receptors to associate and interact at the cell membrane. MOP/DOP 
heterodimers are also involved in the recruitment of BAR2 to the cell membrane 
(Rozenfeld and Devi, 2007).  
 
7.2.3 The role of BAR2 in analgesia and tolerance 
Morphine causes dose-dependent analgesia in BAR2-/- mice that is not 
significantly different to that observed in WT mice. BAR2-/- mice exhibit basal 
analgesia and decreased morphine tolerance after 10 days of once daily 
morphine administration. These effects had been previously reported (Bohn et 
al., 1999, Bohn et al., 2000, Bohn et al., 2002, Lam et al., 2011). DOP receptors 
exhibit constitutive activity (Costa and Herz, 1989). This raises the possibility that 
DOP receptors in the putative MOP/DOP heterodimers of the pain pathway may 
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drive constitutive activity when BAR2 is absent. This possibility was tested using 
the double KO mouse model (BAR2-/-//DOP-/-). These mice exhibit basal 
analgesia that is not significantly different to that observed in the single BAR2-/- 
mice. So DOP receptors are not required for constitutive signalling seen in the 
absence of BAR2. It would be interesting to investigate the effects of combining 
the BAR2-/- mouse model with the MOP+/- mouse line to create a BAR2-/-
//MOP+/- mouse model. As we know that MOP receptor number is reduced in 
the MOP+/- mice this would assist in the elucidation of the importance of 
receptor number and spare receptors in the activation of constitutive signalling 
involving MOP receptors. It would also be interesting to see if a lack of BAR2 is 
able to inhibit the profound analgesic tolerance observed in MOP+/- mice. 
 
7.2.4 The effects of c-Src inhibition within the pain pathway 
We used two tyrosine kinase inhibitors to investigate the role of c-Src in opioid 
receptor signalling and the development of the side effects associated with the 
use of opioid drugs. PP2 is a selective inhibitor of c-Src that has been used 
predominately in vitro (Bain et al., 2007, Uitdehaag et al., 2012). It is unclear 
whether PP2 administered systemically crosses the BBB, however the benefit of 
using this drug is that it has an inactive analogue, PP3, that can be used as a 
matched control. The second drug that we have used is dasatinib, this a clinically 
licensed drug that is used for the treatment of leukaemia. It has been extensively 
tested in vivo and does cross the blood brain barrier (BBB) (Porkka et al., 2008, 
Lagas et al., 2009). However, dasatinib is not a selective inhibitor of c-Src and 
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also affects a number of other tyrosine kinases and their receptors including 
PDGFRβ. This is important as PDGFRβ has been implicated in the development of 
morphine tolerance (Wang et al., 2012).  
 
Dasatinib prevented the development of tolerance in WT mice. Furthermore, 
dasatinib, PP2 (but not PP3) inhibited the development of morphine tolerance in 
MOP+/- mice, which are a good model to study tolerance development as they 
are significantly tolerant to the analgesic effects of morphine after 5 days of 
treatment. Importantly, dasatinib also reversed morphine tolerance in MOP+/- 
mice. This is very exciting as it suggests that tolerance is not an irreversible 
process only recoverable on stopping morphine, but instead tyrosine kinase 
related signalling is involved in its maintenance. In the study from Wang et al 
(2012) they were unable to reverse the development of existing tolerance 
though the administration of imatinib although if this drug was administered 
prior to morphine it prevented the development of tolerance. Suggesting that 
there may be different processes involved and that dasatinib may be more 
effective as an adjunct approach to mitigating tolerance. It would be very 
interesting to know if PP2 is also able to reverse tolerance as this would confirm 
the involvement of c-Src in this process. An important question that remains is 
whether there are differences in the level of phosphorylated c-Src between 
BAR2-/- neurones and WT neurones. It is currently unclear whether the 
activation of c-Src by morphine requires MOP receptors, DOP receptors and/or 
BAR2 as implied by the hypotheses depicted in Figure 7.1. This can now be 
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addressed by assaying phospho-Src (the activated form of c-Src) in WT, MOP-/-, 
DOP-/- and BAR2-/- mice following morphine treatment. 
 
7.2.5 Summary analgesia and tolerance 
DOP receptors and BAR2 are required for the normal development of tolerance 
to the analgesic effects of morphine. This is in spite of the fact that selective DOP 
receptor agonists have only limited analgesic efficacy in acute pain models in 
vivo (Gavériaux-Ruff et al., 2008, Gaveriaux-Ruff and Kieffer, 2011, Gendron et 
al., 2015, Peppin and Raffa, 2015). Some of the selective DOP agonists that have 
been developed, for example SNC-80, have demonstrated proconvulsant effects 
limiting their use (Chu Sin Chung and Kieffer, 2013). Upregulation of DOP 
receptors within the cell membrane of DRG neurones can significantly increase 
the inhibitory effect of selective DOP receptor agonists on VACCs (Walwyn et al., 
2005). In models of chronic pain including neuropathic, inflammatory and bone 
cancer pain models, selective agonists at DOP receptors produce antinociceptive 
effects (Contet et al., 2006, Nadal et al., 2006, Gavériaux-Ruff et al., 2008). 
Knockout of DOP receptors produce a significant increase in neuropathic and 
inflammatory pain and abolishes the antinociceptive effect of DOP selective 
agonists, demonstrating their importance in chronic pain (Martin et al., 2003, 
Nadal et al., 2006, Gavériaux-Ruff et al., 2008). In inflammatory pain models DOP 
receptor function is upregulated through improved coupling to VACC signalling 
(Pradhan et al., 2013). Recombinant MOP and DOP receptors form heterodimers 
(Gomes et al., 2004) and the presence of both MOP and DOP receptors is 
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required for recruitment of BAR2 in the absence of agonist (Rozenfeld and Devi, 
2007, Baptista-Hon et al., 2013). This implicates DOP receptors in BAR2 signalling 
produced by agonist activation of MOP receptors. Following chronic morphine 
treatment it appears that MOP/DOP receptor heteromers are upregulated 
(Gupta et al., 2010, Costantino et al., 2012) and that there is an anti-analgesic 
effect of MOP/DOP heteromers in the pain pathway (Milan-Lobo et al., 2013). 
Methadone, a MOP receptor agonist, administered alone produces rapid 
endocytosis but when administered in combination with a low dose of a DOP 
antagonist (naltriben) the endocytosis of the MOP/DOP heteromer complex is 
blocked. By contrast, the endocytosis of MOP receptor homomers and 
intracellular signalling are not altered (Milan-Lobo and Whistler, 2011). 
MOP/DOP receptor heteromers therefore persist in the cell membrane. The 
mice treated with naltriben and methadone, with the aim of stabilising the 
MOP/DOP heteromers in the cell membrane, developed increased analgesic 
tolerance when compared to those mice treated with methadone alone. This 
implicates MOP/DOP heteromers in analgesic tolerance (Milan-Lobo et al., 
2013).  
 
Morphine analgesic tolerance is reduced in BAR2-/- mice and these animals 
exhibit basal analgesia. BAR2 is recruited to MOP receptors following 
phosphorylation by G protein receptor kinases (GRKs). It is currently unclear 
whether GRK mediated phosphorylation of MOP/DOP oligomers is required for 
basal BAR2 recruitment. Opioid receptor phosphorylation can also occur through 
a number of different pathways including second messenger dependent protein 
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kinases such as PKA and PKC (Ferguson, 2001). The BAR2 mediated pathway 
provides an alternative signalling mechanism that is thought to play a role in 
receptor desensitisation and endocytosis, in addition to the activation of 
alternative intracellular signalling pathways. The development in the 
understanding of this alternative signalling pathway has led to the concept of 
biased agonism or functional selectivity (Reiter and Lefkowitz, 2006, Shukla et 
al., 2011). This concept describes the ability of a ligand to selectively recruit one 
signalling pathway over another to produce differing intracellular effects (Urban 
et al., 2007, Kelly et al., 2008, Kenakin and Miller, 2010). Compounds that can 
selectively stabilise receptor conformation to produce signalling through either G 
protein mediated mechanisms or via BAR2 are now being developed. The 
differing receptor conformations are thought to produce recruitment of differing 
intracellular signalling pathways through a GRK mediated phosphorylation 
“barcode” at the receptor C terminus (Reiter et al., 2012). 
 
Herkinorin, a derivative of Salvinorin A, has limited bioavailability and a bias 
towards G protein signalling. This compound produces analgesia with reduced 
tolerance (Groer et al., 2007). A compound called TRV130 has recently been 
developed by Trevena Inc. TRV130 produces analgesia at MOP receptors through 
the activation of G protein mediated signalling without affecting the BAR2 
signalling pathway. In animal studies this compound produced analgesia with 
reduced gastric and respiratory side effects when compared to morphine 
(DeWire et al., 2013). During Phase I clinical trials in healthy volunteers it also 
appeared to produce improved analgesia with reduced side effects when 
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compared to equivalent doses of morphine and it has now entered Phase II 
clinical trials (Soergel et al., 2014). 
 
Different GRKs are involved in rewarding processes and analgesic tolerance 
(Gluck et al., 2014). It has been demonstrated that c-Src is involved in GPCR 
desensitisation and internalisation (Walwyn et al., 2007, Gavi et al., 2006). The 
beta2-adrenergic receptor requires the recruitment and activation of Src to 
allow desensitisation and internalisation to occur (Fan et al., 2001, Huang et al., 
2004). MOP receptors have not been studied in isolation but there is evidence 
for the requirement of c-Src for DOP receptor desensitisation, internalisation 
and signalling in recombinant cell models (Kramer et al., 2000a, Kramer et al., 
2000b, Gavi et al., 2006, Hong et al., 2009). Interestingly c-Src phosphorylates 
and activates GRK2, which is implicated in opioid receptor signalling and 
functional selectivity (Fan et al., 2001). Inhibition of c-Src using PP2 abolishes the 
phosphorylation of GRK2 and prevents the desensitisation of beta2-adrenergic 
receptor (Fan et al., 2001). While GRK2 knock-out is embryonically lethal, various 
studies have targeted siRNA knockdown of this protein. The results of these 
implicate both GRK2 and GRK3 in opioid receptor phosphorylation, and BAR 
recruitment (Whistler and von Zastrow, 1998, Bohn et al., 2004). GRK3 knock-out 
mice exhibit the development of normal morphine tolerance but reduced 
tolerance to fentanyl (Terman et al., 2004, Kuhar et al., 2015). Src has also been 
implicated in the recruitment of BAR1 and BAR2 to the plasma membrane as PP2 
appears to reduce this in a recombinant cell model (Hong et al., 2009). Src has 
also been implicated in both the activation of protein tyrosine kinase receptors 
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such as PDGFRβ and the downstream effectors following activation of these 
receptors (Thomas and Brugge, 1997). Both the PDGFRα and the PDGFRβ couple 
to Src (Kypta et al., 1990, Twamley et al., 1992), and exposure of fibroblast cells 
to the PDGFRβ agonist PDGFBB produces an upregulation of Src family activity 
(Kypta et al., 1990). This suggests that the reduction of tolerance seen with 
PDGFRβ inhibition (Wang et al., 2012) may actually be due to the inhibition of 
Src and this requires further exploration.  
 
Costa and Herz (1989) were the first to demonstrate agonist independent 
constitutive DOP receptor activity in the NG108-15 neuroblastoma cell line. The 
level of constitutive activity of MOP receptors under normal circumstances is 
thought to be low, but it can be demonstrated when the receptors are 
overexpressed (Burford et al., 2000) or altered by specific mutations (Brillet et 
al., 2003). Long term exposure to opioid drugs such as morphine can also 
produce an increase in constitutive activity in both cell based systems (Wang et 
al., 2001, Sadee et al., 2005) and in the striatum of morphine dependent mice 
(Wang et al 2004).  In DRG neurones from BAR2-/- mice it has been 
demonstrated that there is increased MOP receptor constitutive activity 
(Walwyn et al., 2007). Basal analgesia in the BAR2-/- mice appears to be the 
result of MOP receptor constitutive activity within the pain pathway because it is 
inhibited by inverse agonists but not neutral antagonists (Lam et al., 2011). As 
discussed previously we observe basal analgesia in both BAR2-/- and BAR2-/-
//DOP-/- mice. This demonstrates that constitutive activity of MOP receptors 
occurs in DOP-/- mice, suggesting that DOP receptors do not influence this 
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process but BAR2 does, as it occurs in both the BAR2-/- and the BAR2-/-//DOP-/- 
mice.  
 
There was no basal analgesia in mice treated with c-Src inhibitors. We do not 
know if there are differences in the level of c-Src in BAR2-/- neurones, the 
localisation of c-Src within the cell has been suggested to be disrupted in DRG 
neurones from BAR2-/- mice (Walwyn et al., 2007). There may also be 
differences in pc-Src levels following opioid exposure when BAR2 is absent and 
these are questions that will need to be addressed in future experiments. 
 
7.3 Genetic polymorphisms and opioid activity 
Inter-individual differences in the response to opioids are well known. This 
includes both the analgesic response obtained from a single dose and the side 
effects that are experienced. Polymorphisms in the Oprm1 gene have been 
suggested to be involved in these differences in both humans and rodents (Uhl 
et al., 1999). One of the most studied is the A118G polymorphism where an 
adenine has been replaced by a guanine resulting in an amino acid switch from 
asparagine to aspartate in exon 1 of the Oprm1 gene at position 40 (so 
otherwise known as N40D) (Fillingim et al., 2005). This polymorphism occurs in 
0.8% of the Sub-Saharan population, 8 – 17% of Caucasians and 49% of Asians 
(Walter and Lotsch, 2009). It has been suggested that people who are 
homozygous for this polymorphism have a decreased sensitivity to pressure pain 
(Fillingim et al., 2005). With varying reports of the decreased effectiveness of 
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opioid drugs, increased effect or no change (Diatchenko et al., 2011). A meta-
analysis performed in 2009 suggested that at that point knowledge of the 
patient’s genotype would not be useful for pain management, but there was a 
weak association with decreased nausea and increased opioid requirements in 
the homozygotes (Walter and Lotsch, 2009). There have also been several 
studies using mouse models and humanised mouse models, they reveal that 
MOP receptors containing the A118G polymorphism have a greater binding 
affinity for β-endorphin than the WT MOP receptors and that it is more potent at 
activating associated GIRK channels (Bond et al., 1998). The humanised mouse 
model suggested a decreased morphine potency with attendant decreased 
analgesia, but that the response to fentanyl was unchanged (Mahmoud et al., 
2011). A recent study has revealed that these mice gain less of a reward from 
morphine and this is associated with decreased dopamine release in the nucleus 
accumbens, this is thought to be due to decreased receptor expression at the 
cell surface of the N40D containing receptors (Robinson et al., 2015). This is 
consistent with our work from the MOP+/- mice which exhibit reduced potency 
of morphine analgesia but increased susceptibility to tolerance. The 
demonstration of the importance of polymorphisms in receptor expression 
suggests that this is relevant to the clinical situation and may provide a 
mechanism for the observations of individual variability in the development of 
tolerance to morphine. 
  
The second most common polymorphism in the Oprm1 gene causes an A6V 
substitution, like N40D this occurs in the extracellular domain of the MOP 
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receptor (Ravindranathan et al., 2009). The frequency of occurrence again 
depends on the population tested with identification of this polymorphism in 
<1% of Caucasians tested but 20% of African Americans and the Northern Indian 
population (Knapman and Connor, 2015). It appears that adenylyl cyclase 
activation of the ERK signalling pathway is disrupted following morphine and 
fentanyl exposure of cells containing MOP receptors with this mutation 
(Knapman et al., 2015). Both N40D and A6V are associated with an increased risk 
of alcohol abuse (Rommelspacher et al., 2001). This is interesting as ethanol has 
been demonstrated to reverse morphine tolerance in locus coeruleus neurones 
(Llorente et al., 2013) and analgesic tolerance in a mouse model (Hull et al., 
2013). 
 
 7.4 The psychomotor effects of morphine 
7.4.1 The role of MOP receptors 
In rodents, morphine produces a robust dose-dependent locomotor activation, a 
phenomenon that exhibits sensitisation. This has been well described previously 
(Brase et al., 1977) and is somewhat strain dependent (Mogil et al., 1999, Leo et 
al., 2008). MOP-/- mice do not develop locomotor activation by morphine and 
MOP+/- mice exhibit a reduction in morphine potency to produce locomotor 
activation. Interestingly MOP+/- fail to sensitise to locomotor activation even 
following morphine administration at 30 mg/Kg. Implicating MOP receptor 
number in this process.  
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Studies investigating differences in protein transcription within the nucleus 
accumbens core in response to both acute and chronic administration of 
morphine have identified differences in the level of chaperone proteins known 
as heat shock proteins (Hsp) (Salas et al., 2011). A link between behavioural 
sensitisation and Hsp70 expression has been identified in mice (Luo et al., 2011). 
Levels of Hsp70 expression in the nucleus accumbens core correlate with the 
degree of sensitisation of locomotor activation produced by a dose of morphine. 
This process appears to involve D1 receptors as the administration of D1 
receptor antagonist prevents this sensitisation from occurring (Babovic et al., 
2013). As previously discussed D1 receptors are also implicated in the direct 
activation of hyperactivity in mice after opioid administration and this has been 
associated with a BAR2/ERK signalling complex (Urs et al., 2011). Dopamine 
deficient mice exhibit reinforcement by morphine but the drug induced 
locomotor activation is significantly reduced (Hnasko et al., 2005) revealing that 
dopamine levels within the nucleus accumbens are not solely responsible for the 
reinforcing effects of these drugs but play a significant role in locomotor 
activation.  
 
WT mice display a significant dose dependent preference for morphine following 
conditioning in a two chamber CPP model. MOP-/- do not display a preference 
for morphine as previously described (Matthes et al., 1996). The MOP+/- mice 
do not exhibit a preference for morphine (10 mg/Kg) but do for morphine (30 
mg/Kg) as for locomotor activation this suggests that the reduction in potency is 
greater for this aspect of morphine related behaviour than for analgesia.  
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Morphine and the selective MOP receptor agonist, DAMGO, caused a 
concentration dependent inhibition of sIPSC frequency in the VTA. Previous 
studies have been restricted to the use of morphine, DAMGO or met-enkephalin 
using single concentrations. In MOP+/- neurones morphine has a reduced 
potency which supports the results that we obtained for the CPP experiments. 
As does the fact that there is no significant inhibition of sIPSC frequency in MOP-
/- neurones. MOP-/- mice do not display a preference for morphine or self-
administer the drug (Matthes et al., 1996).  
 
Very low concentrations of morphine (< 0.03 μM) inhibit IPSCs frequency in VTA 
slices. The presence of 5-HT3 receptors within the VTA has been suggested 
(Cameron et al., 1997, Rodd et al., 2007). Morphine is a potent antagonist of 5-
HT3 receptors (Baptista-Hon et al., 2012). Ondansetron alone produced a 
significant inhibition of sIPSC frequency (23.1 ± 6.2%), and its actions were 
approximately additive with those of morphine indicating that these two drugs 
likely act through different sites to inhibit sIPSC frequency. These data suggest 
that while 5-HT3 receptors are present within the VTA and influence sIPSC 
frequency they are probably not responsible for the effects of morphine. 
However, morphine can also activate DOP receptor signalling (Keith et al., 1996) 
and this may be the cause of this inhibition as it does not occur with DAMGO. 
 
We have demonstrated that the sIPSCs that we have recorded are GABAergic, 
the events are abolished by the application of bicuculline a GABAA receptor 
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antagonist. Both GABAA and GABAB receptors are thought to be present within 
the VTA (Xi and Stein, 2002, Margolis et al., 2012, Tan et al., 2012, Ciccarelli et 
al., 2012) it would be useful to perform further experiments to elucidate the 
effects of specific GABA receptor antagonist drugs on the response to opioid 
drugs in this brain area and to establish the GABAA receptor subtypes involved.  
 
The control frequency of IPSC events and the event kinetics are not significantly 
different when TTX is present suggesting that the majority of GABA release is 
action potential independent spontaneous release. However, it will be important 
to establish whether higher concentrations of TTX reduce IPSC frequency. It is 
possible that VTA neurones express TTX resistant Na+ channels. We have 
performed the majority of our experiments in the absence of TTX to enable the 
recording of sIPSC events. This allows for the possibility that there is an intact 
neuronal network present within the slice which is more like the situation in the 
whole brain. The nucleus accumbens is present in our slices and this raises the 
possibility that it may be possible to evoke IPSCs mediated by striatal inhibitory 
neurones projecting back to the VTA. It may be possible to record from 
presynaptic inhibitory neurones originating in the striatum or elsewhere, while 
simultaneously recording from postsynaptic dopaminergic neurones in the VTA. 
This may work if there is a direct connection between the two brain areas. Of 
note is the observation that introduction of MOP receptors into striatal 
GABAergic neurones reinstates opioid reinforcement in MOP-/- mice (Cui et al., 
2014). This implies that the inhibition from the striatum back to the VTA is 
instrumental in this behaviour. The ability to study the effects of conditional 
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opioid receptor KO or of knocking in MOP, DOP and BAR2 into specific neurones 
to establish the role of these components in the individual neuronal populations 
will be important in future studies. 
 
To further address this issue, imaging of VTA neurones and their connectivity 
throughout the brain would be fascinating. It has been postulated that the 
properties of the dopaminergic neurones vary across the VTA depending on their 
target location (Ford et al., 2006). One way of addressing this would be through 
the use of retrograde tracers which could be injected either into the nucleus 
accumbens to investigate specific connectivity to the VTA. Another approach 
would be injection into the VTA to investigate neuronal projections into the VTA. 
A study by Matsui and Williams (2011) identified the rostromedial tegmental 
nucleus as an important input to the VTA utilising this technique. Understanding 
whether the roles of BAR2 and c-Src are specific to individual projection 
neurones would be very useful.  
 
One of the issues that we have encountered has been unambiguous 
identification of the neurone involved in electrophysiological recording. With 
little consensus regarding electrophysiological markers of cell type we are 
dependent on secondary labelling techniques. While we have developed a 
robust protocol to identify the dopaminergic cells within the VTA in the slices 
used for recording, identifying the single biocytin labelled cell has been much 
less reliable. It would be very useful to whole cell patch a number of cells in a WT 
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brain slice with intracellular solution containing biocytin, process this slice for 
IHC immediately after recording and document the percentage of tyrosine 
hydroxylase cells were present that were co-labelled with biocytin. Another 
approach would be to utilise GAD67-GFP mice and patch cells that contained 
GFP and those that did not and compare the effects of morphine on these cell 
types. This approach would also allow the investigation of the effect of cell type 
on sIPSC activity. A longer term approach would be to create mouse lines that 
are both GAD67-GFP positive alongside the genetic models that we have used in 
this study, so for example GAD67-GFP/MOP-/- mice.  
 
We have performed the electrophysiological experiments in brain slices from 
mice that were between 17 and 21 days old and the behavioural experiments in 
adult mice. This has been done due to the limitations of our current imaging 
system, which cannot visualise neurones in brain slices containing the VTA above 
post-natal day 21 due to the increasing myelination. It has been suggested that 
the opioid receptors may utilise differing mechanisms of phosphorylation and 
desensitisation at a young age (less than 20 days post-natal) compared to adult 
neurones with levels of GRK2 expression decreasing with increasing age 
(Llorente et al., 2012). This may account for some of our observed differences 
between the electrophysiological recordings and the behavioural responses to 
morphine.  
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7.4.2 DOP receptors in the psychomotor effects of morphine 
WT mice do not exhibit significant locomotor activity when treated with 3 mg/Kg 
morphine, but do when treated with 10 mg/Kg morphine. DOP-/- mice exhibit no 
significant alterations in locomotor activity compared to WT mice following 
morphine (10 mg/Kg) but did exhibit an increased sensitivity to the locomotor 
activating effects at morphine (3 mg/Kg). This corresponds with previously 
published data that suggests that DOP-/- mice display an increased sensitivity to 
the locomotor activating aspects of morphine (Chefer and Shippenberg, 2009), 
although this study also observed an increased locomotor response when 
compared to the WT control, which we did not see.  
 
DOP-/- mice also exhibit a dose dependent preference for morphine that is not 
significantly different from that which was observed in the WT mice. There have 
been conflicting reports of morphine reinforcement in this mouse model with 
some investigators not demonstrating reinforcement (Chefer and Shippenberg, 
2009) and others reporting that it could be observed in these mice (Le Merrer et 
al., 2011, Le Merrer et al., 2012). As previously discussed in Chapter 4, all of CPP 
was performed in the same way with saline administered in the morning (AM) 
session and morphine in the afternoon (PM) session. It has been suggested that 
the DOP-/- mice require a cue to be able to develop CPP to morphine unlike the 
WT mice. The fact that we have used a specific time related administration 
protocol may have provided enough of a cue to establish the observed 
preference for morphine in the DOP-/- mice. However the preference scores that 
we have recorded for the DOP-/- mice are not significantly different from those 
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of the WT mice and the mice demonstrate a marked dose-dependent increase in 
preference for the morphine paired chamber. This, along with the fact that these 
mice will self-administer morphine (Lutz and Kieffer, 2013), suggests that 
morphine reinforcement is not significantly affected by the removal of DOP 
receptors from the signalling pathway. However, there were only eight mice of 
equal genders in each group in the current study, which is a relatively small 
sample size and an increased sample size will be required to make firm 
conclusions. It would be useful to be able to compare the effects of gender and 
genetic background on this aspect of behaviour as the previous studies used only 
male mice (Chefer and Shippenberg, 2009). They also maintained the mice on a 
different genetic background (129Sv/C57Bl/6 mixed background compared to 
our C57Bl/6J alone) (Le Merrer et al., 2011, Le Merrer et al., 2012). This may 
have implications for the differences in preference that we observed. It has been 
widely published that there are genetic variations in the results of nociceptive 
testing and response to morphine in mice (Mogil et al., 1999, Kest et al., 2000, 
Chesler et al., 2002). There are also variations in morphine preference and self-
administration across different rodent genotypes (Korostynski et al., 2006).  
 
7.4.3 The role of BAR2 in the psychomotor effects of morphine 
BAR2-/- mice exhibit a significantly reduced locomotor response to morphine (10 
mg/Kg) but still sensitise to this effect. We observe the same effects in the BAR2-
/-//DOP-/- mice. Together with the DOP-/- mouse data this implicates the 
involvement of BAR2 in the development of locomotor activation following 
241 
 
morphine administration, but suggests that DOP receptors may also be involved 
in sensitisation. Locomotor activation following morphine administration is 
thought to be produced predominately through dopamine receptor signalling 
although there is a small component that occurs via a dopamine independent 
mechanism (Meye et al., 2012). The dopaminergic dependent component of 
locomotor activation is mediated via a dopamine D1 receptor mechanism (Urs et 
al., 2011). Activation of this pathway produces the formation of a 
BAR2/mitogen-activated protein kinase (MAPK) complex. Systemic 
administration of the MEK inhibitor, SL327, to WT mice inhibits morphine 
induced locomotion in a dose dependent manner (Urs et al., 2011).   
 
BAR2-/- mice exhibit an increased preference score for morphine compared to 
the WT mice at low concentrations of morphine (3 mg/Kg) suggesting that they 
experience a greater sensitivity to the reinforcing effects of morphine when 
compared to WT mice. This confirms a previous report (Bohn et al., 2003). The 
preference score recorded for these mice was not different when either 3 or 10 
mg/Kg of morphine was administered unlike the WT and DOP-/- mice which 
displayed a dose dependency in this range. This suggests that 3 mg/Kg morphine 
is at the top of the dose response curve for reinforcement in BAR2-/- mice and it 
would be interesting to repeat with lower doses to establish the potency of 
morphine. This increased sensitivity to morphine reinforcement appears to occur 
without constitutive activity of MOP receptors, a phenomenon observed in the 
pain pathway of BAR2-/- mice (Walwyn et al., 2007, Lam et al., 2011). We know 
that MOP receptors are involved in mediating hedonic tone as naloxone is 
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aversive in WT, but not in MOP-/- mice (Skoubis et al., 2001). BAR2-/- mice do 
not display any significant alteration in their aversive response to naloxone when 
compared to WT mice suggesting that there is no increase in “basal reward” in 
these animals (Lam et al., 2011).  
 
In contrast to the reported increase in the preference of the BAR2-/- mice for 
morphine (Bohn et al., 2003), it was initially reported that the degree of physical 
dependence produced by morphine was not significantly different between WT 
and BAR2-/- mice (Bohn et al., 2000). A further study utilising osmotic pumps for 
drug delivery instead of the pellet method that had been previously used 
produced slightly different results. It suggests that the withdrawal signs 
observed are dependent on the dose of morphine that is received. So BAR2-/- 
mice that receive high doses of morphine do not show differences in physical 
dependence when compared to WT mice. But for those mice that received a 
lower dose of morphine the signs of physical dependence and withdrawal were 
significantly reduced in the BAR2-/- mice compared to the WT mice (Raehal and 
Bohn, 2011). These results do not explain the increased preference for morphine 
that these mice display. It would be helpful to establish whether BAR2-/- exhibit 
greater morphine self-administration compared to WT mice for a more complete 
understanding of the role of BAR2 signalling in reward.  
 
The BAR2-/-//DOP-/- mice exhibited a dose dependent preference for morphine 
in the two chamber CPP model, this was not significantly different to that 
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observed in the WT mice. Removing DOP receptors as well as BAR2 appears to 
have ameliorated the increased sensitivity to morphine preference observed in 
the BAR2-/- mice. 
 
It would be very interesting to test CPP in mice that have been treated 
chronically with morphine and examine the effects of the different mouse 
strains. Particularly interesting would be the effect of the gene deletions in 
BAR2-/-, DOP-/- and the BAR2-/-//DOP-/- mice as they show a significantly 
reduced or abolished tolerance to the analgesic effects of morphine. It will be 
important to establish whether these genotypes have differences in morphine 
dependence following chronic exposure. This could be investigated using CPA to 
naloxone. Such an approach would also allow us to establish differences 
between the genotypes in withdrawal behaviours (for example vocalising, 
jumping and rearing). This may occur over a similar time course to the 
development of morphine analgesic tolerance. 
 
7.4.4 The role of DOP receptors and BAR2 in VTA signalling 
In the DOP-/-, BAR2-/- and the BAR2-/-//DOP-/- neurones there is a consistent 
reduction in the ability of morphine to inhibit sIPSC frequency compared to the 
WT neurones. The work that we have done also implicates BAR2 in the response 
to DAMGO. As we also observe a significant reduction in the ability of DAMGO to 
inhibit sIPSC frequency in the BAR2-/- neurones compared to the WT neurones.  
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In the DOP-/- mice this supports the previous reports of decreased CPP (Chefer 
and Shippenberg, 2009) but not our data of unchanged CPP and a report of 
unchanged morphine self-administration (Lutz and Kieffer, 2013). The dogma is 
that inhibition of sIPSC frequency within the VTA is responsible for the 
psychomotor effects of morphine through disinhibition of dopaminergic 
neurones in the mesocorticolimbic reward pathway. We also noted that 
naloxone, an antagonist/inverse agonist at MOP receptors, inhibits sIPSC 
frequency in WT, MOP+/- and MOP-/- neurones within the VTA. This MOP 
receptor independent phenomenon was unexpected. The lack of inhibition of 
sIPSC frequency by naloxone in the BAR2-/-, DOP-/- or BAR2-/-//DOP-/- 
neurones suggests that the effect is mediated through DOP receptors and BAR2. 
It has been previously reported that MOP receptor antagonists can increase 
dopamine in the striatum (Devine et al., 1993b) an effect that is normally 
associated with MOP receptor agonists. Furthermore, a low dose of naltrexone 
has been reported to increase the duration of morphine CPP when administered 
with morphine during the conditioning phase of the protocol (Powell et al., 
2002). 
 
The observation that DPDPE inhibits sIPSC frequency in WT but not DOP-/- VTA 
neurones demonstrates that DOP receptors are present within the VTA, in 
agreement with previous labelling studies (Erbs et al., 2015). DPDPE also inhibits 
sIPSC frequency in MOP-/- neurones demonstrating that DOP receptors are able 
to function independent of MOP receptors in the VTA. This is consistent with 
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previously reported behavioural data that rodents will self-administer DPDPE 
directly into the VTA (Devine and Wise, 1994, McBride et al., 1999).  
 
The observation that morphine has a reduced potency as an inhibitor of sIPSC 
frequency in VTA neurones from BAR2-/- mice is surprising as these mice display 
enhanced preference for morphine compared to WT mice. This suggests that 
inhibition of IPSCs in the VTA is not directly responsible for 
reward/reinforcement. We postulated that this synapse may be responsible for 
the locomotor activation rather than reward. As the BAR2-/- mice exhibit 
significantly decreased locomotor activation by morphine when compared to WT 
mice this would be consistent with a decrease in the ability of morphine to 
inhibit sIPSC frequency.  
 
Removing either DOP receptors or BAR2 appears to have the same effect on 
reducing the ability of morphine to inhibit sIPSC frequency, suggesting the 
involvement of both of these factors in alterations in signalling produced by 
morphine within the VTA. It is possible that DOP receptors are required to allow 
the link between MOP receptors and BAR2 to occur perhaps by forming a 
MOP/DOP/BAR2 complex.  
 
The VTA has also been implicated in the modulation of pain transmission 
(Bushnell et al., 2013, Niikura et al., 2010). Neuropathic pain models, such as 
sciatic nerve ligation, can decrease MOP receptor function within the VTA 
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resulting in a decrease in the rewarding effect of MOP agonist drugs (Ozaki et al., 
2003). It is thought that these effects are mediated by separate mechanisms that 
are individually associated with reward and analgesia (Schifirnet et al., 2014). 
 
7.4.5 The effects of c-Src inhibition on the psychomotor effects of morphine 
It has been reported that dasatinib can cross the BBB (Porkka et al., 2008, Lagas 
et al., 2009). There were no significant alterations in reinforcement or locomotor 
activation when dasatinib was administered either alone or together with 
morphine to WT mice. PP2 directly applied to the VTA neurones of WT mice 
reduced the inhibition of sIPSC frequency by morphine, which resembled the 
reduced inhibitory effect of morphine in BAR2-/- neurones. This was unexpected 
given the behavioural findings. We also investigated the effects of a MEK 
inhibitor (SL327) on sIPSC frequency. Inhibition of MEK by SL327 significantly 
decreases locomotor activation in WT mice but does not alter CPP for morphine 
(Urs et al., 2011). We have demonstrated that MEK inhibition does not affect the 
ability of morphine to inhibit sIPSC frequency within the VTA. Taken together 
these data imply that MEK-ERK signalling is not involved in the vesicular release 
of GABA from presynaptic neurones within the VTA but that c-Src is involved in 
this process. We hypothesise that MOP receptors signal through BAR2 (perhaps 
with DOP receptors) to c-Src in which regulates the trafficking of GABAergic 
vesicles within the VTA. There are several experiments that need to be done to 
test this hypothesis. An obvious approach is to test whether c-Src inhibitors 
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reduce the inhibition of sIPSC frequency by morphine in BAR2-/- VTA neurones. 
An absence of an effect of c-Src inhibitors would support the hypothesis.  
 
In DRG neurones c-Src inhibition or the removal of BAR2 (BAR2-/-) has been 
demonstrated to increase constitutive inhibitory coupling of MOP receptors to 
VACCs, reduce constitutive MOP receptor recycling and increase the cell surface 
expression of MOP receptors (Walwyn et al., 2007). It may be that the role of c-
Src is different within the VTA. There are a number of studies that implicate c-Src 
in membrane trafficking, receptor desensitisation and internalisation (Foster-
Barber and Bishop, 1998, Hong et al., 2009).  
 
It would be useful to confirm biochemically that dasatinib is crossing the BBB in 
our model and reaching a significant cerebral concentration. This experiment 
could be performed using western blots for c-Src and phosphorylated c-Src 
following administration of dasatinib to WT mice. This would reveal whether IP 
administered c-Src inhibitors (PP2 and dasatinib) inhibit the phosphorylation of 
c-Src within VTA and striatum and also DRG neurones and spinal cord. 
 
We have implicated c-Src in the development of morphine tolerance. It would be 
interesting to pursue a health informatics approach to investigate whether 
differences in opioid prescribing are apparent in patients receiving dasatinib and 
opioid drugs compared to those that are receiving opioid drugs alone. Our data 
would suggest that patients receiving dasatinib alongside opioid drugs may not 
248 
 
experience tolerance to their analgesic effects and therefore would not require 
the same dose escalation likely to occur in cancer patients not receiving 
dasatinib. 
 
These observations suggest that c-Src participates in the actions of morphine in 
analgesia and also within the VTA. The effects of inhibiting c-Src are similar to 
those observed in DOP-/- and BAR2-/- mice, in that there is a demonstrable 
reduction in analgesic tolerance. When PP2 is directly applied to WT VTA 
neurones the ability of morphine to inhibit sIPSC frequency resembles that 
within the BAR2-/- neurones. Inhibition of c-Src does not appear to affect 
locomotor activation produced by morphine or to alter morphine CPP. It will be 
important to determine whether the activation of c-Src is dependent on the 
MOP/DOP/BAR2 signalling pathway or if c-Src is acting in parallel as an 
independent mechanism. We have demonstrated in SW620 cells that dasatinib 
and PP2 inhibit the phosphorylation of c-Src. We plan to investigate the 
differences in the degree of morphine stimulated phosphorylation of c-Src in the 
VTA and DRG neurones of WT, MOP-/-, DOP-/- and BAR2-/- mice.  
 
The tyrosine kinase system is a very complicated system that may provide 
multiple targets to modify the side effects of opioid drugs. We have 
demonstrated a role for the tyrosine kinase c-Src in the development of 
tolerance to the analgesic effects of morphine. It does not appear that inhibiting 
c-Src affects the rewarding properties of the drug. However this requires 
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verification by the introduction of c-Src inhibitors into specific brain nuclei such 
as the VTA and striatum. It also does not cause basal analgesia in mice or 
constitutive receptor activity like the removal of BAR2. It therefore presents us 
with a very interesting target to reduce opioid tolerance without affecting 
reward. 
 
7.5 Conclusions 
We hypothesised that MOP and DOP receptors interacted in the pain pathway to 
recruit BAR2 and c-Src. The finding that morphine analgesic tolerance is reduced 
in the DOP-/- and the BAR2-/- mice is consistent with the hypothesis. However, 
when both BAR2 and DOP receptors are removed, as in BAR2-/-//DOP-/- mice, 
then tolerance is completely abolished suggesting that both of these elements 
are independently involved in morphine analgesic tolerance. The implication is 
that the actions of DOP receptors and BAR2 are additive and therefore not be in 
a sequential pathway. The inhibition of c-Src also inhibits the development of 
morphine tolerance in both the WT and MOP+/- mice. DOP receptors also 
contribute to the analgesic effects of morphine supporting a role of MOP/DOP 
heteromers in signalling. While there appears to be a significant MOP receptor 
reserve, receptor number influences the development of tolerance. 
 
Secondly we hypothesised that MOP/DOP interactions are not involved in 
signalling within the reward pathway. Our data suggest that this is may not be 
correct. DOP receptors are present within the VTA and they function not only in 
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response to selective agonists but they are also involved in morphine activated 
signalling. Both DOP and BAR2 are required for the full inhibitory effect of 
morphine on sIPSC frequency. The involvement of DOP receptors appears to be 
specific to morphine as their absence does not affect the ability of DAMGO to 
inhibit sIPSC frequency. However BAR2 is implicated in the response to both 
morphine and DAMGO and the inhibition of c-Src produces an effect similar to 
that seen in the BAR2-/- neurones with morphine.  
 
The removal of MOP receptors abolishes the psychomotor effects of morphine. 
The electrophysiological results do not clearly correlate with the observed 
psychomotor differences observed in the DOP-/- and BAR2-/- mice. The absence 
of BAR2 increases the morphine preference score, this alteration does not 
appear to involve DOP receptor signalling as preference is unchanged in DOP-/- 
mice. While locomotor activation is reduced in BAR2-/- mice, sensitisation still 
occurs. The sensitisation of the locomotor response to morphine appears to be 
predominately mediated through MOP receptor signalling. The inhibition of c-Src 
does not appear to alter the psychomotor effects produced by morphine. As we 
have discussed it does reduce morphine analgesic tolerance. This suggests that 
c-Src is an attractive target to prevent the development of morphine analgesic 
tolerance without affecting hedonic homeostasis. 
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